drug1_db
stringlengths
7
7
drug2_db
stringlengths
7
7
drug1_id
int64
0
1.69k
drug2_id
int64
0
1.69k
drug_pair
listlengths
2
2
drug1_name
stringlengths
4
85
drug2_name
stringlengths
4
85
drug1_desc
stringlengths
27
1.09k
drug2_desc
stringlengths
27
6.14k
label
stringclasses
3 values
label_idx
int64
0
2
all_paths
listlengths
1
10
all_paths_str
listlengths
1
10
path_str
stringlengths
0
3.57k
DB00562
DB00635
1,014
1,573
[ "DDInter188", "DDInter1515" ]
Benzthiazide
Prednisone
Benzthiazide is used to treat hypertension and edema. Like other thiazides, benzthiazide promotes water loss from the body (diuretics). They inhibit Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used to treat hypertension, but their hypotensive effects are not necessarily due to their diuretic activity. Thiazides have been shown to prevent hypertension-related morbidity and mortality although the mechanism is not fully understood. Thiazides cause vasodilation by activating calcium-activated potassium channels (large conductance) in vascular smooth muscles and inhibiting various carbonic anhydrases in vascular tissue.
A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955.
Moderate
1
[ [ [ 1014, 24, 1573 ] ], [ [ 1014, 24, 175 ], [ 175, 40, 1573 ] ], [ [ 1014, 63, 251 ], [ 251, 1, 1573 ] ], [ [ 1014, 24, 167 ], [ 167, 1, 1573 ] ], [ [ 1014, 24, 659 ], [ 659, 62, 1573 ] ], [ [ 1014, 63, 127 ], [ 127, 24, 1573 ] ], [ [ 1014, 24, 761 ], [ 761, 63, 1573 ] ], [ [ 1014, 23, 126 ], [ 126, 63, 1573 ] ], [ [ 1014, 24, 355 ], [ 355, 24, 1573 ] ], [ [ 1014, 1, 811 ], [ 811, 24, 1573 ] ] ]
[ [ [ "Benzthiazide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Prednisone" ] ], [ [ "Benzthiazide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Triamcinolone" ], [ "Triamcinolone", "{u} (Compound) resembles {v} (Compound)", "Prednisone" ] ], [ [ "Benzthiazide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Betamethasone" ], [ "Betamethasone", "{u} (Compound) resembles {v} (Compound)", "Prednisone" ] ], [ [ "Benzthiazide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Hydrocortisone" ], [ "Hydrocortisone", "{u} (Compound) resembles {v} (Compound)", "Prednisone" ] ], [ [ "Benzthiazide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Vilanterol" ], [ "Vilanterol", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Prednisone" ] ], [ [ "Benzthiazide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Miglitol" ], [ "Miglitol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Prednisone" ] ], [ [ "Benzthiazide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Saxagliptin" ], [ "Saxagliptin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Prednisone" ] ], [ [ "Benzthiazide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Warfarin" ], [ "Warfarin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Prednisone" ] ], [ [ "Benzthiazide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lactulose" ], [ "Lactulose", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Prednisone" ] ], [ [ "Benzthiazide", "{u} (Compound) resembles {v} (Compound)", "Metolazone" ], [ "Metolazone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Prednisone" ] ] ]
Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Prednisone (Compound) Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles Prednisone (Compound) Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Prednisone (Compound) Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a minor interaction that can limit clinical effects when taken with Prednisone Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Miglitol and Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Prednisone Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Prednisone Benzthiazide may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Prednisone Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Prednisone Benzthiazide (Compound) resembles Metolazone (Compound) and Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Prednisone
DB01100
DB01128
1,568
918
[ "DDInter1470", "DDInter204" ]
Pimozide
Bicalutamide
A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug Evaluations Annual, 1994, p403)
Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor.
Major
2
[ [ [ 1568, 25, 918 ] ], [ [ 1568, 25, 129 ], [ 129, 40, 918 ] ], [ [ 1568, 6, 8374 ], [ 8374, 45, 918 ] ], [ [ 1568, 18, 16974 ], [ 16974, 57, 918 ] ], [ [ 1568, 21, 28642 ], [ 28642, 60, 918 ] ], [ [ 1568, 62, 112 ], [ 112, 23, 918 ] ], [ [ 1568, 25, 392 ], [ 392, 63, 918 ] ], [ [ 1568, 24, 1476 ], [ 1476, 63, 918 ] ], [ [ 1568, 64, 485 ], [ 485, 24, 918 ] ], [ [ 1568, 63, 543 ], [ 543, 24, 918 ] ] ]
[ [ [ "Pimozide", "{u} may lead to a major life threatening interaction when taken with {v}", "Bicalutamide" ] ], [ [ "Pimozide", "{u} may lead to a major life threatening interaction when taken with {v}", "Enzalutamide" ], [ "Enzalutamide", "{u} (Compound) resembles {v} (Compound)", "Bicalutamide" ] ], [ [ "Pimozide", "{u} (Compound) binds {v} (Gene)", "CYP3A4" ], [ "CYP3A4", "{u} (Gene) is bound by {v} (Compound)", "Bicalutamide" ] ], [ [ "Pimozide", "{u} (Compound) downregulates {v} (Gene)", "TUBB6" ], [ "TUBB6", "{u} (Gene) is downregulated by {v} (Compound)", "Bicalutamide" ] ], [ [ "Pimozide", "{u} (Compound) causes {v} (Side Effect)", "Shock" ], [ "Shock", "{u} (Side Effect) is caused by {v} (Compound)", "Bicalutamide" ] ], [ [ "Pimozide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Metronidazole" ], [ "Metronidazole", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Bicalutamide" ] ], [ [ "Pimozide", "{u} may lead to a major life threatening interaction when taken with {v}", "Lapatinib" ], [ "Lapatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bicalutamide" ] ], [ [ "Pimozide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brigatinib" ], [ "Brigatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bicalutamide" ] ], [ [ "Pimozide", "{u} may lead to a major life threatening interaction when taken with {v}", "Pentamidine" ], [ "Pentamidine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bicalutamide" ] ], [ [ "Pimozide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Loperamide" ], [ "Loperamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bicalutamide" ] ] ]
Pimozide may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide (Compound) resembles Bicalutamide (Compound) Pimozide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bicalutamide (Compound) Pimozide (Compound) downregulates TUBB6 (Gene) and TUBB6 (Gene) is downregulated by Bicalutamide (Compound) Pimozide (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Bicalutamide (Compound) Pimozide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Bicalutamide Pimozide may lead to a major life threatening interaction when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide Pimozide may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide Pimozide may lead to a major life threatening interaction when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide Pimozide may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide
DB01044
DB01377
246
1,283
[ "DDInter809", "DDInter1119" ]
Gatifloxacin
Magnesium oxide
Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections. Gatifloxacin is available as tablets and in various aqueous solutions for intravenous therapy. It is also available as eye drops under the brand name Zymar® marketed by Allergan. The FDA withdrew its approval for the use of non-ophthalmic drug products containing gatifloxacin due to the high prevalence of gatifloxacin-associated dysglycemia adverse event reports and the high incidence of hyperglycemic and hypoglycemic episodes in patients taking gatifloxacin compared to those on macrolide antibiotics.[L43942,L44037]
Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses.
Moderate
1
[ [ [ 246, 24, 1283 ] ], [ [ 246, 64, 167 ], [ 167, 23, 1283 ] ], [ [ 246, 23, 60 ], [ 60, 23, 1283 ] ], [ [ 246, 25, 820 ], [ 820, 23, 1283 ] ], [ [ 246, 63, 355 ], [ 355, 23, 1283 ] ], [ [ 246, 63, 1479 ], [ 1479, 24, 1283 ] ], [ [ 246, 25, 1487 ], [ 1487, 63, 1283 ] ], [ [ 246, 24, 286 ], [ 286, 63, 1283 ] ], [ [ 246, 1, 945 ], [ 945, 24, 1283 ] ], [ [ 246, 40, 1176 ], [ 1176, 24, 1283 ] ] ]
[ [ [ "Gatifloxacin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Magnesium oxide" ] ], [ [ "Gatifloxacin", "{u} may lead to a major life threatening interaction when taken with {v}", "Hydrocortisone" ], [ "Hydrocortisone", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Magnesium oxide" ] ], [ [ "Gatifloxacin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Capecitabine" ], [ "Capecitabine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Magnesium oxide" ] ], [ [ "Gatifloxacin", "{u} may lead to a major life threatening interaction when taken with {v}", "Alimemazine" ], [ "Alimemazine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Magnesium oxide" ] ], [ [ "Gatifloxacin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lactulose" ], [ "Lactulose", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Magnesium oxide" ] ], [ [ "Gatifloxacin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Acetylsalicylic acid" ], [ "Acetylsalicylic acid", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Magnesium oxide" ] ], [ [ "Gatifloxacin", "{u} may lead to a major life threatening interaction when taken with {v}", "Hydroxychloroquine" ], [ "Hydroxychloroquine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Magnesium oxide" ] ], [ [ "Gatifloxacin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Magnesium hydroxide" ], [ "Magnesium hydroxide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Magnesium oxide" ] ], [ [ "Gatifloxacin", "{u} (Compound) resembles {v} (Compound)", "Sparfloxacin" ], [ "Sparfloxacin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Magnesium oxide" ] ], [ [ "Gatifloxacin", "{u} (Compound) resembles {v} (Compound)", "Moxifloxacin" ], [ "Moxifloxacin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Magnesium oxide" ] ] ]
Gatifloxacin may lead to a major life threatening interaction when taken with Hydrocortisone and Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide Gatifloxacin may cause a minor interaction that can limit clinical effects when taken with Capecitabine and Capecitabine may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide Gatifloxacin may lead to a major life threatening interaction when taken with Alimemazine and Alimemazine may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide Gatifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide Gatifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Magnesium oxide Gatifloxacin may lead to a major life threatening interaction when taken with Hydroxychloroquine and Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium oxide Gatifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium oxide Gatifloxacin (Compound) resembles Sparfloxacin (Compound) and Sparfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium oxide Gatifloxacin (Compound) resembles Moxifloxacin (Compound) and Moxifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium oxide
DB08860
DB09122
788
1,613
[ "DDInter1479", "DDInter1409" ]
Pitavastatin
Peginterferon beta-1a
Pitavastatin, also known as the brand name product Livalo, is a lipid-lowering drug belonging to the statin class of medications. By inhibiting the endogenous production of cholesterol within the liver, statins lower abnormal cholesterol and lipid levels and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase, which catalyzes the conversion of HMG-CoA to mevalonic acid. This is the third step in a sequence of metabolic reactions involved in the production of several compounds involved in lipid metabolism and transport including cholesterol, low-density lipoprotein (LDL) (sometimes referred to as "bad cholesterol"), and very low-density lipoprotein (VLDL). Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of CVD, such as those
Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792] Peginterferon beta-1a is an interferon therapy used for the management of relapsing forms of MS. It was originally approved by the FDA in 2014 for subcutaneous use, and was approved for intramuscular use in January 2021. Currently, it is the only approved pegylated interferon for the management of MS with an proven ability to reduce relapses and delay the progression of disability resulting from MS.
Moderate
1
[ [ [ 788, 24, 1613 ] ], [ [ 788, 40, 671 ], [ 671, 24, 1613 ] ], [ [ 788, 63, 168 ], [ 168, 24, 1613 ] ], [ [ 788, 64, 1668 ], [ 1668, 24, 1613 ] ], [ [ 788, 24, 1480 ], [ 1480, 63, 1613 ] ], [ [ 788, 24, 1593 ], [ 1593, 24, 1613 ] ], [ [ 788, 74, 14 ], [ 14, 24, 1613 ] ], [ [ 788, 1, 700 ], [ 700, 24, 1613 ] ], [ [ 788, 64, 1377 ], [ 1377, 25, 1613 ] ], [ [ 788, 25, 1510 ], [ 1510, 25, 1613 ] ] ]
[ [ [ "Pitavastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Peginterferon beta-1a" ] ], [ [ "Pitavastatin", "{u} (Compound) resembles {v} (Compound)", "Fluvastatin" ], [ "Fluvastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Peginterferon beta-1a" ] ], [ [ "Pitavastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bortezomib" ], [ "Bortezomib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Peginterferon beta-1a" ] ], [ [ "Pitavastatin", "{u} may lead to a major life threatening interaction when taken with {v}", "Lenalidomide" ], [ "Lenalidomide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Peginterferon beta-1a" ] ], [ [ "Pitavastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ixazomib" ], [ "Ixazomib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Peginterferon beta-1a" ] ], [ [ "Pitavastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Crizotinib" ], [ "Crizotinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Peginterferon beta-1a" ] ], [ [ "Pitavastatin", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Rosuvastatin" ], [ "Rosuvastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Peginterferon beta-1a" ] ], [ [ "Pitavastatin", "{u} (Compound) resembles {v} (Compound)", "Atorvastatin" ], [ "Atorvastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Peginterferon beta-1a" ] ], [ [ "Pitavastatin", "{u} may lead to a major life threatening interaction when taken with {v}", "Leflunomide" ], [ "Leflunomide", "{u} may lead to a major life threatening interaction when taken with {v}", "Peginterferon beta-1a" ] ], [ [ "Pitavastatin", "{u} may lead to a major life threatening interaction when taken with {v}", "Teriflunomide" ], [ "Teriflunomide", "{u} may lead to a major life threatening interaction when taken with {v}", "Peginterferon beta-1a" ] ] ]
Pitavastatin (Compound) resembles Fluvastatin (Compound) and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a Pitavastatin may lead to a major life threatening interaction when taken with Lenalidomide and Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a Pitavastatin (Compound) resembles Rosuvastatin (Compound) and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin and Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a Pitavastatin (Compound) resembles Atorvastatin (Compound) and Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a Pitavastatin may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Peginterferon beta-1a Pitavastatin may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Peginterferon beta-1a
DB00647
DB00835
675
100
[ "DDInter528", "DDInter245" ]
Dextropropoxyphene
Brompheniramine
Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions. Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the market in Europe and the United States. The drug is often referred to as the general form, "propoxyphene", however only the dextro-isomer (dextropropoxyphene) has any analgesic effect. The levo-isomer appears to exhibit a very limited antitussive effect.
Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria.
Major
2
[ [ [ 675, 25, 100 ] ], [ [ 675, 25, 832 ], [ 832, 24, 100 ] ], [ [ 675, 64, 128 ], [ 128, 24, 100 ] ], [ [ 675, 40, 11244 ], [ 11244, 1, 100 ] ], [ [ 675, 24, 28 ], [ 28, 40, 100 ] ], [ [ 675, 40, 649 ], [ 649, 63, 100 ] ], [ [ 675, 75, 1594 ], [ 1594, 24, 100 ] ], [ [ 675, 6, 8374 ], [ 8374, 45, 100 ] ], [ [ 675, 25, 1053 ], [ 1053, 63, 100 ] ], [ [ 675, 63, 352 ], [ 352, 24, 100 ] ] ]
[ [ [ "Dextropropoxyphene", "{u} may lead to a major life threatening interaction when taken with {v}", "Brompheniramine" ] ], [ [ "Dextropropoxyphene", "{u} may lead to a major life threatening interaction when taken with {v}", "Tripelennamine" ], [ "Tripelennamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brompheniramine" ] ], [ [ "Dextropropoxyphene", "{u} may lead to a major life threatening interaction when taken with {v}", "Dexbrompheniramine" ], [ "Dexbrompheniramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brompheniramine" ] ], [ [ "Dextropropoxyphene", "{u} (Compound) resembles {v} (Compound)", "Pheniramine" ], [ "Pheniramine", "{u} (Compound) resembles {v} (Compound)", "Brompheniramine" ] ], [ [ "Dextropropoxyphene", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bisacodyl" ], [ "Bisacodyl", "{u} (Compound) resembles {v} (Compound)", "Brompheniramine" ] ], [ [ "Dextropropoxyphene", "{u} (Compound) resembles {v} (Compound)", "Clofedanol" ], [ "Clofedanol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brompheniramine" ] ], [ [ "Dextropropoxyphene", "{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}", "Doxylamine" ], [ "Doxylamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brompheniramine" ] ], [ [ "Dextropropoxyphene", "{u} (Compound) binds {v} (Gene)", "CYP3A4" ], [ "CYP3A4", "{u} (Gene) is bound by {v} (Compound)", "Brompheniramine" ] ], [ [ "Dextropropoxyphene", "{u} may lead to a major life threatening interaction when taken with {v}", "Procarbazine" ], [ "Procarbazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brompheniramine" ] ], [ [ "Dextropropoxyphene", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Trospium" ], [ "Trospium", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brompheniramine" ] ] ]
Dextropropoxyphene may lead to a major life threatening interaction when taken with Tripelennamine and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine Dextropropoxyphene may lead to a major life threatening interaction when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine Dextropropoxyphene (Compound) resembles Pheniramine (Compound) and Pheniramine (Compound) resembles Brompheniramine (Compound) Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl and Bisacodyl (Compound) resembles Brompheniramine (Compound) Dextropropoxyphene (Compound) resembles Clofedanol (Compound) and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine Dextropropoxyphene (Compound) resembles Doxylamine (Compound) and Dextropropoxyphene may lead to a major life threatening interaction when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine Dextropropoxyphene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Brompheniramine (Compound) Dextropropoxyphene may lead to a major life threatening interaction when taken with Procarbazine and Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
DB01042
DB05679
1,307
1,683
[ "DDInter1144", "DDInter1907" ]
Melphalan
Ustekinumab
Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard.[A261150, A261155] Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is also used to treat uveal melanoma with unresectable hepatic metastases.
Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic disease-modifying anti-rheumatic drug (bDMARDs) that is used in the management of various inflammatory conditions that involve the activation of IL-12 and IL-23 signalling pathways. The therapeutic use of the drug started in Canada, the US, and Europe since 2009 when it was first approved for the treatment of adult patients with moderate to severe plaque psoriasis and active psoriatic arthritis, alone or in combination with [methotrexate]. In September 2016, ustekinumab was additionally approved for the management of moderate to severe Crohn's disease in selected adult patients. In October 2019, it was also approved by the FDA for use to manage moderately to severely active ulcerative colitis in adults. Ustekinumab is currently the first and only approved biologic therapy for ulcerative colitis that targets the interleukin (IL)-12 and IL-23 cytokines. The dosing regimen for ustekinumab is based on the patient's weight and there are intravenous and subcutaneous formulations of the drug based on the dosing schedule and condition being treated. Ustekinumab is commonly marketed under the trade name STELARA. Ustekinumab biosimilars are available in some markets, including Wezlana (ustekinumab-auub) in the US and Jamteki (AVT04) in Canada.
Moderate
1
[ [ [ 1307, 24, 1683 ] ], [ [ 1307, 63, 1461 ], [ 1461, 23, 1683 ] ], [ [ 1307, 23, 1193 ], [ 1193, 62, 1683 ] ], [ [ 1307, 24, 1362 ], [ 1362, 63, 1683 ] ], [ [ 1307, 63, 1001 ], [ 1001, 24, 1683 ] ], [ [ 1307, 24, 1488 ], [ 1488, 24, 1683 ] ], [ [ 1307, 62, 322 ], [ 322, 24, 1683 ] ], [ [ 1307, 64, 770 ], [ 770, 24, 1683 ] ], [ [ 1307, 25, 908 ], [ 908, 64, 1683 ] ], [ [ 1307, 64, 1066 ], [ 1066, 25, 1683 ] ] ]
[ [ [ "Melphalan", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ustekinumab" ] ], [ [ "Melphalan", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Vitamin E" ], [ "Vitamin E", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Ustekinumab" ] ], [ [ "Melphalan", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Zinc gluconate" ], [ "Zinc gluconate", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Ustekinumab" ] ], [ [ "Melphalan", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Olaparib" ], [ "Olaparib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ustekinumab" ] ], [ [ "Melphalan", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mechlorethamine" ], [ "Mechlorethamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ustekinumab" ] ], [ [ "Melphalan", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fludarabine" ], [ "Fludarabine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ustekinumab" ] ], [ [ "Melphalan", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Epirubicin" ], [ "Epirubicin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ustekinumab" ] ], [ [ "Melphalan", "{u} may lead to a major life threatening interaction when taken with {v}", "Thalidomide" ], [ "Thalidomide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ustekinumab" ] ], [ [ "Melphalan", "{u} may lead to a major life threatening interaction when taken with {v}", "Golimumab" ], [ "Golimumab", "{u} may lead to a major life threatening interaction when taken with {v}", "Ustekinumab" ] ], [ [ "Melphalan", "{u} may lead to a major life threatening interaction when taken with {v}", "Natalizumab" ], [ "Natalizumab", "{u} may lead to a major life threatening interaction when taken with {v}", "Ustekinumab" ] ] ]
Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Ustekinumab Melphalan may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Ustekinumab Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Mechlorethamine and Mechlorethamine may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine and Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab Melphalan may cause a minor interaction that can limit clinical effects when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab Melphalan may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab Melphalan may lead to a major life threatening interaction when taken with Golimumab and Golimumab may lead to a major life threatening interaction when taken with Ustekinumab Melphalan may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Ustekinumab
DB00009
DB06209
1,271
256
[ "DDInter56", "DDInter1508" ]
Alteplase
Prasugrel
Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent. It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. In the absence of fibrin, the alteplase-mediated conversion of plasminogen is limited, thanks to the high affinity between alteplase and fibrin.[A252330,L43125] Alteplase is a purified glycoprotein of 527 amino acids expressed in Chinese hamster ovary (CHO) cells.[A252345,L43125] It was first approved by the FDA in 1987 for the management of thromboembolic disease, including acute myocardial infarction (AMI). The use of alteplase to manage AMI has decreased thanks to the availability of safer treatments such as angioplasty and stenting. However, its use for the treatment of acute ischem
Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversibly binds to P2Y12 type ADP receptors on platelets thus preventing activation of the GPIIb/IIIa receptor complex. As a result, inhibition of ADP-mediated platelet activation and aggregation occurs. Prasugrel was developed by Daiichi Sankyo Co. and is currently marketed in the United States and Canada in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary intervention (PCI). FDA approved in 2009.
Major
2
[ [ [ 1271, 25, 256 ] ], [ [ 1271, 23, 944 ], [ 944, 62, 256 ] ], [ [ 1271, 24, 901 ], [ 901, 24, 256 ] ], [ [ 1271, 24, 1427 ], [ 1427, 63, 256 ] ], [ [ 1271, 24, 1317 ], [ 1317, 25, 256 ] ], [ [ 1271, 25, 365 ], [ 365, 64, 256 ] ], [ [ 1271, 25, 1046 ], [ 1046, 25, 256 ] ], [ [ 1271, 64, 1578 ], [ 1578, 25, 256 ] ], [ [ 1271, 24, 1347 ], [ 1347, 36, 256 ] ], [ [ 1271, 23, 944 ], [ 944, 62, 1479 ], [ 1479, 24, 256 ] ] ]
[ [ [ "Alteplase", "{u} may lead to a major life threatening interaction when taken with {v}", "Prasugrel" ] ], [ [ "Alteplase", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Chamomile" ], [ "Chamomile", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Prasugrel" ] ], [ [ "Alteplase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Milnacipran" ], [ "Milnacipran", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Prasugrel" ] ], [ [ "Alteplase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Vortioxetine" ], [ "Vortioxetine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Prasugrel" ] ], [ [ "Alteplase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dipyridamole" ], [ "Dipyridamole", "{u} may lead to a major life threatening interaction when taken with {v}", "Prasugrel" ] ], [ [ "Alteplase", "{u} may lead to a major life threatening interaction when taken with {v}", "Dalteparin" ], [ "Dalteparin", "{u} may lead to a major life threatening interaction when taken with {v}", "Prasugrel" ] ], [ [ "Alteplase", "{u} may lead to a major life threatening interaction when taken with {v}", "Caplacizumab" ], [ "Caplacizumab", "{u} may lead to a major life threatening interaction when taken with {v}", "Prasugrel" ] ], [ [ "Alteplase", "{u} may lead to a major life threatening interaction when taken with {v}", "Lepirudin" ], [ "Lepirudin", "{u} may lead to a major life threatening interaction when taken with {v}", "Prasugrel" ] ], [ [ "Alteplase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clopidogrel" ], [ "Clopidogrel", "{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}", "Prasugrel" ] ], [ [ "Alteplase", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Chamomile" ], [ "Chamomile", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Acetylsalicylic acid" ], [ "Acetylsalicylic acid", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Prasugrel" ] ] ]
Alteplase may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Prasugrel Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran and Milnacipran may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine and Vortioxetine may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Dipyridamole and Dipyridamole may lead to a major life threatening interaction when taken with Prasugrel Alteplase may lead to a major life threatening interaction when taken with Dalteparin and Dalteparin may lead to a major life threatening interaction when taken with Prasugrel Alteplase may lead to a major life threatening interaction when taken with Caplacizumab and Caplacizumab may lead to a major life threatening interaction when taken with Prasugrel Alteplase may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may lead to a major life threatening interaction when taken with Prasugrel Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel and Clopidogrel (Compound) resembles Prasugrel (Compound) and Clopidogrel may lead to a major life threatening interaction when taken with Prasugrel Alteplase may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel
DB00776
DB09073
1,335
951
[ "DDInter1360", "DDInter1379" ]
Oxcarbazepine
Palbociclib
Oxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures that was first approved for use in the United States in 2000.[L8627,L8630,L8633] It is a structural derivative of [carbamazepine] and exerts a majority of its activity via a pharmacologically active metabolite, MHD, which exists as a racemate in the blood - a pro-drug of the more active (S)-enantiomer is also marketed as a separate anti-epileptic under the name [eslicarbazepine]. Compared to other anti-epileptic drugs, which are generally metabolized via the cytochrome P450 system, oxcarbazepine has a reduced propensity for involvement in drug-drug interactions owing to its primarily reductive metabolism.
Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery that identified the cyclin-dependent kinases as key regulators of cell growth. It was originally FDA approved on March 2015 for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer and its indications were updated in April 2019 to include male patients based on findings from postmarketing reports and electronic health records demonstrating safety and clinical efficacy.
Moderate
1
[ [ [ 1335, 24, 951 ] ], [ [ 1335, 24, 1476 ], [ 1476, 63, 951 ] ], [ [ 1335, 63, 467 ], [ 467, 24, 951 ] ], [ [ 1335, 24, 578 ], [ 578, 24, 951 ] ], [ [ 1335, 62, 1101 ], [ 1101, 24, 951 ] ], [ [ 1335, 40, 307 ], [ 307, 24, 951 ] ], [ [ 1335, 24, 129 ], [ 129, 25, 951 ] ], [ [ 1335, 40, 1236 ], [ 1236, 25, 951 ] ], [ [ 1335, 24, 1476 ], [ 1476, 24, 907 ], [ 907, 62, 951 ] ], [ [ 1335, 24, 159 ], [ 159, 62, 907 ], [ 907, 62, 951 ] ] ]
[ [ [ "Oxcarbazepine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Palbociclib" ] ], [ [ "Oxcarbazepine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brigatinib" ], [ "Brigatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Palbociclib" ] ], [ [ "Oxcarbazepine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Simvastatin" ], [ "Simvastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Palbociclib" ] ], [ [ "Oxcarbazepine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ticagrelor" ], [ "Ticagrelor", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Palbociclib" ] ], [ [ "Oxcarbazepine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Bexarotene" ], [ "Bexarotene", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Palbociclib" ] ], [ [ "Oxcarbazepine", "{u} (Compound) resembles {v} (Compound)", "Modafinil" ], [ "Modafinil", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Palbociclib" ] ], [ [ "Oxcarbazepine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Enzalutamide" ], [ "Enzalutamide", "{u} may lead to a major life threatening interaction when taken with {v}", "Palbociclib" ] ], [ [ "Oxcarbazepine", "{u} (Compound) resembles {v} (Compound)", "Carbamazepine" ], [ "Carbamazepine", "{u} may lead to a major life threatening interaction when taken with {v}", "Palbociclib" ] ], [ [ "Oxcarbazepine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brigatinib" ], [ "Brigatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Doravirine" ], [ "Doravirine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Palbociclib" ] ], [ [ "Oxcarbazepine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Larotrectinib" ], [ "Larotrectinib", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Doravirine" ], [ "Doravirine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Palbociclib" ] ] ]
Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib Oxcarbazepine may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib Oxcarbazepine (Compound) resembles Modafinil (Compound) and Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Palbociclib Oxcarbazepine (Compound) resembles Carbamazepine (Compound) and Carbamazepine may lead to a major life threatening interaction when taken with Palbociclib Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Doravirine and Doravirine may cause a minor interaction that can limit clinical effects when taken with Palbociclib Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a minor interaction that can limit clinical effects when taken with Doravirine and Doravirine may cause a minor interaction that can limit clinical effects when taken with Palbociclib
DB00396
DB00491
989
127
[ "DDInter1529", "DDInter1217" ]
Progesterone
Miglitol
Progesterone is a hormone that occurs naturally in females, and is essential for endometrial receptivity, embryo implantation, and the successful establishment of pregnancy. A low progesterone concentration or an insufficient response to progesterone can cause infertility and pregnancy loss. Progesterone is used in various contraceptive preparations to prevent ovulation and fertilization, as well as in other formulations to promote and support pregnancy. Please see [Medroxyprogesterone acetate], [Megestrol acetate], [Dydrogesterone] and [Hydroxyprogesterone] entries for information on various other forms of progesterone. Pharmaceutical progesterone is made from a plant source as a starting material and is chemically identical to progesterone of human ovarian origin [FDA label]. Progesterone is available in gelatinized capsule form, vaginal gel form, tablet form, vaginal insert form, and injection form, all used for various purposes [Label,F389
Miglitol inhibits the breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the body. Miglitol should be taken at the start of a meal for maximal effect and the effect will depend on the amount of poly and oligosaccharides in the diet. Miglitol inhibits alpha-glucosidase, making less sugars available for digestion and reducing postprandial hyperglycemia. Unlike other drugs of the same class, miglitol is not metabolized and the unmetabolized drug is excreted by the kidneys.
Moderate
1
[ [ [ 989, 24, 127 ] ], [ [ 989, 21, 29180 ], [ 29180, 60, 127 ] ], [ [ 989, 1, 984 ], [ 984, 63, 127 ] ], [ [ 989, 63, 245 ], [ 245, 24, 127 ] ], [ [ 989, 24, 1021 ], [ 1021, 63, 127 ] ], [ [ 989, 1, 566 ], [ 566, 24, 127 ] ], [ [ 989, 24, 590 ], [ 590, 24, 127 ] ], [ [ 989, 40, 167 ], [ 167, 63, 127 ] ], [ [ 989, 21, 29180 ], [ 29180, 60, 1625 ], [ 1625, 40, 127 ] ], [ [ 989, 21, 28787 ], [ 28787, 60, 1103 ], [ 1103, 23, 127 ] ] ]
[ [ [ "Progesterone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Miglitol" ] ], [ [ "Progesterone", "{u} (Compound) causes {v} (Side Effect)", "Abdominal distension" ], [ "Abdominal distension", "{u} (Side Effect) is caused by {v} (Compound)", "Miglitol" ] ], [ [ "Progesterone", "{u} (Compound) resembles {v} (Compound)", "Danazol" ], [ "Danazol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Miglitol" ] ], [ [ "Progesterone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Glimepiride" ], [ "Glimepiride", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Miglitol" ] ], [ [ "Progesterone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pramlintide" ], [ "Pramlintide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Miglitol" ] ], [ [ "Progesterone", "{u} (Compound) resembles {v} (Compound)", "Levonorgestrel" ], [ "Levonorgestrel", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Miglitol" ] ], [ [ "Progesterone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Acetohexamide" ], [ "Acetohexamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Miglitol" ] ], [ [ "Progesterone", "{u} (Compound) resembles {v} (Compound)", "Hydrocortisone" ], [ "Hydrocortisone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Miglitol" ] ], [ [ "Progesterone", "{u} (Compound) causes {v} (Side Effect)", "Abdominal distension" ], [ "Abdominal distension", "{u} (Side Effect) is caused by {v} (Compound)", "Miglustat" ], [ "Miglustat", "{u} (Compound) resembles {v} (Compound)", "Miglitol" ] ], [ [ "Progesterone", "{u} (Compound) causes {v} (Side Effect)", "Dermatitis" ], [ "Dermatitis", "{u} (Side Effect) is caused by {v} (Compound)", "Amcinonide" ], [ "Amcinonide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Miglitol" ] ] ]
Progesterone (Compound) causes Abdominal distension (Side Effect) and Abdominal distension (Side Effect) is caused by Miglitol (Compound) Progesterone (Compound) resembles Danazol (Compound) and Danazol may cause a moderate interaction that could exacerbate diseases when taken with Miglitol Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Miglitol Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide and Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Miglitol Progesterone (Compound) resembles Levonorgestrel (Compound) and Levonorgestrel may cause a moderate interaction that could exacerbate diseases when taken with Miglitol Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Miglitol Progesterone (Compound) resembles Hydrocortisone (Compound) and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Miglitol Progesterone (Compound) causes Abdominal distension (Side Effect) and Abdominal distension (Side Effect) is caused by Miglustat (Compound) and Miglustat (Compound) resembles Miglitol (Compound) Progesterone (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Miglitol
DB00196
DB00401
600
84
[ "DDInter743", "DDInter1298" ]
Fluconazole
Nisoldipine
Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole has many advantages over the other antifungal drugs including the option of oral administration. The side effect profile of this drug is minimal. It has been demonstrated as an efficacious treatment for vaginal yeast infections in one single dose.
Nisoldipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nisoldipine prevents calcium-dependent smooth muscle contraction and subsequent vasoconstriction. Nisoldipine may be used in alone or in combination with other agents in the management of hypertension.
Moderate
1
[ [ [ 600, 24, 84 ] ], [ [ 600, 24, 854 ], [ 854, 1, 84 ] ], [ [ 600, 24, 376 ], [ 376, 40, 84 ] ], [ [ 600, 6, 4973 ], [ 4973, 45, 84 ] ], [ [ 600, 21, 28748 ], [ 28748, 60, 84 ] ], [ [ 600, 24, 578 ], [ 578, 62, 84 ] ], [ [ 600, 24, 1031 ], [ 1031, 23, 84 ] ], [ [ 600, 24, 1619 ], [ 1619, 63, 84 ] ], [ [ 600, 25, 927 ], [ 927, 63, 84 ] ], [ [ 600, 23, 1101 ], [ 1101, 24, 84 ] ] ]
[ [ [ "Fluconazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nisoldipine" ] ], [ [ "Fluconazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nimodipine" ], [ "Nimodipine", "{u} (Compound) resembles {v} (Compound)", "Nisoldipine" ] ], [ [ "Fluconazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Amlodipine" ], [ "Amlodipine", "{u} (Compound) resembles {v} (Compound)", "Nisoldipine" ] ], [ [ "Fluconazole", "{u} (Compound) binds {v} (Gene)", "ABCB1" ], [ "ABCB1", "{u} (Gene) is bound by {v} (Compound)", "Nisoldipine" ] ], [ [ "Fluconazole", "{u} (Compound) causes {v} (Side Effect)", "Vertigo" ], [ "Vertigo", "{u} (Side Effect) is caused by {v} (Compound)", "Nisoldipine" ] ], [ [ "Fluconazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ticagrelor" ], [ "Ticagrelor", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Nisoldipine" ] ], [ [ "Fluconazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Theophylline" ], [ "Theophylline", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Nisoldipine" ] ], [ [ "Fluconazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Rucaparib" ], [ "Rucaparib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nisoldipine" ] ], [ [ "Fluconazole", "{u} may lead to a major life threatening interaction when taken with {v}", "Encorafenib" ], [ "Encorafenib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nisoldipine" ] ], [ [ "Fluconazole", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Bexarotene" ], [ "Bexarotene", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nisoldipine" ] ] ]
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Nimodipine and Nimodipine (Compound) resembles Nisoldipine (Compound) Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Amlodipine and Amlodipine (Compound) resembles Nisoldipine (Compound) Fluconazole (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Nisoldipine (Compound) Fluconazole (Compound) causes Vertigo (Side Effect) and Vertigo (Side Effect) is caused by Nisoldipine (Compound) Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Nisoldipine Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a minor interaction that can limit clinical effects when taken with Nisoldipine Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Nisoldipine Fluconazole may lead to a major life threatening interaction when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Nisoldipine Fluconazole may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Nisoldipine
DB11793
DB12887
738
1,598
[ "DDInter1297", "DDInter1750" ]
Niraparib
Tazemetostat
Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, fallopian tube, or primary peritoneal cancer. Niraparib was approved by the European Commission on November 16, 2017 and by Health Canada on June 27, 2019.
Tazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Tazemetostat was first named in literature as EPZ-6438. Tazemetaostat was granted FDA approval on 23 January 2020.
Moderate
1
[ [ [ 738, 24, 1598 ] ], [ [ 738, 63, 168 ], [ 168, 23, 1598 ] ], [ [ 738, 63, 594 ], [ 594, 24, 1598 ] ], [ [ 738, 24, 466 ], [ 466, 63, 1598 ] ], [ [ 738, 24, 971 ], [ 971, 24, 1598 ] ], [ [ 738, 63, 1046 ], [ 1046, 25, 1598 ] ], [ [ 738, 24, 913 ], [ 913, 25, 1598 ] ], [ [ 738, 64, 1292 ], [ 1292, 25, 1598 ] ], [ [ 738, 63, 168 ], [ 168, 23, 985 ], [ 985, 24, 1598 ] ], [ [ 738, 63, 594 ], [ 594, 25, 985 ], [ 985, 24, 1598 ] ] ]
[ [ [ "Niraparib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tazemetostat" ] ], [ [ "Niraparib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bortezomib" ], [ "Bortezomib", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Tazemetostat" ] ], [ [ "Niraparib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bosutinib" ], [ "Bosutinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tazemetostat" ] ], [ [ "Niraparib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Darolutamide" ], [ "Darolutamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tazemetostat" ] ], [ [ "Niraparib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Gilteritinib" ], [ "Gilteritinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tazemetostat" ] ], [ [ "Niraparib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Caplacizumab" ], [ "Caplacizumab", "{u} may lead to a major life threatening interaction when taken with {v}", "Tazemetostat" ] ], [ [ "Niraparib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Apalutamide" ], [ "Apalutamide", "{u} may lead to a major life threatening interaction when taken with {v}", "Tazemetostat" ] ], [ [ "Niraparib", "{u} may lead to a major life threatening interaction when taken with {v}", "Deferiprone" ], [ "Deferiprone", "{u} may lead to a major life threatening interaction when taken with {v}", "Tazemetostat" ] ], [ [ "Niraparib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bortezomib" ], [ "Bortezomib", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Osimertinib" ], [ "Osimertinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tazemetostat" ] ], [ [ "Niraparib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bosutinib" ], [ "Bosutinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Osimertinib" ], [ "Osimertinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tazemetostat" ] ] ]
Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Tazemetostat Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Caplacizumab and Caplacizumab may lead to a major life threatening interaction when taken with Tazemetostat Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Tazemetostat Niraparib may lead to a major life threatening interaction when taken with Deferiprone and Deferiprone may lead to a major life threatening interaction when taken with Tazemetostat Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Osimertinib and Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib may lead to a major life threatening interaction when taken with Osimertinib and Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat
DB00687
DB09038
870
1,450
[ "DDInter747", "DDInter636" ]
Fludrocortisone
Empagliflozin
Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to [cortisol], differing only by a fluorine atom at the 9-position of the steroid structure - this fluorination is thought to be crucial to fludrocortisone's significant mineralocorticoid potency.
Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 diabetes mellitus. The first known inhibitor of SGLTs, phlorizin, was isolated from the bark of apple trees in 1835 and researched extensively into the 20th century, but was ultimately deemed inappropriate for clinical use given its lack of specificity and significant gastrointestinal side effects. Attempts at overcoming these limitations first saw the development of O-glucoside analogs of phlorizin (e.g. [remogliflozin etabonate]), but these molecules proved relatively pharmacokinetically unstable. The development of C-glucoside phlorizin analogs remedied the issues observed in the previous generation, and led to the FDA approval of [canagliflozin] in 2013 and both [dapagliflozin] and empagliflozin in 2014. As the most recently approved of the "flozin" drugs, empagliflozin carries the highest selectivity for SGLT2 over SGLT1 (approximately 2700-fold). Empagliflozin was further approved by the EMA in March 2022 and Health Canada in April 2022, making it the first and only approved treatment in Europe and Canada for adults with symptomatic chronic heart failure regardless of ejection fraction.[L40783,L13916]
Moderate
1
[ [ [ 870, 24, 1450 ] ], [ [ 870, 1, 1103 ], [ 1103, 23, 1450 ] ], [ [ 870, 63, 461 ], [ 461, 24, 1450 ] ], [ [ 870, 23, 659 ], [ 659, 63, 1450 ] ], [ [ 870, 24, 1605 ], [ 1605, 24, 1450 ] ], [ [ 870, 24, 192 ], [ 192, 63, 1450 ] ], [ [ 870, 25, 872 ], [ 872, 24, 1450 ] ], [ [ 870, 1, 1486 ], [ 1486, 24, 1450 ] ], [ [ 870, 64, 1467 ], [ 1467, 24, 1450 ] ], [ [ 870, 23, 688 ], [ 688, 24, 1450 ] ] ]
[ [ [ "Fludrocortisone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Empagliflozin" ] ], [ [ "Fludrocortisone", "{u} (Compound) resembles {v} (Compound)", "Amcinonide" ], [ "Amcinonide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Empagliflozin" ] ], [ [ "Fludrocortisone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Timolol" ], [ "Timolol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Empagliflozin" ] ], [ [ "Fludrocortisone", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Vilanterol" ], [ "Vilanterol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Empagliflozin" ] ], [ [ "Fludrocortisone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Indapamide" ], [ "Indapamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Empagliflozin" ] ], [ [ "Fludrocortisone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Esterified estrogens" ], [ "Esterified estrogens", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Empagliflozin" ] ], [ [ "Fludrocortisone", "{u} may lead to a major life threatening interaction when taken with {v}", "Gemifloxacin" ], [ "Gemifloxacin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Empagliflozin" ] ], [ [ "Fludrocortisone", "{u} (Compound) resembles {v} (Compound)", "Methylprednisolone" ], [ "Methylprednisolone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Empagliflozin" ] ], [ [ "Fludrocortisone", "{u} may lead to a major life threatening interaction when taken with {v}", "Enoxacin" ], [ "Enoxacin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Empagliflozin" ] ], [ [ "Fludrocortisone", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Salbutamol" ], [ "Salbutamol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Empagliflozin" ] ] ]
Fludrocortisone (Compound) resembles Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Empagliflozin Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolol may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin Fludrocortisone may cause a minor interaction that can limit clinical effects when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Indapamide and Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Esterified estrogens and Esterified estrogens may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin Fludrocortisone may lead to a major life threatening interaction when taken with Gemifloxacin and Gemifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin Fludrocortisone (Compound) resembles Methylprednisolone (Compound) and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin Fludrocortisone may lead to a major life threatening interaction when taken with Enoxacin and Enoxacin may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin Fludrocortisone may cause a minor interaction that can limit clinical effects when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
DB01042
DB04865
1,307
4
[ "DDInter1144", "DDInter1335" ]
Melphalan
Omacetaxine mepesuccinate
Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard.[A261150, A261155] Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is also used to treat uveal melanoma with unresectable hepatic metastases.
Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the plant, Cephalotaxus species. In October 2005, omacetaxine mepesuccinate received Orphan Drug designation from the EMEA for the treatment of chronic myeloid leukemia (CML). Then in March 2006, it received Orphan Drug status from the FDA for the treatment of CML. In November 2006, omacetaxine mepesuccinate, for the treatment of CML, was granted Fast Track designation by the FDA. Most recently, in October 2012, omacetaxine mepesuccinate was marketed under the brand name Synribo and FDA approved for patients who are intolerant and/or resistant to two or more tyrosine kinase inhibitors used to treat accelerated or chronic phase CML.
Moderate
1
[ [ [ 1307, 24, 4 ] ], [ [ 1307, 7, 2969 ], [ 2969, 46, 4 ] ], [ [ 1307, 6, 17212 ], [ 17212, 57, 4 ] ], [ [ 1307, 7, 10635 ], [ 10635, 57, 4 ] ], [ [ 1307, 64, 770 ], [ 770, 24, 4 ] ], [ [ 1307, 24, 496 ], [ 496, 63, 4 ] ], [ [ 1307, 63, 66 ], [ 66, 24, 4 ] ], [ [ 1307, 24, 1532 ], [ 1532, 24, 4 ] ], [ [ 1307, 62, 168 ], [ 168, 24, 4 ] ], [ [ 1307, 25, 1292 ], [ 1292, 64, 4 ] ] ]
[ [ [ "Melphalan", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Omacetaxine mepesuccinate" ] ], [ [ "Melphalan", "{u} (Compound) upregulates {v} (Gene)", "CDKN1A" ], [ "CDKN1A", "{u} (Gene) is upregulated by {v} (Compound)", "Omacetaxine mepesuccinate" ] ], [ [ "Melphalan", "{u} (Compound) binds {v} (Gene)", "SLC7A5" ], [ "SLC7A5", "{u} (Gene) is downregulated by {v} (Compound)", "Omacetaxine mepesuccinate" ] ], [ [ "Melphalan", "{u} (Compound) upregulates {v} (Gene)", "BLCAP" ], [ "BLCAP", "{u} (Gene) is downregulated by {v} (Compound)", "Omacetaxine mepesuccinate" ] ], [ [ "Melphalan", "{u} may lead to a major life threatening interaction when taken with {v}", "Thalidomide" ], [ "Thalidomide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Omacetaxine mepesuccinate" ] ], [ [ "Melphalan", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Hepatitis A Vaccine" ], [ "Hepatitis A Vaccine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Omacetaxine mepesuccinate" ] ], [ [ "Melphalan", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Efalizumab" ], [ "Efalizumab", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Omacetaxine mepesuccinate" ] ], [ [ "Melphalan", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ifosfamide" ], [ "Ifosfamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Omacetaxine mepesuccinate" ] ], [ [ "Melphalan", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Bortezomib" ], [ "Bortezomib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Omacetaxine mepesuccinate" ] ], [ [ "Melphalan", "{u} may lead to a major life threatening interaction when taken with {v}", "Deferiprone" ], [ "Deferiprone", "{u} may lead to a major life threatening interaction when taken with {v}", "Omacetaxine mepesuccinate" ] ] ]
Melphalan (Compound) upregulates CDKN1A (Gene) and CDKN1A (Gene) is upregulated by Omacetaxine mepesuccinate (Compound) Melphalan (Compound) binds SLC7A5 (Gene) and SLC7A5 (Gene) is downregulated by Omacetaxine mepesuccinate (Compound) Melphalan (Compound) upregulates BLCAP (Gene) and BLCAP (Gene) is downregulated by Omacetaxine mepesuccinate (Compound) Melphalan may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine and Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate Melphalan may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate Melphalan may lead to a major life threatening interaction when taken with Deferiprone and Deferiprone may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate
DB00425
DB01254
558
1,213
[ "DDInter1970", "DDInter484" ]
Zolpidem
Dasatinib
Zolpidem, also known as _Ambien_, is a hypnotic drug that was initially approved by the FDA in 1992 [FDA label]. Zolpidem improves sleep in patients with insomnia. It is aimed for use in patients with difficulties initiating sleep. This drug decreases the time to fall asleep (sleep latency), increases the duration of sleep, and decreases the number of awakenings during sleep in patients with temporary (transient) insomnia. It is available in both immediate acting and extended release forms [FDA label],. Its tolerability profile is favorable when administered according to the manufacturer’s instructions, with a low risk of drug withdrawal, drug dependence, and drug tolerance. In addition, zolpidem improves sleep quality in patients suffering from chronic insomnia and can show mild muscle relaxant properties. Research also shows that zolpidem is rapid and effective in restoring brain function for patients in a vegetative state following brain injury. This drug has the propensity to completely or partially
Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeric protein BCR-ABL. BCR-ABL is associated with the uncontrolled activity of the ABL tyrosine kinase and is involved in the pathogenesis of CML and 15-30% of ALL cases.[A11377,A33432] Dasatinib also inhibits a spectrum of kinases involved in cancer, including several SRC-family kinases. Unlike [imatinib], another tyrosine kinase used for the treatment of CML and Ph-positive ALL, dasatinib inhibits the active and inactive conformations of the ABL kinase domain.[A2226,A11377] Also, mutations in the kinase domain of BCR-ABL may lead to relapse during imatinib treatment. Since dasatinib does not interact with some of the residues involved in those mutations, the use of this drug represents a therapeutic alternative for patients with cancers that have developed imatinib-resistance. The use of dasatinib was first approved by the FDA in 2006.[L45171,L45186]
Moderate
1
[ [ [ 558, 24, 1213 ] ], [ [ 558, 6, 8374 ], [ 8374, 45, 1213 ] ], [ [ 558, 21, 28882 ], [ 28882, 60, 1213 ] ], [ [ 558, 24, 1619 ], [ 1619, 63, 1213 ] ], [ [ 558, 63, 1051 ], [ 1051, 24, 1213 ] ], [ [ 558, 24, 1419 ], [ 1419, 24, 1213 ] ], [ [ 558, 24, 752 ], [ 752, 25, 1213 ] ], [ [ 558, 63, 702 ], [ 702, 25, 1213 ] ], [ [ 558, 24, 478 ], [ 478, 64, 1213 ] ], [ [ 558, 1, 24 ], [ 24, 25, 1213 ] ] ]
[ [ [ "Zolpidem", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dasatinib" ] ], [ [ "Zolpidem", "{u} (Compound) binds {v} (Gene)", "CYP3A4" ], [ "CYP3A4", "{u} (Gene) is bound by {v} (Compound)", "Dasatinib" ] ], [ [ "Zolpidem", "{u} (Compound) causes {v} (Side Effect)", "Body temperature increased" ], [ "Body temperature increased", "{u} (Side Effect) is caused by {v} (Compound)", "Dasatinib" ] ], [ [ "Zolpidem", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Rucaparib" ], [ "Rucaparib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dasatinib" ] ], [ [ "Zolpidem", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Aminoglutethimide" ], [ "Aminoglutethimide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dasatinib" ] ], [ [ "Zolpidem", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Imatinib" ], [ "Imatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dasatinib" ] ], [ [ "Zolpidem", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Cimetidine" ], [ "Cimetidine", "{u} may lead to a major life threatening interaction when taken with {v}", "Dasatinib" ] ], [ [ "Zolpidem", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Anagrelide" ], [ "Anagrelide", "{u} may lead to a major life threatening interaction when taken with {v}", "Dasatinib" ] ], [ [ "Zolpidem", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nilotinib" ], [ "Nilotinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Dasatinib" ] ], [ [ "Zolpidem", "{u} (Compound) resembles {v} (Compound)", "Tolmetin" ], [ "Tolmetin", "{u} may lead to a major life threatening interaction when taken with {v}", "Dasatinib" ] ] ]
Zolpidem (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dasatinib (Compound) Zolpidem (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Dasatinib (Compound) Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide and Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may lead to a major life threatening interaction when taken with Dasatinib Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Anagrelide and Anagrelide may lead to a major life threatening interaction when taken with Dasatinib Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may lead to a major life threatening interaction when taken with Dasatinib Zolpidem (Compound) resembles Tolmetin (Compound) and Tolmetin may lead to a major life threatening interaction when taken with Dasatinib
DB01129
DB09100
379
320
[ "DDInter1559", "DDInter1799" ]
Rabeprazole
Thyroid, porcine
Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion.
Thyroid extract is dried and powdered thyroid glands from pigs containing tiiodothyronine (T3) and thyroxine (T4) used to supplement low or absent thyroid activity.[A190831,L11755] Thyroid extract has been described in literature to treat hypothyroidism since 1891 but its use dates back as far as the 6th century. Thyroid extract is no longer considered a first line therapy as it delivers a dose that is inconsistent with the stated strength of the tablet. Currently, patients are more likely to be treated with [levothyroxine]. Thyroid extracts were never FDA approved as their use in the United States predates the FDA.
Moderate
1
[ [ [ 379, 24, 320 ] ], [ [ 379, 40, 837 ], [ 837, 24, 320 ] ], [ [ 379, 24, 428 ], [ 428, 63, 320 ] ], [ [ 379, 1, 1215 ], [ 1215, 24, 320 ] ], [ [ 379, 24, 1596 ], [ 1596, 24, 320 ] ], [ [ 379, 63, 126 ], [ 126, 24, 320 ] ], [ [ 379, 23, 16 ], [ 16, 24, 320 ] ], [ [ 379, 40, 837 ], [ 837, 24, 467 ], [ 467, 23, 320 ] ], [ [ 379, 24, 428 ], [ 428, 63, 837 ], [ 837, 24, 320 ] ], [ [ 379, 1, 1215 ], [ 1215, 63, 417 ], [ 417, 23, 320 ] ] ]
[ [ [ "Rabeprazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Thyroid, porcine" ] ], [ [ "Rabeprazole", "{u} (Compound) resembles {v} (Compound)", "Pantoprazole" ], [ "Pantoprazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Thyroid, porcine" ] ], [ [ "Rabeprazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ferrous fumarate" ], [ "Ferrous fumarate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Thyroid, porcine" ] ], [ [ "Rabeprazole", "{u} (Compound) resembles {v} (Compound)", "Lansoprazole" ], [ "Lansoprazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Thyroid, porcine" ] ], [ [ "Rabeprazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iron" ], [ "Iron", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Thyroid, porcine" ] ], [ [ "Rabeprazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Warfarin" ], [ "Warfarin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Thyroid, porcine" ] ], [ [ "Rabeprazole", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Linaclotide" ], [ "Linaclotide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Thyroid, porcine" ] ], [ [ "Rabeprazole", "{u} (Compound) resembles {v} (Compound)", "Pantoprazole" ], [ "Pantoprazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Simvastatin" ], [ "Simvastatin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Thyroid, porcine" ] ], [ [ "Rabeprazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ferrous fumarate" ], [ "Ferrous fumarate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pantoprazole" ], [ "Pantoprazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Thyroid, porcine" ] ], [ [ "Rabeprazole", "{u} (Compound) resembles {v} (Compound)", "Lansoprazole" ], [ "Lansoprazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sucralfate" ], [ "Sucralfate", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Thyroid, porcine" ] ] ]
Rabeprazole (Compound) resembles Pantoprazole (Compound) and Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Thyroid, porcine Rabeprazole may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumarate and Ferrous fumarate may cause a moderate interaction that could exacerbate diseases when taken with Thyroid, porcine Rabeprazole (Compound) resembles Lansoprazole (Compound) and Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Thyroid, porcine Rabeprazole may cause a moderate interaction that could exacerbate diseases when taken with Iron and Iron may cause a moderate interaction that could exacerbate diseases when taken with Thyroid, porcine Rabeprazole may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Thyroid, porcine Rabeprazole may cause a minor interaction that can limit clinical effects when taken with Linaclotide and Linaclotide may cause a moderate interaction that could exacerbate diseases when taken with Thyroid, porcine Rabeprazole (Compound) resembles Pantoprazole (Compound) and Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a minor interaction that can limit clinical effects when taken with Thyroid, porcine Rabeprazole may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumarate and Ferrous fumarate may cause a moderate interaction that could exacerbate diseases when taken with Pantoprazole and Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Thyroid, porcine Rabeprazole (Compound) resembles Lansoprazole (Compound) and Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Sucralfate and Sucralfate may cause a minor interaction that can limit clinical effects when taken with Thyroid, porcine
DB00404
DB09420
523
1,074
[ "DDInter54", "DDInter953" ]
Alprazolam
Iodide I-123
Alprazolam is a triazolobenzodiazepine indicated for the treatment of anxiety and panic disorders.[L34783, L34788] It is mainly metabolized by CYP3As and so is contraindicated with CYP3A inhibitors like ketoconazole and itraconazole.[L34783, L34788] Benzodiazepine treatment should be stopped gradually by tapering down a patient's dose to avoid withdrawal symptoms. Alprazolam's adverse effects are generally related to the sedation it can cause. Alprazolam has been mixed with alcohol as a drug of abuse to potentiate the sedative effects of the drug which may lead to coma and death. Alprazolam was given FDA approval on October 16, 1981.
Iodide I-123 (as sodium Iodide I-123) is a radioactive isotope of iodine used in nuclear medicine for the diagnostic study of thyroid disease. Following oral administration, I-123 is absorbed through the gastrointestinal tract and is taken up by the thyroid gland. After incorporation, a gamma camera is used to detect the decay by electron capture to tellurium-123. Iodine is commonly used in thyroid function diagnostic tests as this gland normally absorbs iodine through the diet for formation of the thyroid hormones triiodothyronine (T3) and its prohormone, thyroxine (T4). Radioactive I-123 in particular is effective for this use as its half-life of approximately 13.13 h (hours) is ideal for the 24-h (hour) iodine uptake test and it has a reduced radiation burden as compared to I-131.
Moderate
1
[ [ [ 523, 24, 1074 ] ], [ [ 523, 24, 516 ], [ 516, 24, 1074 ] ], [ [ 523, 1, 902 ], [ 902, 24, 1074 ] ], [ [ 523, 23, 251 ], [ 251, 24, 1074 ] ], [ [ 523, 40, 1382 ], [ 1382, 24, 1074 ] ], [ [ 523, 63, 1242 ], [ 1242, 24, 1074 ] ], [ [ 523, 24, 516 ], [ 516, 24, 849 ], [ 849, 24, 1074 ] ], [ [ 523, 24, 849 ], [ 849, 63, 516 ], [ 516, 24, 1074 ] ], [ [ 523, 1, 902 ], [ 902, 24, 516 ], [ 516, 24, 1074 ] ], [ [ 523, 23, 251 ], [ 251, 24, 1004 ], [ 1004, 63, 1074 ] ] ]
[ [ [ "Alprazolam", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iodide I-123" ] ], [ [ "Alprazolam", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Levocetirizine" ], [ "Levocetirizine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iodide I-123" ] ], [ [ "Alprazolam", "{u} (Compound) resembles {v} (Compound)", "Clobazam" ], [ "Clobazam", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iodide I-123" ] ], [ [ "Alprazolam", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Betamethasone" ], [ "Betamethasone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iodide I-123" ] ], [ [ "Alprazolam", "{u} (Compound) resembles {v} (Compound)", "Midazolam" ], [ "Midazolam", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iodide I-123" ] ], [ [ "Alprazolam", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Cetirizine" ], [ "Cetirizine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iodide I-123" ] ], [ [ "Alprazolam", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Levocetirizine" ], [ "Levocetirizine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mepyramine" ], [ "Mepyramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iodide I-123" ] ], [ [ "Alprazolam", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mepyramine" ], [ "Mepyramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Levocetirizine" ], [ "Levocetirizine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iodide I-123" ] ], [ [ "Alprazolam", "{u} (Compound) resembles {v} (Compound)", "Clobazam" ], [ "Clobazam", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Levocetirizine" ], [ "Levocetirizine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iodide I-123" ] ], [ [ "Alprazolam", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Betamethasone" ], [ "Betamethasone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Phenyl salicylate" ], [ "Phenyl salicylate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iodide I-123" ] ] ]
Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine and Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123 Alprazolam (Compound) resembles Clobazam (Compound) and Clobazam may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123 Alprazolam may cause a minor interaction that can limit clinical effects when taken with Betamethasone and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123 Alprazolam (Compound) resembles Midazolam (Compound) and Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123 Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123 Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine and Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123 Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine and Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123 Alprazolam (Compound) resembles Clobazam (Compound) and Clobazam may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine and Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123 Alprazolam may cause a minor interaction that can limit clinical effects when taken with Betamethasone and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Phenyl salicylate and Phenyl salicylate may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
DB00574
DB01381
121
958
[ "DDInter717", "DDInter819" ]
Fenfluramine
Ginkgo biloba
Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients typically display delayed development and neurocognitive impairment.[A214694, A214709, A214712, A214715] Fenfluramine is a serotonergic phenethylamine originally used as an appetite suppressant until concerns regarding cardiotoxicity in obese patients lead to its withdrawal from the market in 1997.[A214694, A214718, A11906] Through its ability to modulate neurotransmission, fenfluramine has reemerged as an effective therapy against pharmacoresistant seizures, such as those involved in Dravet syndrome.[A214688, A214691, A214700] Fenfluramine was granted initial FDA approval in 1973 prior to its withdrawal
_Ginkgo biloba_ extract contains a group of terpene lactones (notably, ginkgolides and diterpenes) and ginkgo flavone glycosides (notably, ginkgetin, bilobetin, and sciadopitysin) that have antioxidant and vasoactive properties. Most of the studies that investigate the effect of _ginkgo biloba_ use the standardized extract of _Ginkgo biloba_ (EGb) 761 (EGb761), which was developed by a German pharmaceutical company in 1964. EGb761 contains 6% terpene lactones and 24% flavonoid glycosides. Flavonoids include quercetin, rutin, kaempferol, and isorhamnetin. Lactones include ginkgolide A, ginkgolide B, ginkgolide C, bilobalide, and ginkgotoxin, a lactone that is structurally related to [pyridoxine]. _Ginkgo biloba_ is an herbal plant that is now cultivated worldwide. It is originally native to China, and _ginkgo biloba_ extract has been used in traditional Chinese medicine for centuries. After its nootropic properties were discovered, _ginkgo biloba_ has gained attention as a therapeutic ingredient for memory and concentration enhancement in cognitive impairment and neurogenerative diseases, such as dementia. _Ginkgo biloba_ was investigated in preliminary studies for a variety of therapeutic purposes such as improving cardiovascular health, sexual dysfunction, psychiatric disorders, skin disorders, and glaucoma. _Ginkgo biloba_ is found in a number of homeopathic and over-the-counter herbal products and dietary supplements, but it has no approved therapeutic indications by regulatory bodies, such as the FDA, EMA, and Health Canada. _Ginkgo folium_, the leaf extract of _Ginkgo biloba_, is considered an anti-dementia drug by the World Health Organization.
Moderate
1
[ [ [ 121, 24, 958 ] ], [ [ 121, 24, 1347 ], [ 1347, 24, 958 ] ], [ [ 121, 64, 73 ], [ 73, 24, 958 ] ], [ [ 121, 63, 1271 ], [ 1271, 24, 958 ] ], [ [ 121, 25, 593 ], [ 593, 24, 958 ] ], [ [ 121, 24, 792 ], [ 792, 63, 958 ] ], [ [ 121, 24, 1347 ], [ 1347, 64, 126 ], [ 126, 24, 958 ] ], [ [ 121, 24, 126 ], [ 126, 25, 1347 ], [ 1347, 24, 958 ] ], [ [ 121, 24, 1317 ], [ 1317, 63, 126 ], [ 126, 24, 958 ] ], [ [ 121, 64, 73 ], [ 73, 25, 1466 ], [ 1466, 24, 958 ] ] ]
[ [ [ "Fenfluramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ginkgo biloba" ] ], [ [ "Fenfluramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clopidogrel" ], [ "Clopidogrel", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ginkgo biloba" ] ], [ [ "Fenfluramine", "{u} may lead to a major life threatening interaction when taken with {v}", "Phentermine" ], [ "Phentermine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ginkgo biloba" ] ], [ [ "Fenfluramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Alteplase" ], [ "Alteplase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ginkgo biloba" ] ], [ [ "Fenfluramine", "{u} may lead to a major life threatening interaction when taken with {v}", "Bupropion" ], [ "Bupropion", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ginkgo biloba" ] ], [ [ "Fenfluramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Rivaroxaban" ], [ "Rivaroxaban", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ginkgo biloba" ] ], [ [ "Fenfluramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clopidogrel" ], [ "Clopidogrel", "{u} may lead to a major life threatening interaction when taken with {v}", "Warfarin" ], [ "Warfarin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ginkgo biloba" ] ], [ [ "Fenfluramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Warfarin" ], [ "Warfarin", "{u} may lead to a major life threatening interaction when taken with {v}", "Clopidogrel" ], [ "Clopidogrel", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ginkgo biloba" ] ], [ [ "Fenfluramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dipyridamole" ], [ "Dipyridamole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Warfarin" ], [ "Warfarin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ginkgo biloba" ] ], [ [ "Fenfluramine", "{u} may lead to a major life threatening interaction when taken with {v}", "Phentermine" ], [ "Phentermine", "{u} may lead to a major life threatening interaction when taken with {v}", "Phenylpropanolamine" ], [ "Phenylpropanolamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ginkgo biloba" ] ] ]
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel and Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Ginkgo biloba Fenfluramine may lead to a major life threatening interaction when taken with Phentermine and Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Ginkgo biloba Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Alteplase and Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Ginkgo biloba Fenfluramine may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Ginkgo biloba Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban and Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Ginkgo biloba Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel and Clopidogrel may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Ginkgo biloba Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may lead to a major life threatening interaction when taken with Clopidogrel and Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Ginkgo biloba Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Dipyridamole and Dipyridamole may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Ginkgo biloba Fenfluramine may lead to a major life threatening interaction when taken with Phentermine and Phentermine may lead to a major life threatening interaction when taken with Phenylpropanolamine and Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Ginkgo biloba
DB01114
DB08883
272
1,597
[ "DDInter362", "DDInter1428" ]
Chlorpheniramine
Perampanel
A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine.
Perampanel is a noncompetitive AMPA glutamate receptor antagonist. It is marketed under the name Fycompa™ and is indicated as an adjunct in patients over 12 years old for the treatment of partial-onset seizures that may or may not occur with generalized seizures. The FDA label includes an important black-boxed warning of serious or life-threatening behavioral and psychiatric reactions in patients taking Fycompa™.
Moderate
1
[ [ [ 272, 24, 1597 ] ], [ [ 272, 74, 100 ], [ 100, 24, 1597 ] ], [ [ 272, 24, 649 ], [ 649, 24, 1597 ] ], [ [ 272, 63, 104 ], [ 104, 24, 1597 ] ], [ [ 272, 24, 407 ], [ 407, 63, 1597 ] ], [ [ 272, 74, 100 ], [ 100, 24, 649 ], [ 649, 24, 1597 ] ], [ [ 272, 24, 649 ], [ 649, 63, 100 ], [ 100, 24, 1597 ] ], [ [ 272, 63, 104 ], [ 104, 63, 100 ], [ 100, 24, 1597 ] ], [ [ 272, 24, 868 ], [ 868, 64, 609 ], [ 609, 23, 1597 ] ], [ [ 272, 24, 1264 ], [ 1264, 24, 609 ], [ 609, 23, 1597 ] ] ]
[ [ [ "Chlorpheniramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Perampanel" ] ], [ [ "Chlorpheniramine", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brompheniramine" ], [ "Brompheniramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Perampanel" ] ], [ [ "Chlorpheniramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clofedanol" ], [ "Clofedanol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Perampanel" ] ], [ [ "Chlorpheniramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Methdilazine" ], [ "Methdilazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Perampanel" ] ], [ [ "Chlorpheniramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Opium" ], [ "Opium", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Perampanel" ] ], [ [ "Chlorpheniramine", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brompheniramine" ], [ "Brompheniramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clofedanol" ], [ "Clofedanol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Perampanel" ] ], [ [ "Chlorpheniramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clofedanol" ], [ "Clofedanol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brompheniramine" ], [ "Brompheniramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Perampanel" ] ], [ [ "Chlorpheniramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Methdilazine" ], [ "Methdilazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brompheniramine" ], [ "Brompheniramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Perampanel" ] ], [ [ "Chlorpheniramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Vemurafenib" ], [ "Vemurafenib", "{u} may lead to a major life threatening interaction when taken with {v}", "Clarithromycin" ], [ "Clarithromycin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Perampanel" ] ], [ [ "Chlorpheniramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Doxepin" ], [ "Doxepin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clarithromycin" ], [ "Clarithromycin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Perampanel" ] ] ]
Chlorpheniramine (Compound) resembles Brompheniramine (Compound) and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Perampanel Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Perampanel Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Perampanel Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Perampanel Chlorpheniramine (Compound) resembles Brompheniramine (Compound) and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Perampanel Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Perampanel Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Perampanel Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Perampanel Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Perampanel
DB01197
DB09268
1,603
1,662
[ "DDInter292", "DDInter1464" ]
Captopril
Picosulfuric acid
Captopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Captopril may be used in the treatment of hypertension.
Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been used in European countries for many years.
Moderate
1
[ [ [ 1603, 24, 1662 ] ], [ [ 1603, 24, 708 ], [ 708, 24, 1662 ] ], [ [ 1603, 63, 1573 ], [ 1573, 24, 1662 ] ], [ [ 1603, 24, 407 ], [ 407, 63, 1662 ] ], [ [ 1603, 40, 610 ], [ 610, 24, 1662 ] ], [ [ 1603, 24, 708 ], [ 708, 63, 997 ], [ 997, 24, 1662 ] ], [ [ 1603, 63, 1573 ], [ 1573, 24, 1482 ], [ 1482, 23, 1662 ] ], [ [ 1603, 63, 912 ], [ 912, 24, 484 ], [ 484, 63, 1662 ] ], [ [ 1603, 24, 820 ], [ 820, 74, 1164 ], [ 1164, 24, 1662 ] ], [ [ 1603, 63, 1512 ], [ 1512, 23, 16 ], [ 16, 23, 1662 ] ] ]
[ [ [ "Captopril", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Picosulfuric acid" ] ], [ [ "Captopril", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Corticotropin" ], [ "Corticotropin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Picosulfuric acid" ] ], [ [ "Captopril", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Prednisone" ], [ "Prednisone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Picosulfuric acid" ] ], [ [ "Captopril", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Opium" ], [ "Opium", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Picosulfuric acid" ] ], [ [ "Captopril", "{u} (Compound) resembles {v} (Compound)", "Enalapril" ], [ "Enalapril", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Picosulfuric acid" ] ], [ [ "Captopril", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Corticotropin" ], [ "Corticotropin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Methazolamide" ], [ "Methazolamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Picosulfuric acid" ] ], [ [ "Captopril", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Prednisone" ], [ "Prednisone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Digitoxin" ], [ "Digitoxin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Picosulfuric acid" ] ], [ [ "Captopril", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Interferon beta-1a" ], [ "Interferon beta-1a", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Entrectinib" ], [ "Entrectinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Picosulfuric acid" ] ], [ [ "Captopril", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Alimemazine" ], [ "Alimemazine", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Trimipramine" ], [ "Trimipramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Picosulfuric acid" ] ], [ [ "Captopril", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Diclofenac" ], [ "Diclofenac", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Linaclotide" ], [ "Linaclotide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Picosulfuric acid" ] ] ]
Captopril may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin and Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid Captopril may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid Captopril may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid Captopril (Compound) resembles Enalapril (Compound) and Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid Captopril may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin and Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Methazolamide and Methazolamide may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid Captopril may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Digitoxin and Digitoxin may cause a minor interaction that can limit clinical effects when taken with Picosulfuric acid Captopril may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid Captopril may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine (Compound) resembles Trimipramine (Compound) and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine and Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid Captopril may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a minor interaction that can limit clinical effects when taken with Linaclotide and Linaclotide may cause a minor interaction that can limit clinical effects when taken with Picosulfuric acid
DB00656
DB00692
827
274
[ "DDInter1851", "DDInter1448" ]
Trazodone
Phentolamine
Trazodone is triazolopyridine derivative from the serotonin receptor antagonists and reuptake inhibitors (SARIs) class of antidepressants. It is used in adults and has been shown to be comparable in efficacy to other drugs such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and serotonin-norepinephrine receptor inhibitor (SNRIs) in the treatment of depression. A unique feature of this drug is that it does not promote the anxiety symptoms, sexual symptoms, or insomnia, which are commonly associated with SSRI and SNRI therapy. Trazodone acts on various receptors, including certain histamine, serotonin, and adrenergic receptors, distinguishing it from other antidepressants that cover a narrow range of neurotransmitters. It was initially granted FDA approval in 1981.
Phentolamine is a reversible, non-selective alpha-adrenergic blocker that induces vasodilation. While initially introduced to the market for the treatment of hypertension, this clinical use was halted due to cardiovascular and gastrointestinal adverse effects with the prolonged use of large oral doses of phentolamine.[A261781, A261786] It has several therapeutic uses, including the treatment of hypertensive episodes, prevention of norepinephrine-induced extravasation, diagnosis of pheochromocytoma, reversal of soft-tissue anesthesia, and treatment of pharmacologically-induced mydriasis.[L48420, L48415, L48390] Phentolamine is administered intravenously, intramuscularly, submucosally, and topically.
Moderate
1
[ [ [ 827, 24, 274 ] ], [ [ 827, 6, 5372 ], [ 5372, 45, 274 ] ], [ [ 827, 21, 29118 ], [ 29118, 60, 274 ] ], [ [ 827, 40, 695 ], [ 695, 24, 274 ] ], [ [ 827, 63, 530 ], [ 530, 24, 274 ] ], [ [ 827, 24, 104 ], [ 104, 63, 274 ] ], [ [ 827, 40, 851 ], [ 851, 63, 274 ] ], [ [ 827, 25, 1053 ], [ 1053, 63, 274 ] ], [ [ 827, 1, 252 ], [ 252, 24, 274 ] ], [ [ 827, 1, 623 ], [ 623, 63, 274 ] ] ]
[ [ [ "Trazodone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Phentolamine" ] ], [ [ "Trazodone", "{u} (Compound) binds {v} (Gene)", "ADRA2A" ], [ "ADRA2A", "{u} (Gene) is bound by {v} (Compound)", "Phentolamine" ] ], [ [ "Trazodone", "{u} (Compound) causes {v} (Side Effect)", "Tachycardia" ], [ "Tachycardia", "{u} (Side Effect) is caused by {v} (Compound)", "Phentolamine" ] ], [ [ "Trazodone", "{u} (Compound) resembles {v} (Compound)", "Clozapine" ], [ "Clozapine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Phentolamine" ] ], [ [ "Trazodone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dronabinol" ], [ "Dronabinol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Phentolamine" ] ], [ [ "Trazodone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Methdilazine" ], [ "Methdilazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Phentolamine" ] ], [ [ "Trazodone", "{u} (Compound) resembles {v} (Compound)", "Nefazodone" ], [ "Nefazodone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Phentolamine" ] ], [ [ "Trazodone", "{u} may lead to a major life threatening interaction when taken with {v}", "Procarbazine" ], [ "Procarbazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Phentolamine" ] ], [ [ "Trazodone", "{u} (Compound) resembles {v} (Compound)", "Hydroxyzine" ], [ "Hydroxyzine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Phentolamine" ] ], [ [ "Trazodone", "{u} (Compound) resembles {v} (Compound)", "Quetiapine" ], [ "Quetiapine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Phentolamine" ] ] ]
Trazodone (Compound) binds ADRA2A (Gene) and ADRA2A (Gene) is bound by Phentolamine (Compound) Trazodone (Compound) causes Tachycardia (Side Effect) and Tachycardia (Side Effect) is caused by Phentolamine (Compound) Trazodone (Compound) resembles Clozapine (Compound) and Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Phentolamine Trazodone may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Phentolamine Trazodone may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Phentolamine Trazodone (Compound) resembles Nefazodone (Compound) and Nefazodone may cause a moderate interaction that could exacerbate diseases when taken with Phentolamine Trazodone may lead to a major life threatening interaction when taken with Procarbazine and Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Phentolamine Trazodone (Compound) resembles Hydroxyzine (Compound) and Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Phentolamine Trazodone (Compound) resembles Quetiapine (Compound) and Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Phentolamine
DB01081
DB11823
1,688
858
[ "DDInter571", "DDInter673" ]
Diphenoxylate
Esketamine
A meperidine congener used as an antidiarrheal, usually in combination with atropine. At high doses, it acts like morphine. Its unesterified metabolite difenoxin has similar properties and is used similarly. It has little or no analgesic activity. This medication is classified as a Schedule V under the Controlled Substances Act by the Food and Drug Administration (FDA) and the DEA in the United States when used in preparations. When diphenoxylate is used alone, it is classified as a Schedule II.
Major depressive disorder (MDD) is a significant cause of disability worldwide and the most common illness preceding suicide.[L5596,A175462] On March 5, 2019, the nasal spray drug, _esketamine_, also known as _Spravato_ (by Janssen Pharmaceuticals), was approved by the FDA for treatment-resistant major depression. Esketamine is the s-enantiomer of [Ketamine]. Ketamine is a mixture of two enantiomers (mirror image molecules). This is the first time that the FDA has approved esketamine for any use. The FDA approved ketamine (Ketalar) in 1970. Esketamine may prove to be a promising treatment for patients diagnosed with major depressive disorder who have not experienced an improvement in symptoms despite treatment with various medications and therapies. The intranasal route of administration for this drug allows for easy administration and a fast onset of action, which sets it apart from many other antidepressant agents that may take several weeks to take effect.
Moderate
1
[ [ [ 1688, 24, 858 ] ], [ [ 1688, 63, 506 ], [ 506, 24, 858 ] ], [ [ 1688, 40, 1118 ], [ 1118, 24, 858 ] ], [ [ 1688, 24, 1609 ], [ 1609, 24, 858 ] ], [ [ 1688, 40, 1048 ], [ 1048, 25, 858 ] ], [ [ 1688, 63, 506 ], [ 506, 24, 272 ], [ 272, 24, 858 ] ], [ [ 1688, 63, 1594 ], [ 1594, 35, 272 ], [ 272, 24, 858 ] ], [ [ 1688, 40, 1118 ], [ 1118, 63, 506 ], [ 506, 24, 858 ] ], [ [ 1688, 24, 1609 ], [ 1609, 63, 272 ], [ 272, 24, 858 ] ], [ [ 1688, 40, 543 ], [ 543, 24, 272 ], [ 272, 24, 858 ] ] ]
[ [ [ "Diphenoxylate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Esketamine" ] ], [ [ "Diphenoxylate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dextromethorphan" ], [ "Dextromethorphan", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Esketamine" ] ], [ [ "Diphenoxylate", "{u} (Compound) resembles {v} (Compound)", "Difenoxin" ], [ "Difenoxin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Esketamine" ] ], [ [ "Diphenoxylate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pentoxyverine" ], [ "Pentoxyverine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Esketamine" ] ], [ [ "Diphenoxylate", "{u} (Compound) resembles {v} (Compound)", "Doxapram" ], [ "Doxapram", "{u} may lead to a major life threatening interaction when taken with {v}", "Esketamine" ] ], [ [ "Diphenoxylate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dextromethorphan" ], [ "Dextromethorphan", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Chlorpheniramine" ], [ "Chlorpheniramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Esketamine" ] ], [ [ "Diphenoxylate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Doxylamine" ], [ "Doxylamine", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Chlorpheniramine" ], [ "Chlorpheniramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Esketamine" ] ], [ [ "Diphenoxylate", "{u} (Compound) resembles {v} (Compound)", "Difenoxin" ], [ "Difenoxin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dextromethorphan" ], [ "Dextromethorphan", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Esketamine" ] ], [ [ "Diphenoxylate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pentoxyverine" ], [ "Pentoxyverine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Chlorpheniramine" ], [ "Chlorpheniramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Esketamine" ] ], [ [ "Diphenoxylate", "{u} (Compound) resembles {v} (Compound)", "Loperamide" ], [ "Loperamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Chlorpheniramine" ], [ "Chlorpheniramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Esketamine" ] ] ]
Diphenoxylate may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Esketamine Diphenoxylate (Compound) resembles Difenoxin (Compound) and Difenoxin may cause a moderate interaction that could exacerbate diseases when taken with Esketamine Diphenoxylate may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine and Pentoxyverine may cause a moderate interaction that could exacerbate diseases when taken with Esketamine Diphenoxylate (Compound) resembles Doxapram (Compound) and Doxapram may lead to a major life threatening interaction when taken with Esketamine Diphenoxylate may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Esketamine Diphenoxylate may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine (Compound) resembles Chlorpheniramine (Compound) and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Esketamine Diphenoxylate (Compound) resembles Difenoxin (Compound) and Difenoxin may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Esketamine Diphenoxylate may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine and Pentoxyverine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Esketamine Diphenoxylate (Compound) resembles Loperamide (Compound) and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Esketamine
DB00570
DB01229
147
973
[ "DDInter1936", "DDInter1377" ]
Vinblastine
Paclitaxel
Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)
Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.
Moderate
1
[ [ [ 147, 24, 973 ] ], [ [ 147, 24, 310 ], [ 310, 63, 973 ] ], [ [ 147, 5, 11579 ], [ 11579, 44, 973 ] ], [ [ 147, 6, 8374 ], [ 8374, 45, 973 ] ], [ [ 147, 34, 4944 ], [ 4944, 45, 973 ] ], [ [ 147, 7, 6602 ], [ 6602, 46, 973 ] ], [ [ 147, 18, 5117 ], [ 5117, 57, 973 ] ], [ [ 147, 7, 19811 ], [ 19811, 57, 973 ] ], [ [ 147, 21, 28822 ], [ 28822, 60, 973 ] ], [ [ 147, 23, 945 ], [ 945, 23, 973 ] ] ]
[ [ [ "Vinblastine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Paclitaxel" ] ], [ [ "Vinblastine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Cabazitaxel" ], [ "Cabazitaxel", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Paclitaxel" ] ], [ [ "Vinblastine", "{u} (Compound) treats {v} (Disease)", "breast cancer" ], [ "breast cancer", "{u} (Disease) is treated by {v} (Compound)", "Paclitaxel" ] ], [ [ "Vinblastine", "{u} (Compound) binds {v} (Gene)", "CYP3A4" ], [ "CYP3A4", "{u} (Gene) is bound by {v} (Compound)", "Paclitaxel" ] ], [ [ "Vinblastine", "{u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene)", "TUBB2A" ], [ "TUBB2A", "{u} (Gene) is bound by {v} (Compound)", "Paclitaxel" ] ], [ [ "Vinblastine", "{u} (Compound) upregulates {v} (Gene)", "LBR" ], [ "LBR", "{u} (Gene) is upregulated by {v} (Compound)", "Paclitaxel" ] ], [ [ "Vinblastine", "{u} (Compound) downregulates {v} (Gene)", "RAD9A" ], [ "RAD9A", "{u} (Gene) is downregulated by {v} (Compound)", "Paclitaxel" ] ], [ [ "Vinblastine", "{u} (Compound) upregulates {v} (Gene)", "MLLT11" ], [ "MLLT11", "{u} (Gene) is downregulated by {v} (Compound)", "Paclitaxel" ] ], [ [ "Vinblastine", "{u} (Compound) causes {v} (Side Effect)", "Alopecia" ], [ "Alopecia", "{u} (Side Effect) is caused by {v} (Compound)", "Paclitaxel" ] ], [ [ "Vinblastine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Sparfloxacin" ], [ "Sparfloxacin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Paclitaxel" ] ] ]
Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel Vinblastine (Compound) treats breast cancer (Disease) and breast cancer (Disease) is treated by Paclitaxel (Compound) Vinblastine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Paclitaxel (Compound) Vinblastine (Compound) binds TUBB2A (Gene) and Vinblastine (Compound) upregulates TUBB2A (Gene) and TUBB2A (Gene) is bound by Paclitaxel (Compound) Vinblastine (Compound) upregulates LBR (Gene) and LBR (Gene) is upregulated by Paclitaxel (Compound) Vinblastine (Compound) downregulates RAD9A (Gene) and RAD9A (Gene) is downregulated by Paclitaxel (Compound) Vinblastine (Compound) upregulates MLLT11 (Gene) and MLLT11 (Gene) is downregulated by Paclitaxel (Compound) Vinblastine (Compound) causes Alopecia (Side Effect) and Alopecia (Side Effect) is caused by Paclitaxel (Compound) Vinblastine may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin and Sparfloxacin may cause a minor interaction that can limit clinical effects when taken with Paclitaxel
DB01009
DB01191
935
1,039
[ "DDInter1009", "DDInter518" ]
Ketoprofen
Dexfenfluramine
Ketoprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties.
Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was withdrawn.
Moderate
1
[ [ [ 935, 24, 1039 ] ], [ [ 935, 6, 6017 ], [ 6017, 45, 1039 ] ], [ [ 935, 24, 1046 ], [ 1046, 63, 1039 ] ], [ [ 935, 25, 500 ], [ 500, 63, 1039 ] ], [ [ 935, 63, 702 ], [ 702, 24, 1039 ] ], [ [ 935, 24, 477 ], [ 477, 24, 1039 ] ], [ [ 935, 40, 886 ], [ 886, 24, 1039 ] ], [ [ 935, 64, 834 ], [ 834, 24, 1039 ] ], [ [ 935, 75, 126 ], [ 126, 24, 1039 ] ], [ [ 935, 24, 222 ], [ 222, 25, 1039 ] ] ]
[ [ [ "Ketoprofen", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dexfenfluramine" ] ], [ [ "Ketoprofen", "{u} (Compound) binds {v} (Gene)", "CYP2C9" ], [ "CYP2C9", "{u} (Gene) is bound by {v} (Compound)", "Dexfenfluramine" ] ], [ [ "Ketoprofen", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Caplacizumab" ], [ "Caplacizumab", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dexfenfluramine" ] ], [ [ "Ketoprofen", "{u} may lead to a major life threatening interaction when taken with {v}", "Enoxaparin" ], [ "Enoxaparin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dexfenfluramine" ] ], [ [ "Ketoprofen", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Anagrelide" ], [ "Anagrelide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dexfenfluramine" ] ], [ [ "Ketoprofen", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Cilostazol" ], [ "Cilostazol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dexfenfluramine" ] ], [ [ "Ketoprofen", "{u} (Compound) resembles {v} (Compound)", "Ketorolac" ], [ "Ketorolac", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dexfenfluramine" ] ], [ [ "Ketoprofen", "{u} may lead to a major life threatening interaction when taken with {v}", "Drotrecogin alfa" ], [ "Drotrecogin alfa", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dexfenfluramine" ] ], [ [ "Ketoprofen", "{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}", "Warfarin" ], [ "Warfarin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dexfenfluramine" ] ], [ [ "Ketoprofen", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sibutramine" ], [ "Sibutramine", "{u} may lead to a major life threatening interaction when taken with {v}", "Dexfenfluramine" ] ] ]
Ketoprofen (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Dexfenfluramine (Compound) Ketoprofen may cause a moderate interaction that could exacerbate diseases when taken with Caplacizumab and Caplacizumab may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine Ketoprofen may lead to a major life threatening interaction when taken with Enoxaparin and Enoxaparin may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine Ketoprofen may cause a moderate interaction that could exacerbate diseases when taken with Anagrelide and Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine Ketoprofen may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol and Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine Ketoprofen (Compound) resembles Ketorolac (Compound) and Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine Ketoprofen may lead to a major life threatening interaction when taken with Drotrecogin alfa and Drotrecogin alfa may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine Ketoprofen (Compound) resembles Warfarin (Compound) and Ketoprofen may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine Ketoprofen may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may lead to a major life threatening interaction when taken with Dexfenfluramine
DB08896
DB09049
292
1,135
[ "DDInter1576", "DDInter1261" ]
Regorafenib
Naloxegol
Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017.
Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. The advantage of naloxegol over the opioid antagonist naloxone is that its PEGylated structure allows for high selectivity for peripheral opioid receptors and lack of entry into the central nervous system through the blood-brain barrier.
Minor
0
[ [ [ 292, 23, 1135 ] ], [ [ 292, 64, 1618 ], [ 1618, 23, 1135 ] ], [ [ 292, 40, 79 ], [ 79, 23, 1135 ] ], [ [ 292, 63, 529 ], [ 529, 23, 1135 ] ], [ [ 292, 25, 1456 ], [ 1456, 62, 1135 ] ], [ [ 292, 24, 1033 ], [ 1033, 62, 1135 ] ], [ [ 292, 25, 1468 ], [ 1468, 23, 1135 ] ], [ [ 292, 24, 1654 ], [ 1654, 63, 1135 ] ], [ [ 292, 25, 1598 ], [ 1598, 63, 1135 ] ], [ [ 292, 63, 267 ], [ 267, 24, 1135 ] ] ]
[ [ [ "Regorafenib", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Naloxegol" ] ], [ [ "Regorafenib", "{u} may lead to a major life threatening interaction when taken with {v}", "Cabozantinib" ], [ "Cabozantinib", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Naloxegol" ] ], [ [ "Regorafenib", "{u} (Compound) resembles {v} (Compound)", "Sorafenib" ], [ "Sorafenib", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Naloxegol" ] ], [ [ "Regorafenib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fluvoxamine" ], [ "Fluvoxamine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Naloxegol" ] ], [ [ "Regorafenib", "{u} may lead to a major life threatening interaction when taken with {v}", "Venetoclax" ], [ "Venetoclax", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Naloxegol" ] ], [ [ "Regorafenib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Alpelisib" ], [ "Alpelisib", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Naloxegol" ] ], [ [ "Regorafenib", "{u} may lead to a major life threatening interaction when taken with {v}", "Ponatinib" ], [ "Ponatinib", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Naloxegol" ] ], [ [ "Regorafenib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Somapacitan" ], [ "Somapacitan", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Naloxegol" ] ], [ [ "Regorafenib", "{u} may lead to a major life threatening interaction when taken with {v}", "Tazemetostat" ], [ "Tazemetostat", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Naloxegol" ] ], [ [ "Regorafenib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Naltrexone" ], [ "Naltrexone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Naloxegol" ] ] ]
Regorafenib may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol Regorafenib (Compound) resembles Sorafenib (Compound) and Sorafenib may cause a minor interaction that can limit clinical effects when taken with Naloxegol Regorafenib may cause a moderate interaction that could exacerbate diseases when taken with Fluvoxamine and Fluvoxamine may cause a minor interaction that can limit clinical effects when taken with Naloxegol Regorafenib may lead to a major life threatening interaction when taken with Venetoclax and Venetoclax may cause a minor interaction that can limit clinical effects when taken with Naloxegol Regorafenib may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Alpelisib may cause a minor interaction that can limit clinical effects when taken with Naloxegol Regorafenib may lead to a major life threatening interaction when taken with Ponatinib and Ponatinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol Regorafenib may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan and Somapacitan may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol Regorafenib may lead to a major life threatening interaction when taken with Tazemetostat and Tazemetostat may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol Regorafenib may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol
DB00029
DB00712
25
1,274
[ "DDInter99", "DDInter763" ]
Anistreplase
Flurbiprofen
Human tissue plasminogen activator, purified, glycosylated, 527 residues purified from CHO cells. Eminase is a lyophilized (freeze-dried) formulation of anistreplase, the p-anisoyl derivative of the primary Lys-plasminogen-streptokinase activator complex (a complex of Lys-plasminogen and streptokinase). A p-anisoyl group is chemically conjugated to a complex of bacterial-derived streptokinase and human Plasma-derived Lys-plasminogen proteins.
Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically prior to ocular surgery to prevent or reduce intraoperative miosis. Flurbiprofen is structurally and pharmacologically related to fenoprofen, ibuprofen, and ketoprofen.
Moderate
1
[ [ [ 25, 24, 1274 ] ], [ [ 25, 24, 935 ], [ 935, 63, 1274 ] ], [ [ 25, 23, 297 ], [ 297, 62, 1274 ] ], [ [ 25, 24, 529 ], [ 529, 24, 1274 ] ], [ [ 25, 25, 366 ], [ 366, 24, 1274 ] ], [ [ 25, 64, 942 ], [ 942, 24, 1274 ] ], [ [ 25, 25, 936 ], [ 936, 63, 1274 ] ], [ [ 25, 25, 365 ], [ 365, 64, 1274 ] ], [ [ 25, 24, 886 ], [ 886, 25, 1274 ] ], [ [ 25, 25, 553 ], [ 553, 25, 1274 ] ] ]
[ [ [ "Anistreplase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Flurbiprofen" ] ], [ [ "Anistreplase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ketoprofen" ], [ "Ketoprofen", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Flurbiprofen" ] ], [ [ "Anistreplase", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Clove" ], [ "Clove", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Flurbiprofen" ] ], [ [ "Anistreplase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fluvoxamine" ], [ "Fluvoxamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Flurbiprofen" ] ], [ [ "Anistreplase", "{u} may lead to a major life threatening interaction when taken with {v}", "Eptifibatide" ], [ "Eptifibatide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Flurbiprofen" ] ], [ [ "Anistreplase", "{u} may lead to a major life threatening interaction when taken with {v}", "Bivalirudin" ], [ "Bivalirudin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Flurbiprofen" ] ], [ [ "Anistreplase", "{u} may lead to a major life threatening interaction when taken with {v}", "Cangrelor" ], [ "Cangrelor", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Flurbiprofen" ] ], [ [ "Anistreplase", "{u} may lead to a major life threatening interaction when taken with {v}", "Dalteparin" ], [ "Dalteparin", "{u} may lead to a major life threatening interaction when taken with {v}", "Flurbiprofen" ] ], [ [ "Anistreplase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ketorolac" ], [ "Ketorolac", "{u} may lead to a major life threatening interaction when taken with {v}", "Flurbiprofen" ] ], [ [ "Anistreplase", "{u} may lead to a major life threatening interaction when taken with {v}", "Fondaparinux" ], [ "Fondaparinux", "{u} may lead to a major life threatening interaction when taken with {v}", "Flurbiprofen" ] ] ]
Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Ketoprofen and Ketoprofen may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen Anistreplase may cause a minor interaction that can limit clinical effects when taken with Clove and Clove may cause a minor interaction that can limit clinical effects when taken with Flurbiprofen Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Fluvoxamine and Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen Anistreplase may lead to a major life threatening interaction when taken with Eptifibatide and Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen Anistreplase may lead to a major life threatening interaction when taken with Bivalirudin and Bivalirudin may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen Anistreplase may lead to a major life threatening interaction when taken with Cangrelor and Cangrelor may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen Anistreplase may lead to a major life threatening interaction when taken with Dalteparin and Dalteparin may lead to a major life threatening interaction when taken with Flurbiprofen Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Ketorolac and Ketorolac may lead to a major life threatening interaction when taken with Flurbiprofen Anistreplase may lead to a major life threatening interaction when taken with Fondaparinux and Fondaparinux may lead to a major life threatening interaction when taken with Flurbiprofen
DB00599
DB06282
682
516
[ "DDInter1795", "DDInter1053" ]
Thiopental
Levocetirizine
A barbiturate that is administered intravenously for the induction of general anesthesia or for the production of complete anesthesia of short duration. It is also used for hypnosis and for the control of convulsive states. It has been used in neurosurgical patients to reduce increased intracranial pressure. It does not produce any excitation but has poor analgesic and muscle relaxant properties. Small doses have been shown to be anti-analgesic and lower the pain threshold. (From Martindale, The Extra Pharmacopoeia, 30th ed, p920)
Levocetirizine is a selective histamine H<sub>1</sub> antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine]. Levocetirizine has greater affinity for the histamine H<sub>1</sub> receptor than cetirizine. Levocetirizine was granted FDA approval in 1995.
Moderate
1
[ [ [ 682, 24, 516 ] ], [ [ 682, 63, 1031 ], [ 1031, 23, 516 ] ], [ [ 682, 24, 1074 ], [ 1074, 63, 516 ] ], [ [ 682, 63, 701 ], [ 701, 24, 516 ] ], [ [ 682, 24, 649 ], [ 649, 24, 516 ] ], [ [ 682, 23, 401 ], [ 401, 24, 516 ] ], [ [ 682, 40, 536 ], [ 536, 24, 516 ] ], [ [ 682, 63, 1031 ], [ 1031, 24, 697 ], [ 697, 24, 516 ] ], [ [ 682, 24, 1074 ], [ 1074, 63, 701 ], [ 701, 24, 516 ] ], [ [ 682, 63, 701 ], [ 701, 23, 771 ], [ 771, 62, 516 ] ] ]
[ [ [ "Thiopental", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Levocetirizine" ] ], [ [ "Thiopental", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Theophylline" ], [ "Theophylline", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Levocetirizine" ] ], [ [ "Thiopental", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iodide I-123" ], [ "Iodide I-123", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Levocetirizine" ] ], [ [ "Thiopental", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clemastine" ], [ "Clemastine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Levocetirizine" ] ], [ [ "Thiopental", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clofedanol" ], [ "Clofedanol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Levocetirizine" ] ], [ [ "Thiopental", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Promethazine" ], [ "Promethazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Levocetirizine" ] ], [ [ "Thiopental", "{u} (Compound) resembles {v} (Compound)", "Secobarbital" ], [ "Secobarbital", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Levocetirizine" ] ], [ [ "Thiopental", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Theophylline" ], [ "Theophylline", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Phenobarbital" ], [ "Phenobarbital", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Levocetirizine" ] ], [ [ "Thiopental", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iodide I-123" ], [ "Iodide I-123", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clemastine" ], [ "Clemastine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Levocetirizine" ] ], [ [ "Thiopental", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clemastine" ], [ "Clemastine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Hyaluronidase" ], [ "Hyaluronidase", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Levocetirizine" ] ] ]
Thiopental may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a minor interaction that can limit clinical effects when taken with Levocetirizine Thiopental may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123 and Iodide I-123 may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine Thiopental may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine Thiopental may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine Thiopental may cause a minor interaction that can limit clinical effects when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine Thiopental (Compound) resembles Secobarbital (Compound) and Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine Thiopental may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital and Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine Thiopental may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123 and Iodide I-123 may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine Thiopental may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase and Hyaluronidase may cause a minor interaction that can limit clinical effects when taken with Levocetirizine
DB04938
DB08889
1,423
350
[ "DDInter1353", "DDInter299" ]
Ospemifene
Carfilzomib
Ospemifene is a new selective non-hormonal estrogen receptor modulator (SERM) that is used for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause. FDA approved on February 26, 2013.
Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.
Major
2
[ [ [ 1423, 25, 350 ] ], [ [ 1423, 21, 28785 ], [ 28785, 60, 350 ] ], [ [ 1423, 63, 522 ], [ 522, 24, 350 ] ], [ [ 1423, 64, 770 ], [ 770, 24, 350 ] ], [ [ 1423, 24, 384 ], [ 384, 63, 350 ] ], [ [ 1423, 24, 687 ], [ 687, 64, 350 ] ], [ [ 1423, 74, 888 ], [ 888, 25, 350 ] ], [ [ 1423, 24, 1514 ], [ 1514, 25, 350 ] ], [ [ 1423, 64, 335 ], [ 335, 25, 350 ] ], [ [ 1423, 21, 28785 ], [ 28785, 60, 724 ], [ 724, 1, 350 ] ] ]
[ [ [ "Ospemifene", "{u} may lead to a major life threatening interaction when taken with {v}", "Carfilzomib" ] ], [ [ "Ospemifene", "{u} (Compound) causes {v} (Side Effect)", "Muscle spasms" ], [ "Muscle spasms", "{u} (Side Effect) is caused by {v} (Compound)", "Carfilzomib" ] ], [ [ "Ospemifene", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Zafirlukast" ], [ "Zafirlukast", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Carfilzomib" ] ], [ [ "Ospemifene", "{u} may lead to a major life threatening interaction when taken with {v}", "Thalidomide" ], [ "Thalidomide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Carfilzomib" ] ], [ [ "Ospemifene", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Idelalisib" ], [ "Idelalisib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Carfilzomib" ] ], [ [ "Ospemifene", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Conestat alfa" ], [ "Conestat alfa", "{u} may lead to a major life threatening interaction when taken with {v}", "Carfilzomib" ] ], [ [ "Ospemifene", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tamoxifen" ], [ "Tamoxifen", "{u} may lead to a major life threatening interaction when taken with {v}", "Carfilzomib" ] ], [ [ "Ospemifene", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Human C1-esterase inhibitor" ], [ "Human C1-esterase inhibitor", "{u} may lead to a major life threatening interaction when taken with {v}", "Carfilzomib" ] ], [ [ "Ospemifene", "{u} may lead to a major life threatening interaction when taken with {v}", "Tranexamic acid" ], [ "Tranexamic acid", "{u} may lead to a major life threatening interaction when taken with {v}", "Carfilzomib" ] ], [ [ "Ospemifene", "{u} (Compound) causes {v} (Side Effect)", "Muscle spasms" ], [ "Muscle spasms", "{u} (Side Effect) is caused by {v} (Compound)", "Ritonavir" ], [ "Ritonavir", "{u} (Compound) resembles {v} (Compound)", "Carfilzomib" ] ] ]
Ospemifene (Compound) causes Muscle spasms (Side Effect) and Muscle spasms (Side Effect) is caused by Carfilzomib (Compound) Ospemifene may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast and Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib Ospemifene may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib Ospemifene may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib Ospemifene may cause a moderate interaction that could exacerbate diseases when taken with Conestat alfa and Conestat alfa may lead to a major life threatening interaction when taken with Carfilzomib Ospemifene (Compound) resembles Tamoxifen (Compound) and Ospemifene may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may lead to a major life threatening interaction when taken with Carfilzomib Ospemifene may cause a moderate interaction that could exacerbate diseases when taken with Human C1-esterase inhibitor and Human C1-esterase inhibitor may lead to a major life threatening interaction when taken with Carfilzomib Ospemifene may lead to a major life threatening interaction when taken with Tranexamic acid and Tranexamic acid may lead to a major life threatening interaction when taken with Carfilzomib Ospemifene (Compound) causes Muscle spasms (Side Effect) and Muscle spasms (Side Effect) is caused by Ritonavir (Compound) and Ritonavir (Compound) resembles Carfilzomib (Compound)
DB01253
DB12267
628
1,476
[ "DDInter664", "DDInter233" ]
Ergometrine
Brigatinib
An ergot alkaloid with uterine and vascular smooth muscle contractile properties.
Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a pivotal player in the transformation of susceptible lung parenchyma. Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017.
Moderate
1
[ [ [ 628, 24, 1476 ] ], [ [ 628, 63, 629 ], [ 629, 24, 1476 ] ], [ [ 628, 24, 951 ], [ 951, 24, 1476 ] ], [ [ 628, 1, 588 ], [ 588, 24, 1476 ] ], [ [ 628, 24, 982 ], [ 982, 63, 1476 ] ], [ [ 628, 24, 129 ], [ 129, 25, 1476 ] ], [ [ 628, 25, 384 ], [ 384, 25, 1476 ] ], [ [ 628, 63, 600 ], [ 600, 25, 1476 ] ], [ [ 628, 64, 609 ], [ 609, 25, 1476 ] ], [ [ 628, 24, 283 ], [ 283, 64, 1476 ] ] ]
[ [ [ "Ergometrine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brigatinib" ] ], [ [ "Ergometrine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sirolimus" ], [ "Sirolimus", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brigatinib" ] ], [ [ "Ergometrine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Palbociclib" ], [ "Palbociclib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brigatinib" ] ], [ [ "Ergometrine", "{u} (Compound) resembles {v} (Compound)", "Methylergometrine" ], [ "Methylergometrine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brigatinib" ] ], [ [ "Ergometrine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ivosidenib" ], [ "Ivosidenib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brigatinib" ] ], [ [ "Ergometrine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Enzalutamide" ], [ "Enzalutamide", "{u} may lead to a major life threatening interaction when taken with {v}", "Brigatinib" ] ], [ [ "Ergometrine", "{u} may lead to a major life threatening interaction when taken with {v}", "Idelalisib" ], [ "Idelalisib", "{u} may lead to a major life threatening interaction when taken with {v}", "Brigatinib" ] ], [ [ "Ergometrine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fluconazole" ], [ "Fluconazole", "{u} may lead to a major life threatening interaction when taken with {v}", "Brigatinib" ] ], [ [ "Ergometrine", "{u} may lead to a major life threatening interaction when taken with {v}", "Clarithromycin" ], [ "Clarithromycin", "{u} may lead to a major life threatening interaction when taken with {v}", "Brigatinib" ] ], [ [ "Ergometrine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fedratinib" ], [ "Fedratinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Brigatinib" ] ] ]
Ergometrine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib Ergometrine may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib and Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib Ergometrine (Compound) resembles Methylergometrine (Compound) and Methyl Ergometrine may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib Ergometrine may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Brigatinib Ergometrine may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Brigatinib Ergometrine may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may lead to a major life threatening interaction when taken with Brigatinib Ergometrine may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Brigatinib Ergometrine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may lead to a major life threatening interaction when taken with Brigatinib
DB00880
DB01234
359
1,220
[ "DDInter360", "DDInter513" ]
Chlorothiazide
Dexamethasone
A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812)
Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [hydrocortisone] and [prednisolone]. Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.
Moderate
1
[ [ [ 359, 24, 1220 ] ], [ [ 359, 63, 870 ], [ 870, 1, 1220 ] ], [ [ 359, 63, 175 ], [ 175, 40, 1220 ] ], [ [ 359, 24, 1486 ], [ 1486, 40, 1220 ] ], [ [ 359, 21, 28835 ], [ 28835, 60, 1220 ] ], [ [ 359, 24, 688 ], [ 688, 23, 1220 ] ], [ [ 359, 24, 659 ], [ 659, 62, 1220 ] ], [ [ 359, 63, 1674 ], [ 1674, 23, 1220 ] ], [ [ 359, 24, 959 ], [ 959, 24, 1220 ] ], [ [ 359, 62, 126 ], [ 126, 24, 1220 ] ] ]
[ [ [ "Chlorothiazide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dexamethasone" ] ], [ [ "Chlorothiazide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fludrocortisone" ], [ "Fludrocortisone", "{u} (Compound) resembles {v} (Compound)", "Dexamethasone" ] ], [ [ "Chlorothiazide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Triamcinolone" ], [ "Triamcinolone", "{u} (Compound) resembles {v} (Compound)", "Dexamethasone" ] ], [ [ "Chlorothiazide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Methylprednisolone" ], [ "Methylprednisolone", "{u} (Compound) resembles {v} (Compound)", "Dexamethasone" ] ], [ [ "Chlorothiazide", "{u} (Compound) causes {v} (Side Effect)", "Hyperglycaemia" ], [ "Hyperglycaemia", "{u} (Side Effect) is caused by {v} (Compound)", "Dexamethasone" ] ], [ [ "Chlorothiazide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Salbutamol" ], [ "Salbutamol", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Dexamethasone" ] ], [ [ "Chlorothiazide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Vilanterol" ], [ "Vilanterol", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Dexamethasone" ] ], [ [ "Chlorothiazide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Orciprenaline" ], [ "Orciprenaline", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Dexamethasone" ] ], [ [ "Chlorothiazide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Glipizide" ], [ "Glipizide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dexamethasone" ] ], [ [ "Chlorothiazide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Warfarin" ], [ "Warfarin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dexamethasone" ] ] ]
Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Dexamethasone (Compound) Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Dexamethasone (Compound) Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone (Compound) resembles Dexamethasone (Compound) Chlorothiazide (Compound) causes Hyperglycaemia (Side Effect) and Hyperglycaemia (Side Effect) is caused by Dexamethasone (Compound) Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a minor interaction that can limit clinical effects when taken with Dexamethasone Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a minor interaction that can limit clinical effects when taken with Dexamethasone Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline and Orciprenaline may cause a minor interaction that can limit clinical effects when taken with Dexamethasone Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone Chlorothiazide may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone
DB00545
DB08868
751
1,011
[ "DDInter1548", "DDInter737" ]
Pyridostigmine
Fingolimod
Myasthenia gravis is an autoimmune disease involving dysfunction at the neuromuscular junction, most commonly due to autoantibodies directed against the acetylcholine receptor (AChR), which results in muscle tone loss, muscle weakness, and fatigue. Acetylcholinesterase inhibitors have been the symptomatic treatment of choice in myasthenia gravis since the 1930s with the early use of [physostigmine] and [neostigmine]. By inhibiting the breakdown of acetylcholine in the neuromuscular junction, they increase signalling and relieve symptoms.[A231004, L32408, L32413] Pyridostigmine is the current drug of choice, with superior pharmacokinetics and reduced side effects compared to [neostigmine].[L32408, L32413] In addition to treating myasthenia gravis, pyridostigmine is used to reverse neuromuscular blocks
Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially approved by the FDA in 2010. Fingolimod was also studied for the treatment of COVID-19, the disease caused by infection with the SARS-CoV-2 virus.[L12654,L12657]
Moderate
1
[ [ [ 751, 24, 1011 ] ], [ [ 751, 6, 8374 ], [ 8374, 45, 1011 ] ], [ [ 751, 21, 28892 ], [ 28892, 60, 1011 ] ], [ [ 751, 24, 61 ], [ 61, 24, 1011 ] ], [ [ 751, 24, 1276 ], [ 1276, 63, 1011 ] ], [ [ 751, 40, 1372 ], [ 1372, 24, 1011 ] ], [ [ 751, 24, 175 ], [ 175, 25, 1011 ] ], [ [ 751, 24, 1476 ], [ 1476, 64, 1011 ] ], [ [ 751, 63, 251 ], [ 251, 25, 1011 ] ], [ [ 751, 6, 8374 ], [ 8374, 45, 1247 ], [ 1247, 23, 1011 ] ] ]
[ [ [ "Pyridostigmine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fingolimod" ] ], [ [ "Pyridostigmine", "{u} (Compound) binds {v} (Gene)", "CYP3A4" ], [ "CYP3A4", "{u} (Gene) is bound by {v} (Compound)", "Fingolimod" ] ], [ [ "Pyridostigmine", "{u} (Compound) causes {v} (Side Effect)", "Cardiac arrest" ], [ "Cardiac arrest", "{u} (Side Effect) is caused by {v} (Compound)", "Fingolimod" ] ], [ [ "Pyridostigmine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Edrophonium" ], [ "Edrophonium", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fingolimod" ] ], [ [ "Pyridostigmine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Alectinib" ], [ "Alectinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fingolimod" ] ], [ [ "Pyridostigmine", "{u} (Compound) resembles {v} (Compound)", "Neostigmine" ], [ "Neostigmine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fingolimod" ] ], [ [ "Pyridostigmine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Triamcinolone" ], [ "Triamcinolone", "{u} may lead to a major life threatening interaction when taken with {v}", "Fingolimod" ] ], [ [ "Pyridostigmine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brigatinib" ], [ "Brigatinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Fingolimod" ] ], [ [ "Pyridostigmine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Betamethasone" ], [ "Betamethasone", "{u} may lead to a major life threatening interaction when taken with {v}", "Fingolimod" ] ], [ [ "Pyridostigmine", "{u} (Compound) binds {v} (Gene)", "CYP3A4" ], [ "CYP3A4", "{u} (Gene) is bound by {v} (Compound)", "Sulfamethoxazole" ], [ "Sulfamethoxazole", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Fingolimod" ] ] ]
Pyridostigmine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Fingolimod (Compound) Pyridostigmine (Compound) causes Cardiac arrest (Side Effect) and Cardiac arrest (Side Effect) is caused by Fingolimod (Compound) Pyridostigmine may cause a moderate interaction that could exacerbate diseases when taken with Edrophonium and Edrophonium may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod Pyridostigmine may cause a moderate interaction that could exacerbate diseases when taken with Alectinib and Alectinib may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod Pyridostigmine (Compound) resembles Neostigmine (Compound) and Neostigmine may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod Pyridostigmine may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone may lead to a major life threatening interaction when taken with Fingolimod Pyridostigmine may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may lead to a major life threatening interaction when taken with Fingolimod Pyridostigmine may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone may lead to a major life threatening interaction when taken with Fingolimod Pyridostigmine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sulfamethoxazole (Compound) and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Fingolimod
DB00014
DB11827
521
433
[ "DDInter839", "DDInter669" ]
Goserelin
Ertugliflozin
Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal.
Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018.
Moderate
1
[ [ [ 521, 24, 433 ] ], [ [ 521, 25, 695 ], [ 695, 24, 433 ] ], [ [ 521, 24, 959 ], [ 959, 24, 433 ] ], [ [ 521, 24, 1399 ], [ 1399, 63, 433 ] ], [ [ 521, 25, 246 ], [ 246, 25, 433 ] ], [ [ 521, 25, 695 ], [ 695, 24, 959 ], [ 959, 24, 433 ] ], [ [ 521, 24, 959 ], [ 959, 62, 1103 ], [ 1103, 23, 433 ] ], [ [ 521, 25, 1176 ], [ 1176, 25, 959 ], [ 959, 24, 433 ] ], [ [ 521, 24, 472 ], [ 472, 24, 820 ], [ 820, 24, 433 ] ], [ [ 521, 24, 867 ], [ 867, 1, 695 ], [ 695, 24, 433 ] ] ]
[ [ [ "Goserelin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ertugliflozin" ] ], [ [ "Goserelin", "{u} may lead to a major life threatening interaction when taken with {v}", "Clozapine" ], [ "Clozapine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ertugliflozin" ] ], [ [ "Goserelin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Glipizide" ], [ "Glipizide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ertugliflozin" ] ], [ [ "Goserelin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lithium carbonate" ], [ "Lithium carbonate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ertugliflozin" ] ], [ [ "Goserelin", "{u} may lead to a major life threatening interaction when taken with {v}", "Gatifloxacin" ], [ "Gatifloxacin", "{u} may lead to a major life threatening interaction when taken with {v}", "Ertugliflozin" ] ], [ [ "Goserelin", "{u} may lead to a major life threatening interaction when taken with {v}", "Clozapine" ], [ "Clozapine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Glipizide" ], [ "Glipizide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ertugliflozin" ] ], [ [ "Goserelin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Glipizide" ], [ "Glipizide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Amcinonide" ], [ "Amcinonide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Ertugliflozin" ] ], [ [ "Goserelin", "{u} may lead to a major life threatening interaction when taken with {v}", "Moxifloxacin" ], [ "Moxifloxacin", "{u} may lead to a major life threatening interaction when taken with {v}", "Glipizide" ], [ "Glipizide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ertugliflozin" ] ], [ [ "Goserelin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Alfuzosin" ], [ "Alfuzosin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Alimemazine" ], [ "Alimemazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ertugliflozin" ] ], [ [ "Goserelin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Olanzapine" ], [ "Olanzapine", "{u} (Compound) resembles {v} (Compound)", "Clozapine" ], [ "Clozapine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ertugliflozin" ] ] ]
Goserelin may lead to a major life threatening interaction when taken with Clozapine and Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate and Lithium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin Goserelin may lead to a major life threatening interaction when taken with Gatifloxacin and Gatifloxacin may lead to a major life threatening interaction when taken with Ertugliflozin Goserelin may lead to a major life threatening interaction when taken with Clozapine and Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Ertugliflozin Goserelin may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin may lead to a major life threatening interaction when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Alfuzosin and Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Olanzapine and Olanzapine (Compound) resembles Clozapine (Compound) and Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
DB00006
DB00554
942
1,027
[ "DDInter217", "DDInter1478" ]
Bivalirudin
Piroxicam
Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important to monitor changes in hematocrit, activated partial thromboplastin time, international normalized ratio and blood pressure.
A cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily.
Moderate
1
[ [ [ 942, 24, 1027 ] ], [ [ 942, 24, 1171 ], [ 1171, 1, 1027 ] ], [ [ 942, 24, 222 ], [ 222, 63, 1027 ] ], [ [ 942, 64, 1578 ], [ 1578, 24, 1027 ] ], [ [ 942, 24, 1061 ], [ 1061, 24, 1027 ] ], [ [ 942, 25, 1564 ], [ 1564, 63, 1027 ] ], [ [ 942, 25, 25 ], [ 25, 24, 1027 ] ], [ [ 942, 25, 553 ], [ 553, 64, 1027 ] ], [ [ 942, 25, 1172 ], [ 1172, 25, 1027 ] ], [ [ 942, 24, 1171 ], [ 1171, 1, 11485 ], [ 11485, 1, 1027 ] ] ]
[ [ [ "Bivalirudin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Piroxicam" ] ], [ [ "Bivalirudin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Meloxicam" ], [ "Meloxicam", "{u} (Compound) resembles {v} (Compound)", "Piroxicam" ] ], [ [ "Bivalirudin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sibutramine" ], [ "Sibutramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Piroxicam" ] ], [ [ "Bivalirudin", "{u} may lead to a major life threatening interaction when taken with {v}", "Lepirudin" ], [ "Lepirudin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Piroxicam" ] ], [ [ "Bivalirudin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Treprostinil" ], [ "Treprostinil", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Piroxicam" ] ], [ [ "Bivalirudin", "{u} may lead to a major life threatening interaction when taken with {v}", "Defibrotide" ], [ "Defibrotide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Piroxicam" ] ], [ [ "Bivalirudin", "{u} may lead to a major life threatening interaction when taken with {v}", "Anistreplase" ], [ "Anistreplase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Piroxicam" ] ], [ [ "Bivalirudin", "{u} may lead to a major life threatening interaction when taken with {v}", "Fondaparinux" ], [ "Fondaparinux", "{u} may lead to a major life threatening interaction when taken with {v}", "Piroxicam" ] ], [ [ "Bivalirudin", "{u} may lead to a major life threatening interaction when taken with {v}", "Ibritumomab tiuxetan" ], [ "Ibritumomab tiuxetan", "{u} may lead to a major life threatening interaction when taken with {v}", "Piroxicam" ] ], [ [ "Bivalirudin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Meloxicam" ], [ "Meloxicam", "{u} (Compound) resembles {v} (Compound)", "Tenoxicam" ], [ "Tenoxicam", "{u} (Compound) resembles {v} (Compound)", "Piroxicam" ] ] ]
Bivalirudin may cause a moderate interaction that could exacerbate diseases when taken with Meloxicam and Meloxicam (Compound) resembles Piroxicam (Compound) Bivalirudin may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Piroxicam Bivalirudin may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Piroxicam Bivalirudin may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Piroxicam Bivalirudin may lead to a major life threatening interaction when taken with Defibrotide and Defibrotide may cause a moderate interaction that could exacerbate diseases when taken with Piroxicam Bivalirudin may lead to a major life threatening interaction when taken with Anistreplase and Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Piroxicam Bivalirudin may lead to a major life threatening interaction when taken with Fondaparinux and Fondaparinux may lead to a major life threatening interaction when taken with Piroxicam Bivalirudin may lead to a major life threatening interaction when taken with Ibritumomab tiuxetan and Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Piroxicam Bivalirudin may cause a moderate interaction that could exacerbate diseases when taken with Meloxicam and Meloxicam (Compound) resembles Tenoxicam (Compound) and Tenoxicam (Compound) resembles Piroxicam (Compound)
DB00556
DB00983
1,262
480
[ "DDInter1429", "DDInter776" ]
Perflutren
Formoterol
Perflutren, a diagnostic drug that is intended to be used for contrast enhancement during the indicated echocardiographic procedures, is comprised of lipid-coated microspheres filled with octafluoropropane(OFP) gas. When exposed to ultrasound waves, the microspheres resonate and "echo" strong signals back to the ultrasound machine. The difference in density between the gas-filled bubbles and the blood around them creates an increased level of contrast visible in the resulting ultrasound image. During echocardiography, activated Perflutren enhances images of the inner edges or borders of the heart, producing an improved image that may enable physicians to better diagnose patients.
Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major clinical advantage of formoterol over other inhaled beta-agonists is its rapid onset of action (2-3 minutes), which is at least as fast as [salbutamol], combined with a long duration of action (12 hours) - for this reason, treatment guidelines for asthma recommend its use as both a reliever and maintenance medication. It is available as a single-entity product [L10986,L11223] and in several formulations in combination with both inhaled corticosteroids [L10995,L10619] and long-acting muscarinic antagonists.[L10992,L10989]
Moderate
1
[ [ [ 1262, 24, 480 ] ], [ [ 1262, 24, 1148 ], [ 1148, 63, 480 ] ], [ [ 1262, 21, 28719 ], [ 28719, 60, 480 ] ], [ [ 1262, 25, 868 ], [ 868, 63, 480 ] ], [ [ 1262, 63, 1424 ], [ 1424, 24, 480 ] ], [ [ 1262, 24, 1674 ], [ 1674, 24, 480 ] ], [ [ 1262, 64, 702 ], [ 702, 24, 480 ] ], [ [ 1262, 25, 1166 ], [ 1166, 24, 480 ] ], [ [ 1262, 40, 679 ], [ 679, 63, 480 ] ], [ [ 1262, 24, 877 ], [ 877, 64, 480 ] ] ]
[ [ [ "Perflutren", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Formoterol" ] ], [ [ "Perflutren", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Isoprenaline" ], [ "Isoprenaline", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Formoterol" ] ], [ [ "Perflutren", "{u} (Compound) causes {v} (Side Effect)", "Pain" ], [ "Pain", "{u} (Side Effect) is caused by {v} (Compound)", "Formoterol" ] ], [ [ "Perflutren", "{u} may lead to a major life threatening interaction when taken with {v}", "Vemurafenib" ], [ "Vemurafenib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Formoterol" ] ], [ [ "Perflutren", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Quinine" ], [ "Quinine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Formoterol" ] ], [ [ "Perflutren", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Orciprenaline" ], [ "Orciprenaline", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Formoterol" ] ], [ [ "Perflutren", "{u} may lead to a major life threatening interaction when taken with {v}", "Anagrelide" ], [ "Anagrelide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Formoterol" ] ], [ [ "Perflutren", "{u} may lead to a major life threatening interaction when taken with {v}", "Dolasetron" ], [ "Dolasetron", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Formoterol" ] ], [ [ "Perflutren", "{u} (Compound) resembles {v} (Compound)", "Sevoflurane" ], [ "Sevoflurane", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Formoterol" ] ], [ [ "Perflutren", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Macimorelin" ], [ "Macimorelin", "{u} may lead to a major life threatening interaction when taken with {v}", "Formoterol" ] ] ]
Perflutren may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Formoterol Perflutren (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Formoterol (Compound) Perflutren may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Formoterol Perflutren may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol Perflutren may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline and Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Formoterol Perflutren may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Formoterol Perflutren may lead to a major life threatening interaction when taken with Dolasetron and Dolasetron may cause a moderate interaction that could exacerbate diseases when taken with Formoterol Perflutren (Compound) resembles Sevoflurane (Compound) and Sevoflurane may cause a moderate interaction that could exacerbate diseases when taken with Formoterol Perflutren may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin and Macimorelin may lead to a major life threatening interaction when taken with Formoterol
DB00685
DB11348
1,299
1,065
[ "DDInter1887", "DDInter279" ]
Trovafloxacin
Calcium Phosphate
Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was shown to be more effective against Gram-positive bacteria than Gram-negative bacteria when compared to previous fluoroquinolones. Due to its hepatotoxic potential, trovafloxacin was withdrawn from the market.
Calcium phosphate is typically available as an over the counter supplement, antacid, or as an added ingredient in some toothpastes [FDA Label] .
Moderate
1
[ [ [ 1299, 24, 1065 ] ], [ [ 1299, 1, 956 ], [ 956, 24, 1065 ] ], [ [ 1299, 1, 956 ], [ 956, 40, 246 ], [ 246, 24, 1065 ] ], [ [ 1299, 1, 872 ], [ 872, 1, 945 ], [ 945, 24, 1065 ] ], [ [ 1299, 24, 1606 ], [ 1606, 24, 943 ], [ 943, 63, 1065 ] ], [ [ 1299, 24, 1473 ], [ 1473, 63, 943 ], [ 943, 63, 1065 ] ], [ [ 1299, 24, 1606 ], [ 1606, 63, 819 ], [ 819, 24, 1065 ] ], [ [ 1299, 24, 850 ], [ 850, 24, 810 ], [ 810, 24, 1065 ] ], [ [ 1299, 62, 147 ], [ 147, 24, 943 ], [ 943, 63, 1065 ] ], [ [ 1299, 62, 147 ], [ 147, 63, 839 ], [ 839, 24, 1065 ] ] ]
[ [ [ "Trovafloxacin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Calcium Phosphate" ] ], [ [ "Trovafloxacin", "{u} (Compound) resembles {v} (Compound)", "Norfloxacin" ], [ "Norfloxacin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Calcium Phosphate" ] ], [ [ "Trovafloxacin", "{u} (Compound) resembles {v} (Compound)", "Norfloxacin" ], [ "Norfloxacin", "{u} (Compound) resembles {v} (Compound)", "Gatifloxacin" ], [ "Gatifloxacin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Calcium Phosphate" ] ], [ [ "Trovafloxacin", "{u} (Compound) resembles {v} (Compound)", "Gemifloxacin" ], [ "Gemifloxacin", "{u} (Compound) resembles {v} (Compound)", "Sparfloxacin" ], [ "Sparfloxacin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Calcium Phosphate" ] ], [ [ "Trovafloxacin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lanthanum carbonate" ], [ "Lanthanum carbonate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sarecycline" ], [ "Sarecycline", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Calcium Phosphate" ] ], [ [ "Trovafloxacin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Magnesium gluconate" ], [ "Magnesium gluconate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sarecycline" ], [ "Sarecycline", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Calcium Phosphate" ] ], [ [ "Trovafloxacin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lanthanum carbonate" ], [ "Lanthanum carbonate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Acebutolol" ], [ "Acebutolol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Calcium Phosphate" ] ], [ [ "Trovafloxacin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brentuximab vedotin" ], [ "Brentuximab vedotin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Strontium chloride Sr-89" ], [ "Strontium chloride Sr-89", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Calcium Phosphate" ] ], [ [ "Trovafloxacin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Vinblastine" ], [ "Vinblastine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sarecycline" ], [ "Sarecycline", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Calcium Phosphate" ] ], [ [ "Trovafloxacin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Vinblastine" ], [ "Vinblastine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Grepafloxacin" ], [ "Grepafloxacin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Calcium Phosphate" ] ] ]
Trovafloxacin (Compound) resembles Norfloxacin (Compound) and Norfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate Trovafloxacin (Compound) resembles Norfloxacin (Compound) and Norfloxacin (Compound) resembles Gatifloxacin (Compound) and Gatifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate Trovafloxacin (Compound) resembles Gemifloxacin (Compound) and Gemifloxacin (Compound) resembles Sparfloxacin (Compound) and Sparfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate Trovafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Lanthanum carbonate and Lanthanum carbonate may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline and Sarecycline may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate Trovafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium gluconate and Magnesium gluconate may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline and Sarecycline may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate Trovafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Lanthanum carbonate and Lanthanum carbonate may cause a moderate interaction that could exacerbate diseases when taken with Acebutolol and Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate Trovafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89 and Strontium chloride Sr-89 may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate Trovafloxacin may cause a minor interaction that can limit clinical effects when taken with Vinblastine and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline and Sarecycline may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate Trovafloxacin may cause a minor interaction that can limit clinical effects when taken with Vinblastine and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Grepafloxacin and Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate
DB00738
DB08864
485
786
[ "DDInter1420", "DDInter1595" ]
Pentamidine
Rilpivirine
Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects.
Rilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients. It is a diarylpyrimidine derivative. The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potency and reduces the chance of resistance compared to other NNRTI's. Rilpivirine was developed by Tilbotec, Inc. and FDA approved on May 20, 2011. On November 21, 2017, Rilpivirine, in combination with [dolutegravir], was approved as part of the first complete treatment regimen with only two drugs for the treatment of adults with HIV-1 named Juluca. Rilpivirine in combination with [cabotegravir] was granted FDA approval on 21 January 2021. While previously administered once-monthly only, this combination product was granted FDA approval for dosing every two months on February 01, 2022 and without the need for an oral lead-in period prior.
Moderate
1
[ [ [ 485, 24, 786 ] ], [ [ 485, 6, 8374 ], [ 8374, 45, 786 ] ], [ [ 485, 21, 29343 ], [ 29343, 60, 786 ] ], [ [ 485, 23, 112 ], [ 112, 23, 786 ] ], [ [ 485, 24, 918 ], [ 918, 24, 786 ] ], [ [ 485, 63, 51 ], [ 51, 24, 786 ] ], [ [ 485, 24, 823 ], [ 823, 63, 786 ] ], [ [ 485, 64, 1101 ], [ 1101, 24, 786 ] ], [ [ 485, 25, 1154 ], [ 1154, 25, 786 ] ], [ [ 485, 63, 837 ], [ 837, 25, 786 ] ] ]
[ [ [ "Pentamidine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Rilpivirine" ] ], [ [ "Pentamidine", "{u} (Compound) binds {v} (Gene)", "CYP3A4" ], [ "CYP3A4", "{u} (Gene) is bound by {v} (Compound)", "Rilpivirine" ] ], [ [ "Pentamidine", "{u} (Compound) causes {v} (Side Effect)", "Blood creatinine increased" ], [ "Blood creatinine increased", "{u} (Side Effect) is caused by {v} (Compound)", "Rilpivirine" ] ], [ [ "Pentamidine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Metronidazole" ], [ "Metronidazole", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Rilpivirine" ] ], [ [ "Pentamidine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bicalutamide" ], [ "Bicalutamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Rilpivirine" ] ], [ [ "Pentamidine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Daunorubicin" ], [ "Daunorubicin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Rilpivirine" ] ], [ [ "Pentamidine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Triclabendazole" ], [ "Triclabendazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Rilpivirine" ] ], [ [ "Pentamidine", "{u} may lead to a major life threatening interaction when taken with {v}", "Bexarotene" ], [ "Bexarotene", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Rilpivirine" ] ], [ [ "Pentamidine", "{u} may lead to a major life threatening interaction when taken with {v}", "Pasireotide" ], [ "Pasireotide", "{u} may lead to a major life threatening interaction when taken with {v}", "Rilpivirine" ] ], [ [ "Pentamidine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pantoprazole" ], [ "Pantoprazole", "{u} may lead to a major life threatening interaction when taken with {v}", "Rilpivirine" ] ] ]
Pentamidine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rilpivirine (Compound) Pentamidine (Compound) causes Blood creatinine increased (Side Effect) and Blood creatinine increased (Side Effect) is caused by Rilpivirine (Compound) Pentamidine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Rilpivirine Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole and Triclabendazole may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine Pentamidine may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine Pentamidine may lead to a major life threatening interaction when taken with Pasireotide and Pasireotide may lead to a major life threatening interaction when taken with Rilpivirine Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Pantoprazole and Pantoprazole may lead to a major life threatening interaction when taken with Rilpivirine
DB00662
DB06204
717
768
[ "DDInter1873", "DDInter1746" ]
Trimethobenzamide
Tapentadol
Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against emesis induced by intragastric copper sulfate.
Tapentadol is a centrally-acting synthetic analgesic with a dual mechanism of action. It is a mu-opioid receptor agonist that also inhibits norepinephrine reuptake.[A260721, A36596] Tapentadol was first approved by the FDA on November 20, 2008. The extended-release formulation of tapentadol was also approved by the FDA on August 26, 2011. Used in the management of pain, tapentadol is typically reserved for patients who have limited alternative treatment options.
Moderate
1
[ [ [ 717, 24, 768 ] ], [ [ 717, 21, 28921 ], [ 28921, 60, 768 ] ], [ [ 717, 24, 100 ], [ 100, 24, 768 ] ], [ [ 717, 63, 13 ], [ 13, 24, 768 ] ], [ [ 717, 24, 849 ], [ 849, 63, 768 ] ], [ [ 717, 24, 222 ], [ 222, 25, 768 ] ], [ [ 717, 63, 506 ], [ 506, 25, 768 ] ], [ [ 717, 21, 28921 ], [ 28921, 60, 189 ], [ 189, 40, 768 ] ], [ [ 717, 21, 29648 ], [ 29648, 60, 1532 ], [ 1532, 24, 768 ] ], [ [ 717, 24, 100 ], [ 100, 6, 10215 ], [ 10215, 45, 768 ] ] ]
[ [ [ "Trimethobenzamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tapentadol" ] ], [ [ "Trimethobenzamide", "{u} (Compound) causes {v} (Side Effect)", "Dizziness" ], [ "Dizziness", "{u} (Side Effect) is caused by {v} (Compound)", "Tapentadol" ] ], [ [ "Trimethobenzamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brompheniramine" ], [ "Brompheniramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tapentadol" ] ], [ [ "Trimethobenzamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Cyproheptadine" ], [ "Cyproheptadine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tapentadol" ] ], [ [ "Trimethobenzamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mepyramine" ], [ "Mepyramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tapentadol" ] ], [ [ "Trimethobenzamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sibutramine" ], [ "Sibutramine", "{u} may lead to a major life threatening interaction when taken with {v}", "Tapentadol" ] ], [ [ "Trimethobenzamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dextromethorphan" ], [ "Dextromethorphan", "{u} may lead to a major life threatening interaction when taken with {v}", "Tapentadol" ] ], [ [ "Trimethobenzamide", "{u} (Compound) causes {v} (Side Effect)", "Dizziness" ], [ "Dizziness", "{u} (Side Effect) is caused by {v} (Compound)", "Rivastigmine" ], [ "Rivastigmine", "{u} (Compound) resembles {v} (Compound)", "Tapentadol" ] ], [ [ "Trimethobenzamide", "{u} (Compound) causes {v} (Side Effect)", "Disorientation" ], [ "Disorientation", "{u} (Side Effect) is caused by {v} (Compound)", "Ifosfamide" ], [ "Ifosfamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tapentadol" ] ], [ [ "Trimethobenzamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brompheniramine" ], [ "Brompheniramine", "{u} (Compound) binds {v} (Gene)", "CYP2C19" ], [ "CYP2C19", "{u} (Gene) is bound by {v} (Compound)", "Tapentadol" ] ] ]
Trimethobenzamide (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Tapentadol (Compound) Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Tapentadol Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Tapentadol Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Tapentadol Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may lead to a major life threatening interaction when taken with Tapentadol Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may lead to a major life threatening interaction when taken with Tapentadol Trimethobenzamide (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Rivastigmine (Compound) and Rivastigmine (Compound) resembles Tapentadol (Compound) Trimethobenzamide (Compound) causes Disorientation (Side Effect) and Disorientation (Side Effect) is caused by Ifosfamide (Compound) and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Tapentadol Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Tapentadol (Compound)
DB01076
DB06595
700
1,491
[ "DDInter133", "DDInter1214" ]
Atorvastatin
Midostaurin
Atorvastatin (Lipitor®), is a lipid-lowering drug included in the statin class of medications. By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase, which catalyzes the conversion of HMG-CoA to mevalonic acid. This conversion is a critical metabolic reaction involved in the production of several compounds involved in lipid metabolism and transport, including cholesterol, low-density lipoprotein (LDL) (sometimes referred to as "bad cholesterol"), and very-low-density lipoprotein (VLDL). Prescribing statins is considered standard practice for patients following any cardiovascular event, and for people who are at moderate to high risk of developing cardiovascular disease. The evidence supporting statin use, coupled with minimal
Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hematopoietic tumors . It was approved on April 28, 2017 and has shown to increase the overall survival rate in patients with AML as an adjunct therapy along with chemotherapeutic agents.
Moderate
1
[ [ [ 700, 24, 1491 ] ], [ [ 700, 63, 112 ], [ 112, 23, 1491 ] ], [ [ 700, 63, 58 ], [ 58, 24, 1491 ] ], [ [ 700, 24, 1017 ], [ 1017, 63, 1491 ] ], [ [ 700, 23, 5 ], [ 5, 63, 1491 ] ], [ [ 700, 24, 1250 ], [ 1250, 24, 1491 ] ], [ [ 700, 40, 671 ], [ 671, 24, 1491 ] ], [ [ 700, 40, 788 ], [ 788, 63, 1491 ] ], [ [ 700, 64, 600 ], [ 600, 24, 1491 ] ], [ [ 700, 25, 1377 ], [ 1377, 25, 1491 ] ] ]
[ [ [ "Atorvastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Midostaurin" ] ], [ [ "Atorvastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Metronidazole" ], [ "Metronidazole", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Midostaurin" ] ], [ [ "Atorvastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Alefacept" ], [ "Alefacept", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Midostaurin" ] ], [ [ "Atorvastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lorlatinib" ], [ "Lorlatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Midostaurin" ] ], [ [ "Atorvastatin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Liraglutide" ], [ "Liraglutide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Midostaurin" ] ], [ [ "Atorvastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pazopanib" ], [ "Pazopanib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Midostaurin" ] ], [ [ "Atorvastatin", "{u} (Compound) resembles {v} (Compound)", "Fluvastatin" ], [ "Fluvastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Midostaurin" ] ], [ [ "Atorvastatin", "{u} (Compound) resembles {v} (Compound)", "Pitavastatin" ], [ "Pitavastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Midostaurin" ] ], [ [ "Atorvastatin", "{u} may lead to a major life threatening interaction when taken with {v}", "Fluconazole" ], [ "Fluconazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Midostaurin" ] ], [ [ "Atorvastatin", "{u} may lead to a major life threatening interaction when taken with {v}", "Leflunomide" ], [ "Leflunomide", "{u} may lead to a major life threatening interaction when taken with {v}", "Midostaurin" ] ] ]
Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Midostaurin Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin Atorvastatin may cause a minor interaction that can limit clinical effects when taken with Liraglutide and Liraglutide may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin Atorvastatin (Compound) resembles Fluvastatin (Compound) and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin Atorvastatin (Compound) resembles Pitavastatin (Compound) and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin Atorvastatin may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin Atorvastatin may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Midostaurin
DB00683
DB04837
1,382
649
[ "DDInter1212", "DDInter407" ]
Midazolam
Clofedanol
Midazolam is a short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and amnesic properties. It belongs to a class of drugs called _benzodiazepines_. This drug is unique from others in this class due to its rapid onset of effects and short duration of action. Midazolam is available by oral, rectal, intranasal, intramuscular (IM), and intravenous (IV) routes and has been used in various biomedical applications, including dentistry, cardiac surgery, and endoscopic procedures as pre-anesthetic medication, and as an adjunct to local anesthesia. This drug was initially approved by the US FDA in 1985, and has been approved for various indications since. In late 2018, the intramuscular preparation was approved by the FDA for the treatment of status epilepticus in adults. In May 2019
Clofedanol is a centrally-acting cough suppressant available in Canada under the trade name Ulone. It is not available in the United States.
Moderate
1
[ [ [ 1382, 24, 649 ] ], [ [ 1382, 24, 1376 ], [ 1376, 24, 649 ] ], [ [ 1382, 1, 11275 ], [ 11275, 40, 649 ] ], [ [ 1382, 24, 832 ], [ 832, 40, 649 ] ], [ [ 1382, 63, 701 ], [ 701, 24, 649 ] ], [ [ 1382, 1, 902 ], [ 902, 24, 649 ] ], [ [ 1382, 24, 1609 ], [ 1609, 63, 649 ] ], [ [ 1382, 24, 662 ], [ 662, 35, 649 ] ], [ [ 1382, 24, 1376 ], [ 1376, 74, 21 ], [ 21, 24, 649 ] ], [ [ 1382, 1, 11275 ], [ 11275, 40, 21 ], [ 21, 24, 649 ] ] ]
[ [ [ "Midazolam", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clofedanol" ] ], [ [ "Midazolam", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Diphenhydramine" ], [ "Diphenhydramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clofedanol" ] ], [ [ "Midazolam", "{u} (Compound) resembles {v} (Compound)", "Chlorprothixene" ], [ "Chlorprothixene", "{u} (Compound) resembles {v} (Compound)", "Clofedanol" ] ], [ [ "Midazolam", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tripelennamine" ], [ "Tripelennamine", "{u} (Compound) resembles {v} (Compound)", "Clofedanol" ] ], [ [ "Midazolam", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clemastine" ], [ "Clemastine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clofedanol" ] ], [ [ "Midazolam", "{u} (Compound) resembles {v} (Compound)", "Clobazam" ], [ "Clobazam", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clofedanol" ] ], [ [ "Midazolam", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pentoxyverine" ], [ "Pentoxyverine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clofedanol" ] ], [ [ "Midazolam", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Carbinoxamine" ], [ "Carbinoxamine", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clofedanol" ] ], [ [ "Midazolam", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Diphenhydramine" ], [ "Diphenhydramine", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Amitriptyline" ], [ "Amitriptyline", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clofedanol" ] ], [ [ "Midazolam", "{u} (Compound) resembles {v} (Compound)", "Chlorprothixene" ], [ "Chlorprothixene", "{u} (Compound) resembles {v} (Compound)", "Amitriptyline" ], [ "Amitriptyline", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clofedanol" ] ] ]
Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol Midazolam (Compound) resembles Chlorprothixene (Compound) and Chlorprothixene (Compound) resembles Clofedanol (Compound) Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine (Compound) resembles Clofedanol (Compound) Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol Midazolam (Compound) resembles Clobazam (Compound) and Clobazam may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine and Pentoxyverine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine (Compound) resembles Clofedanol (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine (Compound) resembles Amitriptyline (Compound) and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Amitriptyline and Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol Midazolam (Compound) resembles Chlorprothixene (Compound) and Chlorprothixene (Compound) resembles Amitriptyline (Compound) and Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
DB00842
DB09085
686
587
[ "DDInter1359", "DDInter1779" ]
Oxazepam
Tetracaine
Oxazepam is an intermediate-acting, 3-hydroxybenzodiazepine used in the treatment of alcohol withdrawal and anxiety disorders. Oxazepam, like related 3-hydroxybenzodiazepine [lorazepam], is considered less susceptible to pharmacokinetic variability based on patient-specific factors (e.g. age, liver disease) - this feature is advantageous as compared to other benzodiazepines, and is likely owing in part to oxazepam's relatively simple metabolism. It is an active metabolite of both [diazepam] and [temazepam] and undergoes very little biotransformation following absorption, making it unlikely to participate in pharmacokinetic interactions.
Tetracaine is an ester local anaesthetic currently available in combination with lidocaine as a cream and patch.
Moderate
1
[ [ [ 686, 24, 587 ] ], [ [ 686, 1, 902 ], [ 902, 24, 587 ] ], [ [ 686, 40, 1418 ], [ 1418, 24, 587 ] ], [ [ 686, 1, 902 ], [ 902, 40, 1216 ], [ 1216, 24, 587 ] ], [ [ 686, 40, 1418 ], [ 1418, 1, 1216 ], [ 1216, 24, 587 ] ], [ [ 686, 24, 849 ], [ 849, 23, 771 ], [ 771, 62, 587 ] ], [ [ 686, 1, 1563 ], [ 1563, 1, 481 ], [ 481, 24, 587 ] ], [ [ 686, 63, 1242 ], [ 1242, 23, 771 ], [ 771, 62, 587 ] ], [ [ 686, 24, 849 ], [ 849, 63, 1216 ], [ 1216, 24, 587 ] ], [ [ 686, 63, 1242 ], [ 1242, 24, 1216 ], [ 1216, 24, 587 ] ] ]
[ [ [ "Oxazepam", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tetracaine" ] ], [ [ "Oxazepam", "{u} (Compound) resembles {v} (Compound)", "Clobazam" ], [ "Clobazam", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tetracaine" ] ], [ [ "Oxazepam", "{u} (Compound) resembles {v} (Compound)", "Estazolam" ], [ "Estazolam", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tetracaine" ] ], [ [ "Oxazepam", "{u} (Compound) resembles {v} (Compound)", "Clobazam" ], [ "Clobazam", "{u} (Compound) resembles {v} (Compound)", "Flurazepam" ], [ "Flurazepam", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tetracaine" ] ], [ [ "Oxazepam", "{u} (Compound) resembles {v} (Compound)", "Estazolam" ], [ "Estazolam", "{u} (Compound) resembles {v} (Compound)", "Flurazepam" ], [ "Flurazepam", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tetracaine" ] ], [ [ "Oxazepam", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mepyramine" ], [ "Mepyramine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Hyaluronidase" ], [ "Hyaluronidase", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Tetracaine" ] ], [ [ "Oxazepam", "{u} (Compound) resembles {v} (Compound)", "Halazepam" ], [ "Halazepam", "{u} (Compound) resembles {v} (Compound)", "Quazepam" ], [ "Quazepam", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tetracaine" ] ], [ [ "Oxazepam", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Cetirizine" ], [ "Cetirizine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Hyaluronidase" ], [ "Hyaluronidase", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Tetracaine" ] ], [ [ "Oxazepam", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mepyramine" ], [ "Mepyramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Flurazepam" ], [ "Flurazepam", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tetracaine" ] ], [ [ "Oxazepam", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Cetirizine" ], [ "Cetirizine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Flurazepam" ], [ "Flurazepam", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tetracaine" ] ] ]
Oxazepam (Compound) resembles Clobazam (Compound) and Clobazam may cause a moderate interaction that could exacerbate diseases when taken with Tetracaine Oxazepam (Compound) resembles Estazolam (Compound) and Estazolam may cause a moderate interaction that could exacerbate diseases when taken with Tetracaine Oxazepam (Compound) resembles Clobazam (Compound) and Clobazam (Compound) resembles Flurazepam (Compound) and Flurazepam may cause a moderate interaction that could exacerbate diseases when taken with Tetracaine Oxazepam (Compound) resembles Estazolam (Compound) and Estazolam (Compound) resembles Flurazepam (Compound) and Flurazepam may cause a moderate interaction that could exacerbate diseases when taken with Tetracaine Oxazepam may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase and Hyaluronidase may cause a minor interaction that can limit clinical effects when taken with Tetracaine Oxazepam (Compound) resembles Halazepam (Compound) and Halazepam (Compound) resembles Quazepam (Compound) and Quazepam may cause a moderate interaction that could exacerbate diseases when taken with Tetracaine Oxazepam may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase and Hyaluronidase may cause a minor interaction that can limit clinical effects when taken with Tetracaine Oxazepam may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Flurazepam and Flurazepam may cause a moderate interaction that could exacerbate diseases when taken with Tetracaine Oxazepam may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Flurazepam and Flurazepam may cause a moderate interaction that could exacerbate diseases when taken with Tetracaine
DB00757
DB06218
1,166
136
[ "DDInter581", "DDInter1014" ]
Dolasetron
Lacosamide
Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is not shown to have activity at other known serotonin receptors, and has low affinity for dopamine receptors.
Lacosamide is an antiepileptic drug used to treat seizures. As a chiral functionalized amino acid, it works by blocking slowly inactivating components of voltage-gated sodium currents. Lacosamide exhibits a stereoselective mode of interaction with sodium channels. Lacosamide was first approved by the European Commission in August 2008 and was later approved by the FDA in October 2008. It was granted approval by Health Canada in September 2010.
Major
2
[ [ [ 1166, 25, 136 ] ], [ [ 1166, 25, 633 ], [ 633, 40, 136 ] ], [ [ 1166, 25, 551 ], [ 551, 1, 136 ] ], [ [ 1166, 21, 28681 ], [ 28681, 60, 136 ] ], [ [ 1166, 25, 1011 ], [ 1011, 63, 136 ] ], [ [ 1166, 25, 609 ], [ 609, 24, 136 ] ], [ [ 1166, 24, 1276 ], [ 1276, 63, 136 ] ], [ [ 1166, 64, 1010 ], [ 1010, 24, 136 ] ], [ [ 1166, 24, 770 ], [ 770, 24, 136 ] ], [ [ 1166, 25, 633 ], [ 633, 1, 80 ], [ 80, 40, 136 ] ] ]
[ [ [ "Dolasetron", "{u} may lead to a major life threatening interaction when taken with {v}", "Lacosamide" ] ], [ [ "Dolasetron", "{u} may lead to a major life threatening interaction when taken with {v}", "Lisdexamfetamine" ], [ "Lisdexamfetamine", "{u} (Compound) resembles {v} (Compound)", "Lacosamide" ] ], [ [ "Dolasetron", "{u} may lead to a major life threatening interaction when taken with {v}", "Phenelzine" ], [ "Phenelzine", "{u} (Compound) resembles {v} (Compound)", "Lacosamide" ] ], [ [ "Dolasetron", "{u} (Compound) causes {v} (Side Effect)", "Hypersensitivity" ], [ "Hypersensitivity", "{u} (Side Effect) is caused by {v} (Compound)", "Lacosamide" ] ], [ [ "Dolasetron", "{u} may lead to a major life threatening interaction when taken with {v}", "Fingolimod" ], [ "Fingolimod", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lacosamide" ] ], [ [ "Dolasetron", "{u} may lead to a major life threatening interaction when taken with {v}", "Clarithromycin" ], [ "Clarithromycin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lacosamide" ] ], [ [ "Dolasetron", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Alectinib" ], [ "Alectinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lacosamide" ] ], [ [ "Dolasetron", "{u} may lead to a major life threatening interaction when taken with {v}", "Mefloquine" ], [ "Mefloquine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lacosamide" ] ], [ [ "Dolasetron", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Thalidomide" ], [ "Thalidomide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lacosamide" ] ], [ [ "Dolasetron", "{u} may lead to a major life threatening interaction when taken with {v}", "Lisdexamfetamine" ], [ "Lisdexamfetamine", "{u} (Compound) resembles {v} (Compound)", "Amphetamine" ], [ "Amphetamine", "{u} (Compound) resembles {v} (Compound)", "Lacosamide" ] ] ]
Dolasetron may lead to a major life threatening interaction when taken with Lisdexamfetamine and Lisdexamfetamine (Compound) resembles Lacosamide (Compound) Dolasetron may lead to a major life threatening interaction when taken with Phenelzine and Phenelzine (Compound) resembles Lacosamide (Compound) Dolasetron (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Lacosamide (Compound) Dolasetron may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Lacosamide Dolasetron may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Lacosamide Dolasetron may cause a moderate interaction that could exacerbate diseases when taken with Alectinib and Alectinib may cause a moderate interaction that could exacerbate diseases when taken with Lacosamide Dolasetron may lead to a major life threatening interaction when taken with Mefloquine and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Lacosamide Dolasetron may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Lacosamide Dolasetron may lead to a major life threatening interaction when taken with Lisdexamfetamine and Lisdexamfetamine (Compound) resembles Amphetamine (Compound) and Amphetamine (Compound) resembles Lacosamide (Compound)
DB00313
DB00486
556
1,614
[ "DDInter1913", "DDInter1253" ]
Valproic acid
Nabilone
Valproic acid, or valproate, is an fatty acid derivative and anticonvulsant originally synthesized in 1881 by Beverly S. Burton. It enjoyed use as a popular organic solvent in industry and pharmaceutical manufacturing for nearly a century. In 1963, a serendipitous discovery was made by George Carraz during his investigations into the anticonvulsant effects of khelline when he found that all of his samples, dissolved in valproic acid, exerted a similar degree of anticonvulsive activity. It first received approval on February 28, 1978 from the FDA under the trade name Depakene. Since then, it has been investigated for neuroprotective, anti-manic, and anti-migraine effects. It is currently a compound of interest in the field of oncology for its anti-proliferative effects and is the subject of many clinical trials in a variety of cancer types.
Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, however it is considered to be twice as active as Δ⁹-THC. Nabilone is approved by the FDA for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments [FDA Label]. Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the two most abundant cannabinoids found naturally in the resin of the marijuana plant, both of which are pharmacologically active due to their interaction with cannabinoid receptors that are found throughout the body . While both CBD and THC are used for medicinal purposes, they have different receptor activity, function, and physiological effects. If not provided in their activated form (such as through synthetic forms like Nabilone or ), THC and CBD are obtained through conversion from their precursors, tetrahydrocannabinolic acid-A (THCA-A) and cannabidiolic acid (CBDA), through decarboxylation reactions. This can be achieved through heating, smoking, vaporization, or baking of dried unfertilized female cannabis flowers. From a pharmacological perspective, Cannabis' diverse receptor profile explains its potential application for such a wide variety of medical conditions. Cannabis contains more than 400 different chemical compounds, of which 61 are considered cannabinoids, a class of compounds that act upon endogenous cannabinoid receptors of the body . The endocannabinoid system is widely distributed throughout the central and peripheral nervous system (via the Cannabinoid Receptors CB1 and CB2) and plays a role in many physiological processes such as inflammation, cardiovascular function, learning, pain, memory, stress and emotional regulation, and the sleep/wake cycle among many others . CB1 receptors are found in both the central and peripheral nervous system, and are most abundant in the hippocampus and amygdala, which are the areas of the brain responsible for short-term memory storage and emotional regulation. CB2 receptors are mainly located in the peripheral nervous system and can be found on lymphoid tissue where they are involved in regulation of immune function . In Canada, the United States, the United Kingdom and Mexico, nabilone is marketed as Cesamet. It was approved in 1985 by the United States FDA for treatment of chemotherapy-induced nausea and vomiting that has not responded to conventional antiemetics. Though it was approved by the FDA in 1985, the drug only began marketing in the United States in 2006. It is also approved for use in treatment of anorexia and weight loss in patients with AIDS. Nabilone is a racemate consisting of the (S,S) and the (R,R) isomers.
Moderate
1
[ [ [ 556, 24, 1614 ] ], [ [ 556, 24, 530 ], [ 530, 1, 1614 ] ], [ [ 556, 21, 28803 ], [ 28803, 60, 1614 ] ], [ [ 556, 24, 999 ], [ 999, 24, 1614 ] ], [ [ 556, 24, 516 ], [ 516, 63, 1614 ] ], [ [ 556, 63, 475 ], [ 475, 24, 1614 ] ], [ [ 556, 24, 530 ], [ 530, 6, 10025 ], [ 10025, 45, 1614 ] ], [ [ 556, 21, 28803 ], [ 28803, 60, 1603 ], [ 1603, 63, 1614 ] ], [ [ 556, 21, 28769 ], [ 28769, 60, 530 ], [ 530, 1, 1614 ] ], [ [ 556, 21, 29017 ], [ 29017, 60, 1230 ], [ 1230, 24, 1614 ] ] ]
[ [ [ "Valproic acid", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nabilone" ] ], [ [ "Valproic acid", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dronabinol" ], [ "Dronabinol", "{u} (Compound) resembles {v} (Compound)", "Nabilone" ] ], [ [ "Valproic acid", "{u} (Compound) causes {v} (Side Effect)", "Anaemia" ], [ "Anaemia", "{u} (Side Effect) is caused by {v} (Compound)", "Nabilone" ] ], [ [ "Valproic acid", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Thiethylperazine" ], [ "Thiethylperazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nabilone" ] ], [ [ "Valproic acid", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Levocetirizine" ], [ "Levocetirizine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nabilone" ] ], [ [ "Valproic acid", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Morphine" ], [ "Morphine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nabilone" ] ], [ [ "Valproic acid", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dronabinol" ], [ "Dronabinol", "{u} (Compound) binds {v} (Gene)", "CNR2" ], [ "CNR2", "{u} (Gene) is bound by {v} (Compound)", "Nabilone" ] ], [ [ "Valproic acid", "{u} (Compound) causes {v} (Side Effect)", "Anaemia" ], [ "Anaemia", "{u} (Side Effect) is caused by {v} (Compound)", "Captopril" ], [ "Captopril", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nabilone" ] ], [ [ "Valproic acid", "{u} (Compound) causes {v} (Side Effect)", "Feeling abnormal" ], [ "Feeling abnormal", "{u} (Side Effect) is caused by {v} (Compound)", "Dronabinol" ], [ "Dronabinol", "{u} (Compound) resembles {v} (Compound)", "Nabilone" ] ], [ [ "Valproic acid", "{u} (Compound) causes {v} (Side Effect)", "Sweating increased" ], [ "Sweating increased", "{u} (Side Effect) is caused by {v} (Compound)", "Citalopram" ], [ "Citalopram", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nabilone" ] ] ]
Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol (Compound) resembles Nabilone (Compound) Valproic acid (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Nabilone (Compound) Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Nabilone Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine and Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Nabilone Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Nabilone Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol (Compound) binds CNR2 (Gene) and CNR2 (Gene) is bound by Nabilone (Compound) Valproic acid (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Captopril (Compound) and Captopril may cause a moderate interaction that could exacerbate diseases when taken with Nabilone Valproic acid (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Dronabinol (Compound) and Dronabinol (Compound) resembles Nabilone (Compound) Valproic acid (Compound) causes Sweating increased (Side Effect) and Sweating increased (Side Effect) is caused by Citalopram (Compound) and Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Nabilone
DB00439
DB00526
289
1,555
[ "DDInter341", "DDInter1355" ]
Cerivastatin
Oxaliplatin
On August 8, 2001 the U.S. Food and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of fatal rhabdomyolysis, a severe adverse reaction from this cholesterol-lowering (lipid-lowering) product. It has also been withdrawn from the Canadian market.[A669,L43942]
Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties. Due to this chemical moiety, oxaliplatin readily undergoes non-enzymatic biotransformation, thus complicating oxaliplatin's pharmacokinetics. Like most platinum-based compounds, oxaliplatin's mechanism of action is primarily through DNA damage through DNA crosslinking, particularly intrastrand and interstrand crosslinking. However, due to the structure of oxaliplatin, its adducts make the binding of mismatch repair protein to DNA harder compared to cisplatin or carboplatin's adducts, resulting in greater cytotoxic effects. The DACH moiety also prevents cross-resistance with cisplatin and carboplatin. Although oxaliplatin has been investigated as a monotherapy, it is typically administered in combination with fluorouracil and leucovorin, known as the FOLFOX regimen, for the treatment of colorectal cancer.[A796,A797] This is an effective combination treatment both as a first-line treatment and in patients refractory to an initial fluorouracil and leucovorin combination. Ongoing trials have also shown promising results for oxaliplatin use in nonHodgkin’s lymphoma, breast cancer, mesothelioma, and non-small cell lung cancer. Oxaliplatin was approved by the FDA on January 9, 2004 and is currently marketed by Sanofi-Aventis under the trademark Eloxatin&reg;.
Moderate
1
[ [ [ 289, 24, 1555 ] ], [ [ 289, 24, 1213 ], [ 1213, 63, 1555 ] ], [ [ 289, 63, 10 ], [ 10, 24, 1555 ] ], [ [ 289, 24, 597 ], [ 597, 24, 1555 ] ], [ [ 289, 25, 609 ], [ 609, 63, 1555 ] ], [ [ 289, 64, 600 ], [ 600, 24, 1555 ] ], [ [ 289, 24, 868 ], [ 868, 64, 1555 ] ], [ [ 289, 63, 581 ], [ 581, 25, 1555 ] ], [ [ 289, 25, 1510 ], [ 1510, 64, 1555 ] ], [ [ 289, 24, 1213 ], [ 1213, 6, 17404 ], [ 17404, 45, 1555 ] ] ]
[ [ [ "Cerivastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Oxaliplatin" ] ], [ [ "Cerivastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dasatinib" ], [ "Dasatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Oxaliplatin" ] ], [ [ "Cerivastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dapsone" ], [ "Dapsone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Oxaliplatin" ] ], [ [ "Cerivastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Chloramphenicol" ], [ "Chloramphenicol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Oxaliplatin" ] ], [ [ "Cerivastatin", "{u} may lead to a major life threatening interaction when taken with {v}", "Clarithromycin" ], [ "Clarithromycin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Oxaliplatin" ] ], [ [ "Cerivastatin", "{u} may lead to a major life threatening interaction when taken with {v}", "Fluconazole" ], [ "Fluconazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Oxaliplatin" ] ], [ [ "Cerivastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Vemurafenib" ], [ "Vemurafenib", "{u} may lead to a major life threatening interaction when taken with {v}", "Oxaliplatin" ] ], [ [ "Cerivastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Infliximab" ], [ "Infliximab", "{u} may lead to a major life threatening interaction when taken with {v}", "Oxaliplatin" ] ], [ [ "Cerivastatin", "{u} may lead to a major life threatening interaction when taken with {v}", "Teriflunomide" ], [ "Teriflunomide", "{u} may lead to a major life threatening interaction when taken with {v}", "Oxaliplatin" ] ], [ [ "Cerivastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dasatinib" ], [ "Dasatinib", "{u} (Compound) binds {v} (Gene)", "ABCG2" ], [ "ABCG2", "{u} (Gene) is bound by {v} (Compound)", "Oxaliplatin" ] ] ]
Cerivastatin may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin Cerivastatin may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin Cerivastatin may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin Cerivastatin may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin Cerivastatin may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin Cerivastatin may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may lead to a major life threatening interaction when taken with Oxaliplatin Cerivastatin may cause a moderate interaction that could exacerbate diseases when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Oxaliplatin Cerivastatin may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Oxaliplatin Cerivastatin may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Oxaliplatin (Compound)
DB04574
DB08889
177
350
[ "DDInter684", "DDInter299" ]
Estrone sulfate (topical)
Carfilzomib
Estrone 3-sulfate is a steroid sulfate that is the 3-sulfate of estrone. It has a role as a human metabolite and a mouse metabolite. It is a 17-oxo steroid and a steroid sulfate. It is functionally related to an estrone. It is a conjugate acid of an estrone 3-sulfate(1-). It derives from a hydride of an estrane.
Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.
Major
2
[ [ [ 177, 25, 350 ] ], [ [ 177, 21, 28762 ], [ 28762, 60, 350 ] ], [ [ 177, 64, 770 ], [ 770, 24, 350 ] ], [ [ 177, 40, 1438 ], [ 1438, 25, 350 ] ], [ [ 177, 21, 28762 ], [ 28762, 60, 724 ], [ 724, 1, 350 ] ], [ [ 177, 21, 28643 ], [ 28643, 60, 310 ], [ 310, 24, 350 ] ], [ [ 177, 21, 29354 ], [ 29354, 60, 1468 ], [ 1468, 63, 350 ] ], [ [ 177, 64, 770 ], [ 770, 24, 833 ], [ 833, 1, 350 ] ], [ [ 177, 40, 1438 ], [ 1438, 6, 4973 ], [ 4973, 45, 350 ] ], [ [ 177, 40, 35 ], [ 35, 64, 770 ], [ 770, 24, 350 ] ] ]
[ [ [ "Estrone sulfate", "{u} may lead to a major life threatening interaction when taken with {v}", "Carfilzomib" ] ], [ [ "Estrone sulfate", "{u} (Compound) causes {v} (Side Effect)", "Headache" ], [ "Headache", "{u} (Side Effect) is caused by {v} (Compound)", "Carfilzomib" ] ], [ [ "Estrone sulfate", "{u} may lead to a major life threatening interaction when taken with {v}", "Thalidomide" ], [ "Thalidomide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Carfilzomib" ] ], [ [ "Estrone sulfate", "{u} (Compound) resembles {v} (Compound)", "Estradiol" ], [ "Estradiol", "{u} may lead to a major life threatening interaction when taken with {v}", "Carfilzomib" ] ], [ [ "Estrone sulfate", "{u} (Compound) causes {v} (Side Effect)", "Headache" ], [ "Headache", "{u} (Side Effect) is caused by {v} (Compound)", "Ritonavir" ], [ "Ritonavir", "{u} (Compound) resembles {v} (Compound)", "Carfilzomib" ] ], [ [ "Estrone sulfate", "{u} (Compound) causes {v} (Side Effect)", "Infection" ], [ "Infection", "{u} (Side Effect) is caused by {v} (Compound)", "Cabazitaxel" ], [ "Cabazitaxel", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Carfilzomib" ] ], [ [ "Estrone sulfate", "{u} (Compound) causes {v} (Side Effect)", "Hypercalcaemia" ], [ "Hypercalcaemia", "{u} (Side Effect) is caused by {v} (Compound)", "Ponatinib" ], [ "Ponatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Carfilzomib" ] ], [ [ "Estrone sulfate", "{u} may lead to a major life threatening interaction when taken with {v}", "Thalidomide" ], [ "Thalidomide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lopinavir" ], [ "Lopinavir", "{u} (Compound) resembles {v} (Compound)", "Carfilzomib" ] ], [ [ "Estrone sulfate", "{u} (Compound) resembles {v} (Compound)", "Estradiol" ], [ "Estradiol", "{u} (Compound) binds {v} (Gene)", "ABCB1" ], [ "ABCB1", "{u} (Gene) is bound by {v} (Compound)", "Carfilzomib" ] ], [ [ "Estrone sulfate", "{u} (Compound) resembles {v} (Compound)", "Quinestrol" ], [ "Quinestrol", "{u} may lead to a major life threatening interaction when taken with {v}", "Thalidomide" ], [ "Thalidomide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Carfilzomib" ] ] ]
Estrone sulfate may lead to a major life threatening interaction when taken with Carfilzomib Estrone sulfate (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Carfilzomib (Compound) Estrone sulfate may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib Estrone sulfate (Compound) resembles Estradiol (Compound) and Estradiol may lead to a major life threatening interaction when taken with Carfilzomib Estrone sulfate (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ritonavir (Compound) and Ritonavir (Compound) resembles Carfilzomib (Compound) Estrone sulfate (Compound) causes Infection (Side Effect) and Infection (Side Effect) is caused by Cabazitaxel (Compound) and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib Estrone sulfate (Compound) causes Hypercalcaemia (Side Effect) and Hypercalcaemia (Side Effect) is caused by Ponatinib (Compound) and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib Estrone sulfate may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Lopinavir and Lopinavir (Compound) resembles Carfilzomib (Compound) Estrone sulfate (Compound) resembles Estradiol (Compound) and Estradiol (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Carfilzomib (Compound) Estrone sulfate (Compound) resembles Quinestrol (Compound) and Quinestrol may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib
DB00220
DB00530
798
1,195
[ "DDInter1276", "DDInter667" ]
Nelfinavir
Erlotinib
Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.
Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor. Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloproliferative disorders.
Moderate
1
[ [ [ 798, 24, 1195 ] ], [ [ 798, 24, 883 ], [ 883, 40, 1195 ] ], [ [ 798, 6, 7950 ], [ 7950, 45, 1195 ] ], [ [ 798, 7, 5196 ], [ 5196, 46, 1195 ] ], [ [ 798, 18, 2650 ], [ 2650, 57, 1195 ] ], [ [ 798, 21, 28759 ], [ 28759, 60, 1195 ] ], [ [ 798, 24, 760 ], [ 760, 63, 1195 ] ], [ [ 798, 23, 752 ], [ 752, 24, 1195 ] ], [ [ 798, 25, 1406 ], [ 1406, 63, 1195 ] ], [ [ 798, 23, 1194 ], [ 1194, 63, 1195 ] ] ]
[ [ [ "Nelfinavir", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Erlotinib" ] ], [ [ "Nelfinavir", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Gefitinib" ], [ "Gefitinib", "{u} (Compound) resembles {v} (Compound)", "Erlotinib" ] ], [ [ "Nelfinavir", "{u} (Compound) binds {v} (Gene)", "CYP1A2" ], [ "CYP1A2", "{u} (Gene) is bound by {v} (Compound)", "Erlotinib" ] ], [ [ "Nelfinavir", "{u} (Compound) upregulates {v} (Gene)", "CBLB" ], [ "CBLB", "{u} (Gene) is upregulated by {v} (Compound)", "Erlotinib" ] ], [ [ "Nelfinavir", "{u} (Compound) downregulates {v} (Gene)", "RPIA" ], [ "RPIA", "{u} (Gene) is downregulated by {v} (Compound)", "Erlotinib" ] ], [ [ "Nelfinavir", "{u} (Compound) causes {v} (Side Effect)", "Connective tissue disorder" ], [ "Connective tissue disorder", "{u} (Side Effect) is caused by {v} (Compound)", "Erlotinib" ] ], [ [ "Nelfinavir", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Cobicistat" ], [ "Cobicistat", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Erlotinib" ] ], [ [ "Nelfinavir", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Cimetidine" ], [ "Cimetidine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Erlotinib" ] ], [ [ "Nelfinavir", "{u} may lead to a major life threatening interaction when taken with {v}", "Neratinib" ], [ "Neratinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Erlotinib" ] ], [ [ "Nelfinavir", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Ranitidine" ], [ "Ranitidine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Erlotinib" ] ] ]
Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib (Compound) resembles Erlotinib (Compound) Nelfinavir (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Erlotinib (Compound) Nelfinavir (Compound) upregulates CBLB (Gene) and CBLB (Gene) is upregulated by Erlotinib (Compound) Nelfinavir (Compound) downregulates RPIA (Gene) and RPIA (Gene) is downregulated by Erlotinib (Compound) Nelfinavir (Compound) causes Connective tissue disorder (Side Effect) and Connective tissue disorder (Side Effect) is caused by Erlotinib (Compound) Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat and Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Erlotinib Nelfinavir may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Erlotinib Nelfinavir may lead to a major life threatening interaction when taken with Neratinib and Neratinib may cause a moderate interaction that could exacerbate diseases when taken with Erlotinib Nelfinavir may cause a minor interaction that can limit clinical effects when taken with Ranitidine and Ranitidine may cause a moderate interaction that could exacerbate diseases when taken with Erlotinib
DB00247
DB08820
1,131
1,478
[ "DDInter1194", "DDInter997" ]
Methysergide
Ivacaftor
An ergot derivative that is a congener of lysergic acid diethylamide. It antagonizes the effects of serotonin in blood vessels and gastrointestinal smooth muscle, but has few of the properties of other ergot alkaloids. Methysergide is used prophylactically in migraine and other vascular headaches and to antagonize serotonin in the carcinoid syndrome.
Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and also administered in combination with other drugs for the management of CF.[L6814,L6979,L6847] Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, an ion channel involved in the transport of chloride and sodium ions across cell membranes. CFTR is active in epithelial cells of organs such as of the lungs, pancreas, liver, digestive system, and reproductive tract. Alterations in the CFTR gene result in altered production, misfolding, or function of the protein and consequently abnormal fluid and ion transport across cell membranes.[A20298, A20299] As a result, CF patients produce thick, sticky mucus that clogs the ducts of organs where it is produced making patients more susceptible to complications such as infections, lung damage, pancreatic insufficiency, and malnutrition. Prior to the development of ivacaftor, management of CF primarily involved therapies for the control of infections, nutritional support, clearance of mucus, and management of symptoms rather than improvements in the underlying disease process or lung function (FEV1). Notably, ivacaftor was the first medication approved for the management of the underlying causes of CF (abnormalities in CFTR protein function) rather than control of symptoms.
Moderate
1
[ [ [ 1131, 24, 1478 ] ], [ [ 1131, 21, 29998 ], [ 29998, 60, 1478 ] ], [ [ 1131, 24, 985 ], [ 985, 63, 1478 ] ], [ [ 1131, 24, 752 ], [ 752, 24, 1478 ] ], [ [ 1131, 40, 588 ], [ 588, 24, 1478 ] ], [ [ 1131, 63, 1324 ], [ 1324, 24, 1478 ] ], [ [ 1131, 1, 469 ], [ 469, 24, 1478 ] ], [ [ 1131, 63, 600 ], [ 600, 25, 1478 ] ], [ [ 1131, 24, 1593 ], [ 1593, 64, 1478 ] ], [ [ 1131, 25, 609 ], [ 609, 25, 1478 ] ] ]
[ [ [ "Methysergide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ivacaftor" ] ], [ [ "Methysergide", "{u} (Compound) causes {v} (Side Effect)", "Hyperaesthesia" ], [ "Hyperaesthesia", "{u} (Side Effect) is caused by {v} (Compound)", "Ivacaftor" ] ], [ [ "Methysergide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Osimertinib" ], [ "Osimertinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ivacaftor" ] ], [ [ "Methysergide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Cimetidine" ], [ "Cimetidine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ivacaftor" ] ], [ [ "Methysergide", "{u} (Compound) resembles {v} (Compound)", "Methylergometrine" ], [ "Methylergometrine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ivacaftor" ] ], [ [ "Methysergide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Troglitazone" ], [ "Troglitazone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ivacaftor" ] ], [ [ "Methysergide", "{u} (Compound) resembles {v} (Compound)", "Bromocriptine" ], [ "Bromocriptine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ivacaftor" ] ], [ [ "Methysergide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fluconazole" ], [ "Fluconazole", "{u} may lead to a major life threatening interaction when taken with {v}", "Ivacaftor" ] ], [ [ "Methysergide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Crizotinib" ], [ "Crizotinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Ivacaftor" ] ], [ [ "Methysergide", "{u} may lead to a major life threatening interaction when taken with {v}", "Clarithromycin" ], [ "Clarithromycin", "{u} may lead to a major life threatening interaction when taken with {v}", "Ivacaftor" ] ] ]
Methysergide (Compound) causes Hyperaesthesia (Side Effect) and Hyperaesthesia (Side Effect) is caused by Ivacaftor (Compound) Methysergide may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib and Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor Methysergide may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor Methysergide (Compound) resembles Methylergometrine (Compound) and Methylergometrine may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor Methysergide may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor Methysergide (Compound) resembles Bromocriptine (Compound) and Bromocriptine may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor Methysergide may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may lead to a major life threatening interaction when taken with Ivacaftor Methysergide may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may lead to a major life threatening interaction when taken with Ivacaftor Methysergide may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Ivacaftor
DB06237
DB12130
438
1,017
[ "DDInter141", "DDInter1094" ]
Avanafil
Lorlatinib
Avanafil is a phosphodiesterase-5 (PDE5) inhibitor used in the treatment of erectile dysfunction. In comparison with other drugs of the same class, it shows greater selectivity for PDE5 over PDE6 than both [sildenafil] and [vardenafil] but less selectivity than [tadalafil], suggesting a relatively lower risk of visual disturbances associated with off-target PDE6 inhibition. It first received FDA approval on April 27, 2012, with subsequent EMA approval in June 2013.
Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to include lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC.
Moderate
1
[ [ [ 438, 24, 1017 ] ], [ [ 438, 63, 1101 ], [ 1101, 23, 1017 ] ], [ [ 438, 24, 549 ], [ 549, 24, 1017 ] ], [ [ 438, 24, 159 ], [ 159, 63, 1017 ] ], [ [ 438, 64, 1419 ], [ 1419, 24, 1017 ] ], [ [ 438, 25, 1593 ], [ 1593, 24, 1017 ] ], [ [ 438, 63, 1324 ], [ 1324, 24, 1017 ] ], [ [ 438, 63, 1220 ], [ 1220, 25, 1017 ] ], [ [ 438, 24, 129 ], [ 129, 25, 1017 ] ], [ [ 438, 25, 283 ], [ 283, 64, 1017 ] ] ]
[ [ [ "Avanafil", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lorlatinib" ] ], [ [ "Avanafil", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bexarotene" ], [ "Bexarotene", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Lorlatinib" ] ], [ [ "Avanafil", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dapagliflozin" ], [ "Dapagliflozin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lorlatinib" ] ], [ [ "Avanafil", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Larotrectinib" ], [ "Larotrectinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lorlatinib" ] ], [ [ "Avanafil", "{u} may lead to a major life threatening interaction when taken with {v}", "Imatinib" ], [ "Imatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lorlatinib" ] ], [ [ "Avanafil", "{u} may lead to a major life threatening interaction when taken with {v}", "Crizotinib" ], [ "Crizotinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lorlatinib" ] ], [ [ "Avanafil", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Troglitazone" ], [ "Troglitazone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lorlatinib" ] ], [ [ "Avanafil", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dexamethasone" ], [ "Dexamethasone", "{u} may lead to a major life threatening interaction when taken with {v}", "Lorlatinib" ] ], [ [ "Avanafil", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Enzalutamide" ], [ "Enzalutamide", "{u} may lead to a major life threatening interaction when taken with {v}", "Lorlatinib" ] ], [ [ "Avanafil", "{u} may lead to a major life threatening interaction when taken with {v}", "Fedratinib" ], [ "Fedratinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Lorlatinib" ] ] ]
Avanafil may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lorlatinib Avanafil may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib Avanafil may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib Avanafil may lead to a major life threatening interaction when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib Avanafil may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib Avanafil may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib Avanafil may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may lead to a major life threatening interaction when taken with Lorlatinib Avanafil may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Lorlatinib Avanafil may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may lead to a major life threatening interaction when taken with Lorlatinib
DB00912
DB01128
473
918
[ "DDInter1581", "DDInter204" ]
Repaglinide
Bicalutamide
Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia
Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor.
Moderate
1
[ [ [ 473, 24, 918 ] ], [ [ 473, 24, 129 ], [ 129, 40, 918 ] ], [ [ 473, 6, 8374 ], [ 8374, 45, 918 ] ], [ [ 473, 21, 29232 ], [ 29232, 60, 918 ] ], [ [ 473, 24, 1247 ], [ 1247, 23, 918 ] ], [ [ 473, 24, 392 ], [ 392, 63, 918 ] ], [ [ 473, 63, 485 ], [ 485, 24, 918 ] ], [ [ 473, 25, 956 ], [ 956, 24, 918 ] ], [ [ 473, 24, 1148 ], [ 1148, 24, 918 ] ], [ [ 473, 25, 1539 ], [ 1539, 63, 918 ] ] ]
[ [ [ "Repaglinide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bicalutamide" ] ], [ [ "Repaglinide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Enzalutamide" ], [ "Enzalutamide", "{u} (Compound) resembles {v} (Compound)", "Bicalutamide" ] ], [ [ "Repaglinide", "{u} (Compound) binds {v} (Gene)", "CYP3A4" ], [ "CYP3A4", "{u} (Gene) is bound by {v} (Compound)", "Bicalutamide" ] ], [ [ "Repaglinide", "{u} (Compound) causes {v} (Side Effect)", "Urticaria" ], [ "Urticaria", "{u} (Side Effect) is caused by {v} (Compound)", "Bicalutamide" ] ], [ [ "Repaglinide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sulfamethoxazole" ], [ "Sulfamethoxazole", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Bicalutamide" ] ], [ [ "Repaglinide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lapatinib" ], [ "Lapatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bicalutamide" ] ], [ [ "Repaglinide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pentamidine" ], [ "Pentamidine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bicalutamide" ] ], [ [ "Repaglinide", "{u} may lead to a major life threatening interaction when taken with {v}", "Norfloxacin" ], [ "Norfloxacin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bicalutamide" ] ], [ [ "Repaglinide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Isoprenaline" ], [ "Isoprenaline", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bicalutamide" ] ], [ [ "Repaglinide", "{u} may lead to a major life threatening interaction when taken with {v}", "Ofloxacin" ], [ "Ofloxacin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bicalutamide" ] ] ]
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide (Compound) resembles Bicalutamide (Compound) Repaglinide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bicalutamide (Compound) Repaglinide (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Bicalutamide (Compound) Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Bicalutamide Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide Repaglinide may lead to a major life threatening interaction when taken with Norfloxacin and Norfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide Repaglinide may lead to a major life threatening interaction when taken with Ofloxacin and Ofloxacin may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide
DB01403
DB11978
9
124
[ "DDInter1175", "DDInter822" ]
Methotrimeprazine
Glasdegib
A phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604)
Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionality. The great lipophilicity of this group of compounds brought interest to further modification. This analysis concluded that the presence of p-cyano ureas presented good physicochemical and pharmacokinetic properties from which glasdegib was developed. Glasdegib was developed by Pfizer Inc and approved on November 21, 2018 by the FDA for the treatment of Acute Myeloid Leukemia (AML). Glasdegib targets cancerous cells by inhibiting the sonic hedgehog receptor smoothened (SMO), a transmembrane protein involved in the Hedgehog (Hh) signaling cascade. Aberrant of Hh signaling is one of the main pathophysiologies of AML, with observed overexpression or constitutive activation of SMO.[A258498,A258503] Although the efficacy of glasdegib monotherapy is limited, the landmark Phase 2 Bright AML 1003 trial showed a superior overall survival and complete response when glasdegib is combined with low dose cytarabine. Currently, the current gold standard of AML in older patients is still venetoclax with hypomethylation agents, new clinical combinations of glasdegib are being tested in hope of replacing venetoclax due to glasdegib's more favorable side effects profile.
Moderate
1
[ [ [ 9, 24, 124 ] ], [ [ 9, 62, 112 ], [ 112, 23, 124 ] ], [ [ 9, 63, 475 ], [ 475, 24, 124 ] ], [ [ 9, 1, 1237 ], [ 1237, 24, 124 ] ], [ [ 9, 25, 1670 ], [ 1670, 24, 124 ] ], [ [ 9, 24, 1342 ], [ 1342, 24, 124 ] ], [ [ 9, 24, 823 ], [ 823, 63, 124 ] ], [ [ 9, 40, 1164 ], [ 1164, 24, 124 ] ], [ [ 9, 64, 702 ], [ 702, 25, 124 ] ], [ [ 9, 25, 982 ], [ 982, 64, 124 ] ] ]
[ [ [ "Methotrimeprazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Glasdegib" ] ], [ [ "Methotrimeprazine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Metronidazole" ], [ "Metronidazole", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Glasdegib" ] ], [ [ "Methotrimeprazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Morphine" ], [ "Morphine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Glasdegib" ] ], [ [ "Methotrimeprazine", "{u} (Compound) resembles {v} (Compound)", "Clomipramine" ], [ "Clomipramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Glasdegib" ] ], [ [ "Methotrimeprazine", "{u} may lead to a major life threatening interaction when taken with {v}", "Eliglustat" ], [ "Eliglustat", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Glasdegib" ] ], [ [ "Methotrimeprazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Romidepsin" ], [ "Romidepsin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Glasdegib" ] ], [ [ "Methotrimeprazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Triclabendazole" ], [ "Triclabendazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Glasdegib" ] ], [ [ "Methotrimeprazine", "{u} (Compound) resembles {v} (Compound)", "Trimipramine" ], [ "Trimipramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Glasdegib" ] ], [ [ "Methotrimeprazine", "{u} may lead to a major life threatening interaction when taken with {v}", "Anagrelide" ], [ "Anagrelide", "{u} may lead to a major life threatening interaction when taken with {v}", "Glasdegib" ] ], [ [ "Methotrimeprazine", "{u} may lead to a major life threatening interaction when taken with {v}", "Ivosidenib" ], [ "Ivosidenib", "{u} may lead to a major life threatening interaction when taken with {v}", "Glasdegib" ] ] ]
Methotrimeprazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Glasdegib Methotrimeprazine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib Methotrimeprazine (Compound) resembles Clomipramine (Compound) and Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib Methotrimeprazine may lead to a major life threatening interaction when taken with Eliglustat and Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib Methotrimeprazine may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin and Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib Methotrimeprazine may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole and Triclabendazole may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib Methotrimeprazine (Compound) resembles Trimipramine (Compound) and Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib Methotrimeprazine may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may lead to a major life threatening interaction when taken with Glasdegib Methotrimeprazine may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may lead to a major life threatening interaction when taken with Glasdegib
DB00372
DB00397
999
1,466
[ "DDInter1793", "DDInter1458" ]
Thiethylperazine
Phenylpropanolamine
A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457)
Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor. It has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes.
Moderate
1
[ [ [ 999, 24, 1466 ] ], [ [ 999, 63, 73 ], [ 73, 25, 1466 ] ], [ [ 999, 63, 80 ], [ 80, 24, 1466 ] ], [ [ 999, 24, 1178 ], [ 1178, 63, 1466 ] ], [ [ 999, 25, 684 ], [ 684, 63, 1466 ] ], [ [ 999, 24, 1161 ], [ 1161, 64, 1466 ] ], [ [ 999, 25, 593 ], [ 593, 64, 1466 ] ], [ [ 999, 64, 534 ], [ 534, 25, 1466 ] ], [ [ 999, 24, 93 ], [ 93, 74, 1466 ] ], [ [ 999, 24, 551 ], [ 551, 75, 1466 ] ] ]
[ [ [ "Thiethylperazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Phenylpropanolamine" ] ], [ [ "Thiethylperazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Phentermine" ], [ "Phentermine", "{u} may lead to a major life threatening interaction when taken with {v}", "Phenylpropanolamine" ] ], [ [ "Thiethylperazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Amphetamine" ], [ "Amphetamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Phenylpropanolamine" ] ], [ [ "Thiethylperazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Trifluoperazine" ], [ "Trifluoperazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Phenylpropanolamine" ] ], [ [ "Thiethylperazine", "{u} may lead to a major life threatening interaction when taken with {v}", "Thioridazine" ], [ "Thioridazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Phenylpropanolamine" ] ], [ [ "Thiethylperazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Selegiline" ], [ "Selegiline", "{u} may lead to a major life threatening interaction when taken with {v}", "Phenylpropanolamine" ] ], [ [ "Thiethylperazine", "{u} may lead to a major life threatening interaction when taken with {v}", "Bupropion" ], [ "Bupropion", "{u} may lead to a major life threatening interaction when taken with {v}", "Phenylpropanolamine" ] ], [ [ "Thiethylperazine", "{u} may lead to a major life threatening interaction when taken with {v}", "Tramadol" ], [ "Tramadol", "{u} may lead to a major life threatening interaction when taken with {v}", "Phenylpropanolamine" ] ], [ [ "Thiethylperazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dextroamphetamine" ], [ "Dextroamphetamine", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Phenylpropanolamine" ] ], [ [ "Thiethylperazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Phenelzine" ], [ "Phenelzine", "{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}", "Phenylpropanolamine" ] ] ]
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phentermine may lead to a major life threatening interaction when taken with Phenylpropanolamine Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Amphetamine and Amphetamine may cause a moderate interaction that could exacerbate diseases when taken with Phenylpropanolamine Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine may cause a moderate interaction that could exacerbate diseases when taken with Phenylpropanolamine Thiethylperazine may lead to a major life threatening interaction when taken with Thioridazine and Thioridazine may cause a moderate interaction that could exacerbate diseases when taken with Phenylpropanolamine Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Selegiline and Selegiline may lead to a major life threatening interaction when taken with Phenylpropanolamine Thiethylperazine may lead to a major life threatening interaction when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Phenylpropanolamine Thiethylperazine may lead to a major life threatening interaction when taken with Tramadol and Tramadol may lead to a major life threatening interaction when taken with Phenylpropanolamine Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Dextroamphetamine and Dextroamphetamine (Compound) resembles Phenylpropanolamine (Compound) and Dextroamphetamine may cause a moderate interaction that could exacerbate diseases when taken with Phenylpropanolamine Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Phenelzine and Phenelzine (Compound) resembles Phenylpropanolamine (Compound) and Phenelzine may lead to a major life threatening interaction when taken with Phenylpropanolamine
DB00446
DB00604
597
1,425
[ "DDInter351", "DDInter385" ]
Chloramphenicol
Cisapride
An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The Extra Pharmacopoeia, 29th ed, p106) The FDA has withdrawn all oral drug products containing chloramphenicol, due to the high risk of fatal aplastic anemia associated with this specific route of administration.[L43942,L44022]
In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients.
Major
2
[ [ [ 597, 25, 1425 ] ], [ [ 597, 63, 883 ], [ 883, 1, 1425 ] ], [ [ 597, 6, 21998 ], [ 21998, 45, 1425 ] ], [ [ 597, 24, 112 ], [ 112, 62, 1425 ] ], [ [ 597, 24, 1362 ], [ 1362, 63, 1425 ] ], [ [ 597, 23, 479 ], [ 479, 63, 1425 ] ], [ [ 597, 25, 1476 ], [ 1476, 63, 1425 ] ], [ [ 597, 62, 1101 ], [ 1101, 24, 1425 ] ], [ [ 597, 24, 932 ], [ 932, 64, 1425 ] ], [ [ 597, 62, 1230 ], [ 1230, 25, 1425 ] ] ]
[ [ [ "Chloramphenicol", "{u} may lead to a major life threatening interaction when taken with {v}", "Cisapride" ] ], [ [ "Chloramphenicol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Gefitinib" ], [ "Gefitinib", "{u} (Compound) resembles {v} (Compound)", "Cisapride" ] ], [ [ "Chloramphenicol", "{u} (Compound) binds {v} (Gene)", "CYP3A7-CYP3A51P" ], [ "CYP3A7-CYP3A51P", "{u} (Gene) is bound by {v} (Compound)", "Cisapride" ] ], [ [ "Chloramphenicol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Metronidazole" ], [ "Metronidazole", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Cisapride" ] ], [ [ "Chloramphenicol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Olaparib" ], [ "Olaparib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Cisapride" ] ], [ [ "Chloramphenicol", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Donepezil" ], [ "Donepezil", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Cisapride" ] ], [ [ "Chloramphenicol", "{u} may lead to a major life threatening interaction when taken with {v}", "Brigatinib" ], [ "Brigatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Cisapride" ] ], [ [ "Chloramphenicol", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Bexarotene" ], [ "Bexarotene", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Cisapride" ] ], [ [ "Chloramphenicol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mifepristone" ], [ "Mifepristone", "{u} may lead to a major life threatening interaction when taken with {v}", "Cisapride" ] ], [ [ "Chloramphenicol", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Citalopram" ], [ "Citalopram", "{u} may lead to a major life threatening interaction when taken with {v}", "Cisapride" ] ] ]
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib (Compound) resembles Cisapride (Compound) Chloramphenicol (Compound) binds CYP3A7-CYP3A51P (Gene) and CYP3A7-CYP3A51P (Gene) is bound by Cisapride (Compound) Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Cisapride Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Cisapride Chloramphenicol may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Cisapride Chloramphenicol may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Cisapride Chloramphenicol may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Cisapride Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Mifepristone and Mifepristone may lead to a major life threatening interaction when taken with Cisapride Chloramphenicol may cause a minor interaction that can limit clinical effects when taken with Citalopram and Citalopram may lead to a major life threatening interaction when taken with Cisapride
DB01042
DB08913
1,307
1,186
[ "DDInter1144", "DDInter1561" ]
Melphalan
Radium Ra 223 dichloride
Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard.[A261150, A261155] Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is also used to treat uveal melanoma with unresectable hepatic metastases.
Radium Ra 223 Dichloride is a radiopharmaceutical containing the radioisotope radium-223 that emits short range but high linear energy alpha particles. As a cation, radium mimics calicum and binds to hydroxyapatite, which is a bone mineral found in areas of high bone turnover as seen in bone metastases. It was first approved by the FDA in May 2013 and is currently marketed under the brand name Xofigo, which was formerly called Alpharadin. Xofigo is indicated in patients who have metastatic bone cancer that is symptomatic with no visceral metastases and patients who have prostate cancer that is castration resistant. The FDA label includes a warning that Radium Ra 223 Dichloride should not be used in women who are pregnant or may become pregnant due to the high risk of fetal harm.
Moderate
1
[ [ [ 1307, 24, 1186 ] ], [ [ 1307, 21, 28872 ], [ 28872, 60, 1186 ] ], [ [ 1307, 24, 37 ], [ 37, 24, 1186 ] ], [ [ 1307, 63, 134 ], [ 134, 24, 1186 ] ], [ [ 1307, 62, 168 ], [ 168, 24, 1186 ] ], [ [ 1307, 24, 1362 ], [ 1362, 63, 1186 ] ], [ [ 1307, 25, 1377 ], [ 1377, 24, 1186 ] ], [ [ 1307, 25, 1259 ], [ 1259, 63, 1186 ] ], [ [ 1307, 64, 1064 ], [ 1064, 24, 1186 ] ], [ [ 1307, 21, 28872 ], [ 28872, 60, 134 ], [ 134, 24, 1186 ] ] ]
[ [ [ "Melphalan", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Radium Ra 223 dichloride" ] ], [ [ "Melphalan", "{u} (Compound) causes {v} (Side Effect)", "Extravasation" ], [ "Extravasation", "{u} (Side Effect) is caused by {v} (Compound)", "Radium Ra 223 dichloride" ] ], [ [ "Melphalan", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lomustine" ], [ "Lomustine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Radium Ra 223 dichloride" ] ], [ [ "Melphalan", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Vinorelbine" ], [ "Vinorelbine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Radium Ra 223 dichloride" ] ], [ [ "Melphalan", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Bortezomib" ], [ "Bortezomib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Radium Ra 223 dichloride" ] ], [ [ "Melphalan", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Olaparib" ], [ "Olaparib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Radium Ra 223 dichloride" ] ], [ [ "Melphalan", "{u} may lead to a major life threatening interaction when taken with {v}", "Leflunomide" ], [ "Leflunomide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Radium Ra 223 dichloride" ] ], [ [ "Melphalan", "{u} may lead to a major life threatening interaction when taken with {v}", "Baricitinib" ], [ "Baricitinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Radium Ra 223 dichloride" ] ], [ [ "Melphalan", "{u} may lead to a major life threatening interaction when taken with {v}", "Cladribine" ], [ "Cladribine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Radium Ra 223 dichloride" ] ], [ [ "Melphalan", "{u} (Compound) causes {v} (Side Effect)", "Extravasation" ], [ "Extravasation", "{u} (Side Effect) is caused by {v} (Compound)", "Vinorelbine" ], [ "Vinorelbine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Radium Ra 223 dichloride" ] ] ]
Melphalan (Compound) causes Extravasation (Side Effect) and Extravasation (Side Effect) is caused by Radium Ra 223 dichloride (Compound) Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Lomustine and Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride Melphalan may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride Melphalan may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride Melphalan may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride Melphalan may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride Melphalan (Compound) causes Extravasation (Side Effect) and Extravasation (Side Effect) is caused by Vinorelbine (Compound) and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride
DB08870
DB12015
850
1,033
[ "DDInter228", "DDInter53" ]
Brentuximab vedotin
Alpelisib
Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post-treatment. The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy. Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodg
Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metabolism. Alpelisib was designed to target this enzyme that appears to be mutated at a rate of nearly 30% in human cancers, leading to hyperactivation. There are several isoform-specific PI3K inhibitors that are under clinical development or currently approved, such as [idelalisib] used for chronic lymphocytic leukemia (CLL). Approved by the FDA in May 2019, alpelisib is the first approved PI3K inhibitor indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer in combination with [fulvestrant] for postmenopausal women and male patients. To initiate alpelisib therapy, it is required that the presence of a PIK3CA mutation in the tissue and/or liquid biopsy sample collection should be confirmed via FDA-approved diagnostic tests. Alpelisib is marketed under the trade name Piqray and is available as oral tablets. Studies evaluating the therapeutic effectiveness of alpelisib in other cancers, such as ovarian cancer and colorectal cancer , are under ongoing investigations. Alpelisib was granted FDA approval on 24 May 2019. In April 2022, the FDA granted the use of alpelisib in the treatment of PIK3CA-Related Overgrowth Spectrum (PROS) in adults and children who require systemic therapy.
Moderate
1
[ [ [ 850, 24, 1033 ] ], [ [ 850, 63, 1254 ], [ 1254, 24, 1033 ] ], [ [ 850, 24, 738 ], [ 738, 24, 1033 ] ], [ [ 850, 25, 1510 ], [ 1510, 24, 1033 ] ], [ [ 850, 24, 1385 ], [ 1385, 63, 1033 ] ], [ [ 850, 64, 1064 ], [ 1064, 24, 1033 ] ], [ [ 850, 63, 362 ], [ 362, 25, 1033 ] ], [ [ 850, 24, 129 ], [ 129, 25, 1033 ] ], [ [ 850, 63, 1254 ], [ 1254, 24, 154 ], [ 154, 24, 1033 ] ], [ [ 850, 24, 738 ], [ 738, 64, 1510 ], [ 1510, 24, 1033 ] ] ]
[ [ [ "Brentuximab vedotin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Alpelisib" ] ], [ [ "Brentuximab vedotin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Insulin glulisine" ], [ "Insulin glulisine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Alpelisib" ] ], [ [ "Brentuximab vedotin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Niraparib" ], [ "Niraparib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Alpelisib" ] ], [ [ "Brentuximab vedotin", "{u} may lead to a major life threatening interaction when taken with {v}", "Teriflunomide" ], [ "Teriflunomide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Alpelisib" ] ], [ [ "Brentuximab vedotin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Semaglutide" ], [ "Semaglutide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Alpelisib" ] ], [ [ "Brentuximab vedotin", "{u} may lead to a major life threatening interaction when taken with {v}", "Cladribine" ], [ "Cladribine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Alpelisib" ] ], [ [ "Brentuximab vedotin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Phenytoin" ], [ "Phenytoin", "{u} may lead to a major life threatening interaction when taken with {v}", "Alpelisib" ] ], [ [ "Brentuximab vedotin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Enzalutamide" ], [ "Enzalutamide", "{u} may lead to a major life threatening interaction when taken with {v}", "Alpelisib" ] ], [ [ "Brentuximab vedotin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Insulin glulisine" ], [ "Insulin glulisine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lurasidone" ], [ "Lurasidone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Alpelisib" ] ], [ [ "Brentuximab vedotin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Niraparib" ], [ "Niraparib", "{u} may lead to a major life threatening interaction when taken with {v}", "Teriflunomide" ], [ "Teriflunomide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Alpelisib" ] ] ]
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine and Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib Brentuximab vedotin may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide and Semaglutide may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib Brentuximab vedotin may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin may lead to a major life threatening interaction when taken with Alpelisib Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Alpelisib Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine and Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Lurasidone and Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
DB00657
DB08907
1,360
1,344
[ "DDInter1130", "DDInter280" ]
Mecamylamine
Canagliflozin
A nicotinic antagonist that is well absorbed from the gastrointestinal tract and crosses the blood-brain barrier. Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool.
Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 for a second indication of reducing the risk of cardiovascular events in patients diagnosed with type 2 diabetes mellitus , [FDA label]. Canagliflozin is the first oral antidiabetic drug approved for the prevention of cardiovascular events in patients with type 2 diabetes . Cardiovascular disease is the most common cause of death in these patients .
Moderate
1
[ [ [ 1360, 24, 1344 ] ], [ [ 1360, 24, 549 ], [ 549, 1, 1344 ] ], [ [ 1360, 21, 28827 ], [ 28827, 60, 1344 ] ], [ [ 1360, 24, 1445 ], [ 1445, 24, 1344 ] ], [ [ 1360, 63, 999 ], [ 999, 24, 1344 ] ], [ [ 1360, 24, 1455 ], [ 1455, 63, 1344 ] ], [ [ 1360, 24, 549 ], [ 549, 6, 16207 ], [ 16207, 45, 1344 ] ], [ [ 1360, 21, 28827 ], [ 28827, 60, 549 ], [ 549, 1, 1344 ] ], [ [ 1360, 21, 28789 ], [ 28789, 60, 739 ], [ 739, 24, 1344 ] ], [ [ 1360, 24, 1445 ], [ 1445, 24, 549 ], [ 549, 1, 1344 ] ] ]
[ [ [ "Mecamylamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Canagliflozin" ] ], [ [ "Mecamylamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dapagliflozin" ], [ "Dapagliflozin", "{u} (Compound) resembles {v} (Compound)", "Canagliflozin" ] ], [ [ "Mecamylamine", "{u} (Compound) causes {v} (Side Effect)", "Orthostatic hypotension" ], [ "Orthostatic hypotension", "{u} (Side Effect) is caused by {v} (Compound)", "Canagliflozin" ] ], [ [ "Mecamylamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pseudoephedrine" ], [ "Pseudoephedrine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Canagliflozin" ] ], [ [ "Mecamylamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Thiethylperazine" ], [ "Thiethylperazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Canagliflozin" ] ], [ [ "Mecamylamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nitrous acid" ], [ "Nitrous acid", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Canagliflozin" ] ], [ [ "Mecamylamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dapagliflozin" ], [ "Dapagliflozin", "{u} (Compound) binds {v} (Gene)", "SLC5A1" ], [ "SLC5A1", "{u} (Gene) is bound by {v} (Compound)", "Canagliflozin" ] ], [ [ "Mecamylamine", "{u} (Compound) causes {v} (Side Effect)", "Orthostatic hypotension" ], [ "Orthostatic hypotension", "{u} (Side Effect) is caused by {v} (Compound)", "Dapagliflozin" ], [ "Dapagliflozin", "{u} (Compound) resembles {v} (Compound)", "Canagliflozin" ] ], [ [ "Mecamylamine", "{u} (Compound) causes {v} (Side Effect)", "Loss of consciousness" ], [ "Loss of consciousness", "{u} (Side Effect) is caused by {v} (Compound)", "Lomefloxacin" ], [ "Lomefloxacin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Canagliflozin" ] ], [ [ "Mecamylamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pseudoephedrine" ], [ "Pseudoephedrine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dapagliflozin" ], [ "Dapagliflozin", "{u} (Compound) resembles {v} (Compound)", "Canagliflozin" ] ] ]
Mecamylamine may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound) Mecamylamine (Compound) causes Orthostatic hypotension (Side Effect) and Orthostatic hypotension (Side Effect) is caused by Canagliflozin (Compound) Mecamylamine may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine and Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin Mecamylamine may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin Mecamylamine may cause a moderate interaction that could exacerbate diseases when taken with Nitrous acid and Nitrous acid may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin Mecamylamine may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) binds SLC5A1 (Gene) and SLC5A1 (Gene) is bound by Canagliflozin (Compound) Mecamylamine (Compound) causes Orthostatic hypotension (Side Effect) and Orthostatic hypotension (Side Effect) is caused by Dapagliflozin (Compound) and Dapagliflozin (Compound) resembles Canagliflozin (Compound) Mecamylamine (Compound) causes Loss of consciousness (Side Effect) and Loss of consciousness (Side Effect) is caused by Lomefloxacin (Compound) and Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin Mecamylamine may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine and Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
DB00086
DB01225
1,167
500
[ "DDInter1712", "DDInter645" ]
Streptokinase
Enoxaparin
Streptokinase, is a sterile, purified preparation of a bacterial protein elaborated by group C (beta) -hemolytic streptococci.
Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the incidence of venous thromboembolism in hospitalized patients when compared to unfractionated [heparin], without increasing the risk of serious bleeding.[A228178,A228313]
Major
2
[ [ [ 1167, 25, 500 ] ], [ [ 1167, 23, 1631 ], [ 1631, 62, 500 ] ], [ [ 1167, 24, 1004 ], [ 1004, 63, 500 ] ], [ [ 1167, 24, 1230 ], [ 1230, 24, 500 ] ], [ [ 1167, 63, 1595 ], [ 1595, 24, 500 ] ], [ [ 1167, 24, 1317 ], [ 1317, 25, 500 ] ], [ [ 1167, 25, 840 ], [ 840, 64, 500 ] ], [ [ 1167, 25, 553 ], [ 553, 25, 500 ] ], [ [ 1167, 24, 578 ], [ 578, 64, 500 ] ], [ [ 1167, 64, 1578 ], [ 1578, 25, 500 ] ] ]
[ [ [ "Streptokinase", "{u} may lead to a major life threatening interaction when taken with {v}", "Enoxaparin" ] ], [ [ "Streptokinase", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Turmeric" ], [ "Turmeric", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Enoxaparin" ] ], [ [ "Streptokinase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Phenyl salicylate" ], [ "Phenyl salicylate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Enoxaparin" ] ], [ [ "Streptokinase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Citalopram" ], [ "Citalopram", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Enoxaparin" ] ], [ [ "Streptokinase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Collagenase clostridium histolyticum" ], [ "Collagenase clostridium histolyticum", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Enoxaparin" ] ], [ [ "Streptokinase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dipyridamole" ], [ "Dipyridamole", "{u} may lead to a major life threatening interaction when taken with {v}", "Enoxaparin" ] ], [ [ "Streptokinase", "{u} may lead to a major life threatening interaction when taken with {v}", "Vorapaxar" ], [ "Vorapaxar", "{u} may lead to a major life threatening interaction when taken with {v}", "Enoxaparin" ] ], [ [ "Streptokinase", "{u} may lead to a major life threatening interaction when taken with {v}", "Fondaparinux" ], [ "Fondaparinux", "{u} may lead to a major life threatening interaction when taken with {v}", "Enoxaparin" ] ], [ [ "Streptokinase", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ticagrelor" ], [ "Ticagrelor", "{u} may lead to a major life threatening interaction when taken with {v}", "Enoxaparin" ] ], [ [ "Streptokinase", "{u} may lead to a major life threatening interaction when taken with {v}", "Lepirudin" ], [ "Lepirudin", "{u} may lead to a major life threatening interaction when taken with {v}", "Enoxaparin" ] ] ]
Streptokinase may cause a minor interaction that can limit clinical effects when taken with Turmeric and Turmeric may cause a minor interaction that can limit clinical effects when taken with Enoxaparin Streptokinase may cause a moderate interaction that could exacerbate diseases when taken with Phenyl salicylate and Phenyl salicylate may cause a moderate interaction that could exacerbate diseases when taken with Enoxaparin Streptokinase may cause a moderate interaction that could exacerbate diseases when taken with Citalopram and Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Enoxaparin Streptokinase may cause a moderate interaction that could exacerbate diseases when taken with Collagenase clostridium histolyticum and Collagenase clostridium histolyticum may cause a moderate interaction that could exacerbate diseases when taken with Enoxaparin Streptokinase may cause a moderate interaction that could exacerbate diseases when taken with Dipyridamole and Dipyridamole may lead to a major life threatening interaction when taken with Enoxaparin Streptokinase may lead to a major life threatening interaction when taken with Vorapaxar and Vorapaxar may lead to a major life threatening interaction when taken with Enoxaparin Streptokinase may lead to a major life threatening interaction when taken with Fondaparinux and Fondaparinux may lead to a major life threatening interaction when taken with Enoxaparin Streptokinase may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may lead to a major life threatening interaction when taken with Enoxaparin Streptokinase may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may lead to a major life threatening interaction when taken with Enoxaparin
DB08880
DB09122
1,510
1,613
[ "DDInter1771", "DDInter1409" ]
Teriflunomide
Peginterferon beta-1a
Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of hepatoxicity and teratogenicity for patients using teriflunomide.
Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792] Peginterferon beta-1a is an interferon therapy used for the management of relapsing forms of MS. It was originally approved by the FDA in 2014 for subcutaneous use, and was approved for intramuscular use in January 2021. Currently, it is the only approved pegylated interferon for the management of MS with an proven ability to reduce relapses and delay the progression of disability resulting from MS.
Major
2
[ [ [ 1510, 25, 1613 ] ], [ [ 1510, 64, 671 ], [ 671, 24, 1613 ] ], [ [ 1510, 25, 1627 ], [ 1627, 24, 1613 ] ], [ [ 1510, 25, 975 ], [ 975, 63, 1613 ] ], [ [ 1510, 24, 242 ], [ 242, 63, 1613 ] ], [ [ 1510, 63, 1031 ], [ 1031, 24, 1613 ] ], [ [ 1510, 64, 1377 ], [ 1377, 25, 1613 ] ], [ [ 1510, 64, 671 ], [ 671, 63, 600 ], [ 600, 24, 1613 ] ], [ [ 1510, 25, 1627 ], [ 1627, 62, 600 ], [ 600, 24, 1613 ] ], [ [ 1510, 25, 975 ], [ 975, 64, 600 ], [ 600, 24, 1613 ] ] ]
[ [ [ "Teriflunomide", "{u} may lead to a major life threatening interaction when taken with {v}", "Peginterferon beta-1a" ] ], [ [ "Teriflunomide", "{u} may lead to a major life threatening interaction when taken with {v}", "Fluvastatin" ], [ "Fluvastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Peginterferon beta-1a" ] ], [ [ "Teriflunomide", "{u} may lead to a major life threatening interaction when taken with {v}", "Cannabidiol" ], [ "Cannabidiol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Peginterferon beta-1a" ] ], [ [ "Teriflunomide", "{u} may lead to a major life threatening interaction when taken with {v}", "Lurbinectedin" ], [ "Lurbinectedin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Peginterferon beta-1a" ] ], [ [ "Teriflunomide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Remdesivir" ], [ "Remdesivir", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Peginterferon beta-1a" ] ], [ [ "Teriflunomide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Theophylline" ], [ "Theophylline", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Peginterferon beta-1a" ] ], [ [ "Teriflunomide", "{u} may lead to a major life threatening interaction when taken with {v}", "Leflunomide" ], [ "Leflunomide", "{u} may lead to a major life threatening interaction when taken with {v}", "Peginterferon beta-1a" ] ], [ [ "Teriflunomide", "{u} may lead to a major life threatening interaction when taken with {v}", "Fluvastatin" ], [ "Fluvastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fluconazole" ], [ "Fluconazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Peginterferon beta-1a" ] ], [ [ "Teriflunomide", "{u} may lead to a major life threatening interaction when taken with {v}", "Cannabidiol" ], [ "Cannabidiol", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Fluconazole" ], [ "Fluconazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Peginterferon beta-1a" ] ], [ [ "Teriflunomide", "{u} may lead to a major life threatening interaction when taken with {v}", "Lurbinectedin" ], [ "Lurbinectedin", "{u} may lead to a major life threatening interaction when taken with {v}", "Fluconazole" ], [ "Fluconazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Peginterferon beta-1a" ] ] ]
Teriflunomide may lead to a major life threatening interaction when taken with Fluvastatin and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a Teriflunomide may lead to a major life threatening interaction when taken with Cannabidiol and Cannabidiol may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a Teriflunomide may lead to a major life threatening interaction when taken with Lurbinectedin and Lurbinectedin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir and Remdesivir may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a Teriflunomide may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Peginterferon beta-1a Teriflunomide may lead to a major life threatening interaction when taken with Fluvastatin and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a Teriflunomide may lead to a major life threatening interaction when taken with Cannabidiol and Cannabidiol may cause a minor interaction that can limit clinical effects when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a Teriflunomide may lead to a major life threatening interaction when taken with Lurbinectedin and Lurbinectedin may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
DB00497
DB01069
828
401
[ "DDInter1366", "DDInter1533" ]
Oxycodone
Promethazine
Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917. It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label] The first oxycodone containing product, Percodan, was approved by the FDA on April 12, 1950.
Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A190153,A190159,A190150,A190171] Promethazine was granted FDA approval before 29 March 1951.[A190177,L4000]
Moderate
1
[ [ [ 828, 24, 401 ] ], [ [ 828, 24, 1264 ], [ 1264, 63, 401 ] ], [ [ 828, 24, 104 ], [ 104, 24, 401 ] ], [ [ 828, 6, 12523 ], [ 12523, 45, 401 ] ], [ [ 828, 21, 28709 ], [ 28709, 60, 401 ] ], [ [ 828, 25, 283 ], [ 283, 63, 401 ] ], [ [ 828, 63, 701 ], [ 701, 24, 401 ] ], [ [ 828, 1, 560 ], [ 560, 63, 401 ] ], [ [ 828, 40, 421 ], [ 421, 24, 401 ] ], [ [ 828, 64, 475 ], [ 475, 24, 401 ] ] ]
[ [ [ "Oxycodone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Promethazine" ] ], [ [ "Oxycodone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Doxepin" ], [ "Doxepin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Promethazine" ] ], [ [ "Oxycodone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Methdilazine" ], [ "Methdilazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Promethazine" ] ], [ [ "Oxycodone", "{u} (Compound) binds {v} (Gene)", "CYP2D6" ], [ "CYP2D6", "{u} (Gene) is bound by {v} (Compound)", "Promethazine" ] ], [ [ "Oxycodone", "{u} (Compound) causes {v} (Side Effect)", "Decreased appetite" ], [ "Decreased appetite", "{u} (Side Effect) is caused by {v} (Compound)", "Promethazine" ] ], [ [ "Oxycodone", "{u} may lead to a major life threatening interaction when taken with {v}", "Fedratinib" ], [ "Fedratinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Promethazine" ] ], [ [ "Oxycodone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clemastine" ], [ "Clemastine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Promethazine" ] ], [ [ "Oxycodone", "{u} (Compound) resembles {v} (Compound)", "Oxymorphone" ], [ "Oxymorphone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Promethazine" ] ], [ [ "Oxycodone", "{u} (Compound) resembles {v} (Compound)", "Hydromorphone" ], [ "Hydromorphone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Promethazine" ] ], [ [ "Oxycodone", "{u} may lead to a major life threatening interaction when taken with {v}", "Morphine" ], [ "Morphine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Promethazine" ] ] ]
Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine Oxycodone (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Promethazine (Compound) Oxycodone (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Promethazine (Compound) Oxycodone may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Promethazine Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine Oxycodone (Compound) resembles Oxymorphone (Compound) and Oxymorphone may cause a moderate interaction that could exacerbate diseases when taken with Promethazine Oxycodone (Compound) resembles Hydromorphone (Compound) and Hydromorphone may cause a moderate interaction that could exacerbate diseases when taken with Promethazine Oxycodone may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
DB00792
DB00980
832
969
[ "DDInter1878", "DDInter1564" ]
Tripelennamine
Ramelteon
A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. Tripelennamine is administered by various routes, including topically.
Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN). It is used for insomnia, particularly delayed sleep onset. Ramelteon has not been shown to produce dependence and has shown no potential for abuse.
Moderate
1
[ [ [ 832, 24, 969 ] ], [ [ 832, 24, 100 ], [ 100, 24, 969 ] ], [ [ 832, 63, 1242 ], [ 1242, 24, 969 ] ], [ [ 832, 40, 649 ], [ 649, 63, 969 ] ], [ [ 832, 74, 662 ], [ 662, 24, 969 ] ], [ [ 832, 24, 1376 ], [ 1376, 63, 969 ] ], [ [ 832, 35, 272 ], [ 272, 63, 969 ] ], [ [ 832, 63, 475 ], [ 475, 25, 969 ] ], [ [ 832, 24, 100 ], [ 100, 6, 8374 ], [ 8374, 45, 969 ] ], [ [ 832, 63, 1242 ], [ 1242, 21, 28714 ], [ 28714, 60, 969 ] ] ]
[ [ [ "Tripelennamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ramelteon" ] ], [ [ "Tripelennamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brompheniramine" ], [ "Brompheniramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ramelteon" ] ], [ [ "Tripelennamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Cetirizine" ], [ "Cetirizine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ramelteon" ] ], [ [ "Tripelennamine", "{u} (Compound) resembles {v} (Compound)", "Clofedanol" ], [ "Clofedanol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ramelteon" ] ], [ [ "Tripelennamine", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Carbinoxamine" ], [ "Carbinoxamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ramelteon" ] ], [ [ "Tripelennamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Diphenhydramine" ], [ "Diphenhydramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ramelteon" ] ], [ [ "Tripelennamine", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Chlorpheniramine" ], [ "Chlorpheniramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ramelteon" ] ], [ [ "Tripelennamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Morphine" ], [ "Morphine", "{u} may lead to a major life threatening interaction when taken with {v}", "Ramelteon" ] ], [ [ "Tripelennamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brompheniramine" ], [ "Brompheniramine", "{u} (Compound) binds {v} (Gene)", "CYP3A4" ], [ "CYP3A4", "{u} (Gene) is bound by {v} (Compound)", "Ramelteon" ] ], [ [ "Tripelennamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Cetirizine" ], [ "Cetirizine", "{u} (Compound) causes {v} (Side Effect)", "Asthenia" ], [ "Asthenia", "{u} (Side Effect) is caused by {v} (Compound)", "Ramelteon" ] ] ]
Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Ramelteon Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Ramelteon Tripelennamine (Compound) resembles Clofedanol (Compound) and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Ramelteon Tripelennamine (Compound) resembles Carbinoxamine (Compound) and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Ramelteon Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Ramelteon Tripelennamine (Compound) resembles Chlorpheniramine (Compound) and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Ramelteon Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threatening interaction when taken with Ramelteon Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ramelteon (Compound) Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Ramelteon (Compound)
DB00443
DB13179
251
68
[ "DDInter195", "DDInter1882" ]
Betamethasone
Troleandomycin
Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and negligible mineralocorticoid activity.
A macrolide antibiotic that is similar to erythromycin.
Moderate
1
[ [ [ 251, 24, 68 ] ], [ [ 251, 63, 1101 ], [ 1101, 23, 68 ] ], [ [ 251, 24, 1662 ], [ 1662, 24, 68 ] ], [ [ 251, 40, 167 ], [ 167, 24, 68 ] ], [ [ 251, 1, 1220 ], [ 1220, 24, 68 ] ], [ [ 251, 63, 1031 ], [ 1031, 24, 68 ] ], [ [ 251, 23, 659 ], [ 659, 24, 68 ] ], [ [ 251, 23, 455 ], [ 455, 25, 68 ] ], [ [ 251, 1, 175 ], [ 175, 25, 68 ] ], [ [ 251, 25, 976 ], [ 976, 25, 68 ] ] ]
[ [ [ "Betamethasone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Troleandomycin" ] ], [ [ "Betamethasone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bexarotene" ], [ "Bexarotene", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Troleandomycin" ] ], [ [ "Betamethasone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Picosulfuric acid" ], [ "Picosulfuric acid", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Troleandomycin" ] ], [ [ "Betamethasone", "{u} (Compound) resembles {v} (Compound)", "Hydrocortisone" ], [ "Hydrocortisone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Troleandomycin" ] ], [ [ "Betamethasone", "{u} (Compound) resembles {v} (Compound)", "Dexamethasone" ], [ "Dexamethasone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Troleandomycin" ] ], [ [ "Betamethasone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Theophylline" ], [ "Theophylline", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Troleandomycin" ] ], [ [ "Betamethasone", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Vilanterol" ], [ "Vilanterol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Troleandomycin" ] ], [ [ "Betamethasone", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Salmeterol" ], [ "Salmeterol", "{u} may lead to a major life threatening interaction when taken with {v}", "Troleandomycin" ] ], [ [ "Betamethasone", "{u} (Compound) resembles {v} (Compound)", "Triamcinolone" ], [ "Triamcinolone", "{u} may lead to a major life threatening interaction when taken with {v}", "Troleandomycin" ] ], [ [ "Betamethasone", "{u} may lead to a major life threatening interaction when taken with {v}", "Tofacitinib" ], [ "Tofacitinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Troleandomycin" ] ] ]
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Troleandomycin Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Troleandomycin Betamethasone (Compound) resembles Hydrocortisone (Compound) and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Troleandomycin Betamethasone (Compound) resembles Dexamethasone (Compound) and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Troleandomycin Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Troleandomycin Betamethasone may cause a minor interaction that can limit clinical effects when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Troleandomycin Betamethasone may cause a minor interaction that can limit clinical effects when taken with Salmeterol and Salmeterol may lead to a major life threatening interaction when taken with Troleandomycin Betamethasone (Compound) resembles Triamcinolone (Compound) and Triamcinolone may lead to a major life threatening interaction when taken with Troleandomycin Betamethasone may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may lead to a major life threatening interaction when taken with Troleandomycin
DB00390
DB00635
1,252
1,573
[ "DDInter554", "DDInter1515" ]
Digoxin
Prednisone
Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954. This drug originates from the foxglove plant, also known as the _Digitalis_ plant, studied by William Withering, an English physician and botanist in the 1780s.[A178237,A178240] Prior to this, a Welsh family, historically referred to as the _Physicians of Myddvai_, formulated drugs from this plant. They were one of the first to prescribe cardiac glycosides, according to ancient literature dating as early as the 1250s.
A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955.
Moderate
1
[ [ [ 1252, 24, 1573 ] ], [ [ 1252, 24, 175 ], [ 175, 40, 1573 ] ], [ [ 1252, 24, 251 ], [ 251, 1, 1573 ] ], [ [ 1252, 6, 8374 ], [ 8374, 45, 1573 ] ], [ [ 1252, 7, 1899 ], [ 1899, 45, 1573 ] ], [ [ 1252, 7, 11955 ], [ 11955, 46, 1573 ] ], [ [ 1252, 18, 17148 ], [ 17148, 57, 1573 ] ], [ [ 1252, 7, 20113 ], [ 20113, 57, 1573 ] ], [ [ 1252, 21, 28900 ], [ 28900, 60, 1573 ] ], [ [ 1252, 23, 115 ], [ 115, 62, 1573 ] ] ]
[ [ [ "Digoxin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Prednisone" ] ], [ [ "Digoxin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Triamcinolone" ], [ "Triamcinolone", "{u} (Compound) resembles {v} (Compound)", "Prednisone" ] ], [ [ "Digoxin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Betamethasone" ], [ "Betamethasone", "{u} (Compound) resembles {v} (Compound)", "Prednisone" ] ], [ [ "Digoxin", "{u} (Compound) binds {v} (Gene)", "CYP3A4" ], [ "CYP3A4", "{u} (Gene) is bound by {v} (Compound)", "Prednisone" ] ], [ [ "Digoxin", "{u} (Compound) upregulates {v} (Gene)", "NR3C1" ], [ "NR3C1", "{u} (Gene) is bound by {v} (Compound)", "Prednisone" ] ], [ [ "Digoxin", "{u} (Compound) upregulates {v} (Gene)", "SYNGR3" ], [ "SYNGR3", "{u} (Gene) is upregulated by {v} (Compound)", "Prednisone" ] ], [ [ "Digoxin", "{u} (Compound) downregulates {v} (Gene)", "ZDHHC6" ], [ "ZDHHC6", "{u} (Gene) is downregulated by {v} (Compound)", "Prednisone" ] ], [ [ "Digoxin", "{u} (Compound) upregulates {v} (Gene)", "IER3" ], [ "IER3", "{u} (Gene) is downregulated by {v} (Compound)", "Prednisone" ] ], [ [ "Digoxin", "{u} (Compound) causes {v} (Side Effect)", "Abdominal pain" ], [ "Abdominal pain", "{u} (Side Effect) is caused by {v} (Compound)", "Prednisone" ] ], [ [ "Digoxin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Aluminum hydroxide" ], [ "Aluminum hydroxide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Prednisone" ] ] ]
Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Prednisone (Compound) Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles Prednisone (Compound) Digoxin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Prednisone (Compound) Digoxin (Compound) upregulates NR3C1 (Gene) and NR3C1 (Gene) is bound by Prednisone (Compound) Digoxin (Compound) upregulates SYNGR3 (Gene) and SYNGR3 (Gene) is upregulated by Prednisone (Compound) Digoxin (Compound) downregulates ZDHHC6 (Gene) and ZDHHC6 (Gene) is downregulated by Prednisone (Compound) Digoxin (Compound) upregulates IER3 (Gene) and IER3 (Gene) is downregulated by Prednisone (Compound) Digoxin (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Prednisone (Compound) Digoxin may cause a minor interaction that can limit clinical effects when taken with Aluminum hydroxide and Aluminum hydroxide may cause a minor interaction that can limit clinical effects when taken with Prednisone
DB06655
DB14731
5
1,518
[ "DDInter1077", "DDInter1741" ]
Liraglutide
Tagraxofusp
Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmitic acid) with a glutamic acid spacer on the remaining lysine residue at position 26 of the peptide precursor. Liraglutide was granted FDA approval on January 25, 2010.
Tagraxofusp is a CD123-directed cytotoxin. It is a fusion protein composed of a human interleukin-3 (IL-3) that is genetically fused to the catalytic and translocation domains of truncated diphtheria toxin (DT) produced in _Escherichia coli_.[A253762, A253887, L43702] Tagraxofusp received its first global approval by the FDA on December 21, 2018 as the first FDA-approved treatment for blastic plasmacytoid dendritic cell neoplasm, which is a myeloid malignancy in the dendritic cell lineage. It was also approved by the European Commission on January 7, 2021.
Moderate
1
[ [ [ 5, 24, 1518 ] ], [ [ 5, 63, 176 ], [ 176, 24, 1518 ] ], [ [ 5, 24, 850 ], [ 850, 24, 1518 ] ], [ [ 5, 63, 695 ], [ 695, 25, 1518 ] ], [ [ 5, 63, 176 ], [ 176, 24, 123 ], [ 123, 24, 1518 ] ], [ [ 5, 24, 850 ], [ 850, 63, 123 ], [ 123, 24, 1518 ] ], [ [ 5, 63, 1254 ], [ 1254, 63, 123 ], [ 123, 24, 1518 ] ], [ [ 5, 62, 1252 ], [ 1252, 23, 123 ], [ 123, 24, 1518 ] ], [ [ 5, 62, 1103 ], [ 1103, 62, 1324 ], [ 1324, 24, 1518 ] ], [ [ 5, 62, 1252 ], [ 1252, 63, 1647 ], [ 1647, 24, 1518 ] ] ]
[ [ [ "Liraglutide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tagraxofusp" ] ], [ [ "Liraglutide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Insulin glargine" ], [ "Insulin glargine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tagraxofusp" ] ], [ [ "Liraglutide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brentuximab vedotin" ], [ "Brentuximab vedotin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tagraxofusp" ] ], [ [ "Liraglutide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clozapine" ], [ "Clozapine", "{u} may lead to a major life threatening interaction when taken with {v}", "Tagraxofusp" ] ], [ [ "Liraglutide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Insulin glargine" ], [ "Insulin glargine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Exenatide" ], [ "Exenatide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tagraxofusp" ] ], [ [ "Liraglutide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brentuximab vedotin" ], [ "Brentuximab vedotin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Exenatide" ], [ "Exenatide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tagraxofusp" ] ], [ [ "Liraglutide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Insulin glulisine" ], [ "Insulin glulisine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Exenatide" ], [ "Exenatide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tagraxofusp" ] ], [ [ "Liraglutide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Digoxin" ], [ "Digoxin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Exenatide" ], [ "Exenatide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tagraxofusp" ] ], [ [ "Liraglutide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Amcinonide" ], [ "Amcinonide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Troglitazone" ], [ "Troglitazone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tagraxofusp" ] ], [ [ "Liraglutide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Digoxin" ], [ "Digoxin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Acarbose" ], [ "Acarbose", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tagraxofusp" ] ] ]
Liraglutide may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Tagraxofusp Liraglutide may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Tagraxofusp Liraglutide may cause a moderate interaction that could exacerbate diseases when taken with Clozapine and Clozapine may lead to a major life threatening interaction when taken with Tagraxofusp Liraglutide may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Exenatide and Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Tagraxofusp Liraglutide may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Exenatide and Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Tagraxofusp Liraglutide may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine and Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Exenatide and Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Tagraxofusp Liraglutide may cause a minor interaction that can limit clinical effects when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Exenatide and Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Tagraxofusp Liraglutide may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Tagraxofusp Liraglutide may cause a minor interaction that can limit clinical effects when taken with Digoxin and Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Acarbose and Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Tagraxofusp
DB00238
DB00620
188
175
[ "DDInter1285", "DDInter1855" ]
Nevirapine
Triamcinolone
A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class.
Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermatoses. Triamcinolone is more commonly seen in the forms triamcinolone hexacetonide, triamcinolone acetonide, and triamcinolone diacetate.[L8246,L8249,L8252,L8255,L8258,L8261,L8264] Triamcinolone was granted FDA approval on 3 December 1957. In October 2021, a suspension of triamcinolone acetonide was approved for suprachoroidal injection - the first suprachoroidal injection to receive FDA approval - for the treatment of patients with macular edema associated with uveitis.
Moderate
1
[ [ [ 188, 24, 175 ] ], [ [ 188, 24, 1573 ], [ 1573, 1, 175 ] ], [ [ 188, 24, 617 ], [ 617, 40, 175 ] ], [ [ 188, 6, 8374 ], [ 8374, 45, 175 ] ], [ [ 188, 21, 28762 ], [ 28762, 60, 175 ] ], [ [ 188, 24, 659 ], [ 659, 62, 175 ] ], [ [ 188, 25, 1017 ], [ 1017, 63, 175 ] ], [ [ 188, 63, 600 ], [ 600, 24, 175 ] ], [ [ 188, 24, 98 ], [ 98, 63, 175 ] ], [ [ 188, 24, 1419 ], [ 1419, 24, 175 ] ] ]
[ [ [ "Nevirapine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Triamcinolone" ] ], [ [ "Nevirapine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Prednisone" ], [ "Prednisone", "{u} (Compound) resembles {v} (Compound)", "Triamcinolone" ] ], [ [ "Nevirapine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Budesonide" ], [ "Budesonide", "{u} (Compound) resembles {v} (Compound)", "Triamcinolone" ] ], [ [ "Nevirapine", "{u} (Compound) binds {v} (Gene)", "CYP3A4" ], [ "CYP3A4", "{u} (Gene) is bound by {v} (Compound)", "Triamcinolone" ] ], [ [ "Nevirapine", "{u} (Compound) causes {v} (Side Effect)", "Headache" ], [ "Headache", "{u} (Side Effect) is caused by {v} (Compound)", "Triamcinolone" ] ], [ [ "Nevirapine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Vilanterol" ], [ "Vilanterol", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Triamcinolone" ] ], [ [ "Nevirapine", "{u} may lead to a major life threatening interaction when taken with {v}", "Lorlatinib" ], [ "Lorlatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Triamcinolone" ] ], [ [ "Nevirapine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fluconazole" ], [ "Fluconazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Triamcinolone" ] ], [ [ "Nevirapine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Somatrem" ], [ "Somatrem", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Triamcinolone" ] ], [ [ "Nevirapine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Imatinib" ], [ "Imatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Triamcinolone" ] ] ]
Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone (Compound) resembles Triamcinolone (Compound) Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Budesonide (Compound) resembles Triamcinolone (Compound) Nevirapine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Triamcinolone (Compound) Nevirapine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Triamcinolone (Compound) Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a minor interaction that can limit clinical effects when taken with Triamcinolone Nevirapine may lead to a major life threatening interaction when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone
DB00959
DB11601
1,486
1,270
[ "DDInter1191", "DDInter1889" ]
Methylprednisolone
Tuberculin purified protein derivative
Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was successful in treating COVID-19-associated pneumonia in one patient with long-term immunosuppression. The efficacy of methylprednisolone in novel coronavirus pneumonia is being investigated further in clinical trials.
Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycobacterium tuberculosis* through early diagnosis and appropriate therapeutic intervention. The purified protein fraction is isolated from culture media filtrates of a human strain of Mycobacterium tuberculosis. It is included in the World Health Organization's List of Essential Medicines.
Moderate
1
[ [ [ 1486, 24, 1270 ] ], [ [ 1486, 24, 1531 ], [ 1531, 24, 1270 ] ], [ [ 1486, 64, 1064 ], [ 1064, 24, 1270 ] ], [ [ 1486, 63, 599 ], [ 599, 24, 1270 ] ], [ [ 1486, 25, 1259 ], [ 1259, 63, 1270 ] ], [ [ 1486, 25, 976 ], [ 976, 24, 1270 ] ], [ [ 1486, 40, 870 ], [ 870, 24, 1270 ] ], [ [ 1486, 24, 1619 ], [ 1619, 63, 1270 ] ], [ [ 1486, 1, 175 ], [ 175, 24, 1270 ] ], [ [ 1486, 24, 1531 ], [ 1531, 24, 350 ], [ 350, 24, 1270 ] ] ]
[ [ [ "Methylprednisolone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tuberculin purified protein derivative" ] ], [ [ "Methylprednisolone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Canakinumab" ], [ "Canakinumab", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tuberculin purified protein derivative" ] ], [ [ "Methylprednisolone", "{u} may lead to a major life threatening interaction when taken with {v}", "Cladribine" ], [ "Cladribine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tuberculin purified protein derivative" ] ], [ [ "Methylprednisolone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Alemtuzumab" ], [ "Alemtuzumab", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tuberculin purified protein derivative" ] ], [ [ "Methylprednisolone", "{u} may lead to a major life threatening interaction when taken with {v}", "Baricitinib" ], [ "Baricitinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tuberculin purified protein derivative" ] ], [ [ "Methylprednisolone", "{u} may lead to a major life threatening interaction when taken with {v}", "Tofacitinib" ], [ "Tofacitinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tuberculin purified protein derivative" ] ], [ [ "Methylprednisolone", "{u} (Compound) resembles {v} (Compound)", "Fludrocortisone" ], [ "Fludrocortisone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tuberculin purified protein derivative" ] ], [ [ "Methylprednisolone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Rucaparib" ], [ "Rucaparib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tuberculin purified protein derivative" ] ], [ [ "Methylprednisolone", "{u} (Compound) resembles {v} (Compound)", "Triamcinolone" ], [ "Triamcinolone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tuberculin purified protein derivative" ] ], [ [ "Methylprednisolone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Canakinumab" ], [ "Canakinumab", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Carfilzomib" ], [ "Carfilzomib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tuberculin purified protein derivative" ] ] ]
Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative Methylprednisolone may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative Methylprednisolone may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative Methylprednisolone may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative Methylprednisolone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative Methylprednisolone (Compound) resembles Triamcinolone (Compound) and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
DB00334
DB01075
867
1,376
[ "DDInter1326", "DDInter569" ]
Olanzapine
Diphenhydramine
Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug interactions. Olanzapine very closely resembles [clozapine] and only differs by two additional methyl groups and the absence of a chloride moiety. It was discovered by scientists at Eli Lilly and approved to be marketed in the US in 1996.
Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnotic, and antiparkinson properties [L5269, F3352]. As histamine receptors exist both peripherally and in the central nervous system, diphenhydramine has been shown to cause sedation due to its competitive antagonism of histamine H1 receptors within the central nervous system [L5263, L5266, L5269, F3379, A174541]. While its use in allergy therapy can sometimes fall out of favor due to its sedative effect, diphenhydramine has been repurposed for use within many non-prescription over-the-counter sleep aids and cough-and-cold medications that have been marketed for "night time" use [L5263, L5281, L5287]. Diphenhydramine is also used in combination with as the anti-nausea drug where it is utilized primarily for its antagonism of H1 histamine receptors within the vestibular system . Diphenhydramine has also been shown to be implicated in a number of neurotransmitter systems that affect behaviour including dopamine, norepinephrine, serotonin, acetylcholine, and opioid . As a result, diphenhydramine is being investigated for its anxiolytic and anti-depressant properties.
Moderate
1
[ [ [ 867, 24, 1376 ] ], [ [ 867, 24, 649 ], [ 649, 63, 1376 ] ], [ [ 867, 24, 11 ], [ 11, 1, 1376 ] ], [ [ 867, 24, 128 ], [ 128, 24, 1376 ] ], [ [ 867, 24, 888 ], [ 888, 25, 1376 ] ], [ [ 867, 6, 12523 ], [ 12523, 45, 1376 ] ], [ [ 867, 10, 11584 ], [ 11584, 49, 1376 ] ], [ [ 867, 1, 623 ], [ 623, 63, 1376 ] ], [ [ 867, 63, 701 ], [ 701, 24, 1376 ] ], [ [ 867, 1, 695 ], [ 695, 24, 1376 ] ] ]
[ [ [ "Olanzapine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Diphenhydramine" ] ], [ [ "Olanzapine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clofedanol" ], [ "Clofedanol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Diphenhydramine" ] ], [ [ "Olanzapine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Toremifene" ], [ "Toremifene", "{u} (Compound) resembles {v} (Compound)", "Diphenhydramine" ] ], [ [ "Olanzapine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dexbrompheniramine" ], [ "Dexbrompheniramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Diphenhydramine" ] ], [ [ "Olanzapine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tamoxifen" ], [ "Tamoxifen", "{u} may lead to a major life threatening interaction when taken with {v}", "Diphenhydramine" ] ], [ [ "Olanzapine", "{u} (Compound) binds {v} (Gene)", "CYP2D6" ], [ "CYP2D6", "{u} (Gene) is bound by {v} (Compound)", "Diphenhydramine" ] ], [ [ "Olanzapine", "{u} (Compound) palliates {v} (Disease)", "schizophrenia" ], [ "schizophrenia", "{u} (Disease) is palliated by {v} (Compound)", "Diphenhydramine" ] ], [ [ "Olanzapine", "{u} (Compound) resembles {v} (Compound)", "Quetiapine" ], [ "Quetiapine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Diphenhydramine" ] ], [ [ "Olanzapine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clemastine" ], [ "Clemastine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Diphenhydramine" ] ], [ [ "Olanzapine", "{u} (Compound) resembles {v} (Compound)", "Clozapine" ], [ "Clozapine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Diphenhydramine" ] ] ]
Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Toremifene and Toremifene (Compound) resembles Diphenhydramine (Compound) Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may lead to a major life threatening interaction when taken with Diphenhydramine Olanzapine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Diphenhydramine (Compound) Olanzapine (Compound) palliates schizophrenia (Disease) and schizophrenia (Disease) is palliated by Diphenhydramine (Compound) Olanzapine (Compound) resembles Quetiapine (Compound) and Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine Olanzapine (Compound) resembles Clozapine (Compound) and Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
DB00835
DB01563
100
680
[ "DDInter245", "DDInter349" ]
Brompheniramine
Chloral hydrate
Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria.
A hypnotic and sedative used in the treatment of insomnia. The safety margin is too narrow for chloral hydrate to be used as a general anesthetic in humans, but it is commonly used for that purpose in animal experiments. It is no longer considered useful as an anti-anxiety medication.
Moderate
1
[ [ [ 100, 24, 680 ] ], [ [ 100, 35, 272 ], [ 272, 24, 680 ] ], [ [ 100, 63, 1614 ], [ 1614, 24, 680 ] ], [ [ 100, 24, 1609 ], [ 1609, 63, 680 ] ], [ [ 100, 24, 401 ], [ 401, 24, 680 ] ], [ [ 100, 74, 662 ], [ 662, 24, 680 ] ], [ [ 100, 35, 849 ], [ 849, 63, 680 ] ], [ [ 100, 63, 475 ], [ 475, 25, 680 ] ], [ [ 100, 35, 272 ], [ 272, 63, 1614 ], [ 1614, 24, 680 ] ], [ [ 100, 63, 1614 ], [ 1614, 24, 272 ], [ 272, 24, 680 ] ] ]
[ [ [ "Brompheniramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Chloral hydrate" ] ], [ [ "Brompheniramine", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Chlorpheniramine" ], [ "Chlorpheniramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Chloral hydrate" ] ], [ [ "Brompheniramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nabilone" ], [ "Nabilone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Chloral hydrate" ] ], [ [ "Brompheniramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pentoxyverine" ], [ "Pentoxyverine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Chloral hydrate" ] ], [ [ "Brompheniramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Promethazine" ], [ "Promethazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Chloral hydrate" ] ], [ [ "Brompheniramine", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Carbinoxamine" ], [ "Carbinoxamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Chloral hydrate" ] ], [ [ "Brompheniramine", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mepyramine" ], [ "Mepyramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Chloral hydrate" ] ], [ [ "Brompheniramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Morphine" ], [ "Morphine", "{u} may lead to a major life threatening interaction when taken with {v}", "Chloral hydrate" ] ], [ [ "Brompheniramine", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Chlorpheniramine" ], [ "Chlorpheniramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nabilone" ], [ "Nabilone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Chloral hydrate" ] ], [ [ "Brompheniramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nabilone" ], [ "Nabilone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Chlorpheniramine" ], [ "Chlorpheniramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Chloral hydrate" ] ] ]
Brompheniramine (Compound) resembles Chlorpheniramine (Compound) and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Chloral hydrate Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Chloral hydrate Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine and Pentoxyverine may cause a moderate interaction that could exacerbate diseases when taken with Chloral hydrate Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Chloral hydrate Brompheniramine (Compound) resembles Carbinoxamine (Compound) and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Chloral hydrate Brompheniramine (Compound) resembles Mepyramine (Compound) and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Chloral hydrate Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threatening interaction when taken with Chloral hydrate Brompheniramine (Compound) resembles Chlorpheniramine (Compound) and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Chloral hydrate Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Chloral hydrate
DB08875
DB13074
1,618
877
[ "DDInter262", "DDInter1110" ]
Cabozantinib
Macimorelin
Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formulation gained additional approval in both the US and Canada in 2019 for the treatment of hepatocellular carcinoma in previously treated patients.[L15128,L15133]
Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dependently increase GH levels . Growth hormone secretagogues (GHS) represent a new class of pharmacological agents which have the potential to be used in numerous clinical applications. They include treatment for growth retardation in children and cachexia associated with chronic disease such as AIDS and cancer. Growth hormone (GH) is classically linked with linear growth during childhood. In deficiency of this hormone, AGHD is commonly associated with increased fat mass (particularly in the abdominal region), decreased lean body mass, osteopenia, dyslipidemia, insulin resistance, and/or glucose intolerance overtime. In addition, individuals with may be susceptible to cardiovascular complications from altered structures and function . Risk factors of AGHD include a history of childhood-onset GH deficiency or with hypothalamic/pituitary disease, surgery, or irradiation to these areas, head trauma, or evidence of other pituitary hormone deficiencies . While there are various therapies available such as GH replacement therapy, the absence of panhypopituitarism and low serum IGF-I levels with nonspecific clinical symptoms pose challenges to the detection and diagnosis of AGHD. The diagnosis of AGHD requires biochemical confirmation with at least 1 GH stimulation test . Macimorelin is clinically useful since it displays good stability and oral bioavailability with comparable affinity to ghrelin receptor as its endogenous ligand. In clinical studies involving healthy subjects, macimorelin stimulated GH release in a dose-dependent manner with good tolerability . Macimorelin, developed by Aeterna Zentaris, was approved by the FDA in December 2017 under the market name Macrilen for oral solution.
Major
2
[ [ [ 1618, 25, 877 ] ], [ [ 1618, 62, 112 ], [ 112, 23, 877 ] ], [ [ 1618, 24, 1320 ], [ 1320, 24, 877 ] ], [ [ 1618, 64, 1479 ], [ 1479, 24, 877 ] ], [ [ 1618, 63, 673 ], [ 673, 24, 877 ] ], [ [ 1618, 25, 913 ], [ 913, 24, 877 ] ], [ [ 1618, 24, 1654 ], [ 1654, 63, 877 ] ], [ [ 1618, 76, 1274 ], [ 1274, 24, 877 ] ], [ [ 1618, 64, 485 ], [ 485, 25, 877 ] ], [ [ 1618, 24, 144 ], [ 144, 25, 877 ] ] ]
[ [ [ "Cabozantinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Macimorelin" ] ], [ [ "Cabozantinib", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Metronidazole" ], [ "Metronidazole", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Macimorelin" ] ], [ [ "Cabozantinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Elagolix" ], [ "Elagolix", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Macimorelin" ] ], [ [ "Cabozantinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Acetylsalicylic acid" ], [ "Acetylsalicylic acid", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Macimorelin" ] ], [ [ "Cabozantinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Aripiprazole" ], [ "Aripiprazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Macimorelin" ] ], [ [ "Cabozantinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Apalutamide" ], [ "Apalutamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Macimorelin" ] ], [ [ "Cabozantinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Somapacitan" ], [ "Somapacitan", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Macimorelin" ] ], [ [ "Cabozantinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}", "Flurbiprofen" ], [ "Flurbiprofen", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Macimorelin" ] ], [ [ "Cabozantinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Pentamidine" ], [ "Pentamidine", "{u} may lead to a major life threatening interaction when taken with {v}", "Macimorelin" ] ], [ [ "Cabozantinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Olodaterol" ], [ "Olodaterol", "{u} may lead to a major life threatening interaction when taken with {v}", "Macimorelin" ] ] ]
Cabozantinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin Cabozantinib may lead to a major life threatening interaction when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Aripiprazole and Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin Cabozantinib may lead to a major life threatening interaction when taken with Apalutamide and Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan and Somapacitan may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Cabozantinib may lead to a major life threatening interaction when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin Cabozantinib may lead to a major life threatening interaction when taken with Pentamidine and Pentamidine may lead to a major life threatening interaction when taken with Macimorelin Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol and Olodaterol may lead to a major life threatening interaction when taken with Macimorelin
DB00802
DB11130
1,322
407
[ "DDInter43", "DDInter1344" ]
Alfentanil
Opium
A short-acting opioid anesthetic and analgesic derivative of fentanyl. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients.
Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive. Opium is extracted from _Papaver somniferum_, which is more known as poppies. This plant is an integrant of the Papaveraceae family, and it is characterized by solitary leaves and capsulated fruits. Therefore, opium is a sticky brown resin obtained by collecting and drying the latex that exudes from the poppy pods. Once extracted, opium contains two main groups of alkaloids; the psychoactive constituents which are in the category of phenanthrenes and alkaloids that have no central nervous system effect in the category of isoquinolines. Morphine is the most prevalent and principal alkaloid in opium, and it is responsible for most of the harmful effects of opium. Opium has gradually been superseded by a variety of synthetic opioids and general anesthetics. Some of the isolated derivatives of opium are morphine, noscapine, strychnine, veratrine, colchicine, codeine, and quinine. Opium is a prohibited drug of abuse in most countries, but the illegal production of this drug and its derivatives keeps being registered. There is some legal production of opium in different countries for the obtention of alkaloids by extraction.
Moderate
1
[ [ [ 1322, 24, 407 ] ], [ [ 1322, 63, 662 ], [ 662, 24, 407 ] ], [ [ 1322, 40, 1454 ], [ 1454, 24, 407 ] ], [ [ 1322, 24, 976 ], [ 976, 24, 407 ] ], [ [ 1322, 24, 1259 ], [ 1259, 63, 407 ] ], [ [ 1322, 25, 222 ], [ 222, 24, 407 ] ], [ [ 1322, 25, 1053 ], [ 1053, 25, 407 ] ], [ [ 1322, 64, 267 ], [ 267, 25, 407 ] ], [ [ 1322, 63, 662 ], [ 662, 63, 558 ], [ 558, 24, 407 ] ], [ [ 1322, 40, 1454 ], [ 1454, 24, 662 ], [ 662, 24, 407 ] ] ]
[ [ [ "Alfentanil", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Opium" ] ], [ [ "Alfentanil", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Carbinoxamine" ], [ "Carbinoxamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Opium" ] ], [ [ "Alfentanil", "{u} (Compound) resembles {v} (Compound)", "Sufentanil" ], [ "Sufentanil", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Opium" ] ], [ [ "Alfentanil", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tofacitinib" ], [ "Tofacitinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Opium" ] ], [ [ "Alfentanil", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Baricitinib" ], [ "Baricitinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Opium" ] ], [ [ "Alfentanil", "{u} may lead to a major life threatening interaction when taken with {v}", "Sibutramine" ], [ "Sibutramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Opium" ] ], [ [ "Alfentanil", "{u} may lead to a major life threatening interaction when taken with {v}", "Procarbazine" ], [ "Procarbazine", "{u} may lead to a major life threatening interaction when taken with {v}", "Opium" ] ], [ [ "Alfentanil", "{u} may lead to a major life threatening interaction when taken with {v}", "Naltrexone" ], [ "Naltrexone", "{u} may lead to a major life threatening interaction when taken with {v}", "Opium" ] ], [ [ "Alfentanil", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Carbinoxamine" ], [ "Carbinoxamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Zolpidem" ], [ "Zolpidem", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Opium" ] ], [ [ "Alfentanil", "{u} (Compound) resembles {v} (Compound)", "Sufentanil" ], [ "Sufentanil", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Carbinoxamine" ], [ "Carbinoxamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Opium" ] ] ]
Alfentanil may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Opium Alfentanil (Compound) resembles Sufentanil (Compound) and Sufentanil may cause a moderate interaction that could exacerbate diseases when taken with Opium Alfentanil may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Opium Alfentanil may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib and Baricitinib may cause a moderate interaction that could exacerbate diseases when taken with Opium Alfentanil may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Opium Alfentanil may lead to a major life threatening interaction when taken with Procarbazine and Procarbazine may lead to a major life threatening interaction when taken with Opium Alfentanil may lead to a major life threatening interaction when taken with Naltrexone and Naltrexone may lead to a major life threatening interaction when taken with Opium Alfentanil may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Zolpidem and Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Opium Alfentanil (Compound) resembles Sufentanil (Compound) and Sufentanil may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Opium
DB00010
DB00222
1,649
245
[ "DDInter1661", "DDInter825" ]
Sermorelin
Glimepiride
Sermorelin acetate is the acetate salt of an amidated synthetic 29-amino acid peptide (GRF 1-29 NH 2 ) that corresponds to the amino-terminal segment of the naturally occurring human growth hormone-releasing hormone (GHRH or GRF) consisting of 44 amino acid residues
First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in accordance with progressive β cell failure and long-term microvascular and macrovascular complications that lead to co-morbidities and mortalities. Sulfonylureas are one of the insulin secretagogues widely used for the management of type 2 diabetes to lower blood glucose levels. The main effect of SUs is thought to be effective when residual pancreatic β-cells are present, as they work by stimulating the release of insulin from the pancreatic beta cells and they are also thought to exert extra-pancreatic effects, such as increasing the insulin-mediated peripheral glucose uptake. Glimepiride works by stimulating the secretion of insulin granules from pancreatic islet beta cells by blocking ATP-sensitive potassium channels (K<SUB>ATP</SUB> channels) and causing depolarization of the beta cells. Compared to [glipizide], another second SU drug, glimepiride has a longer duration of action. It is sometimes classified as a third-generation SU because it has larger substitutions than other second-generation SUs. Compared to other SUs, glimepiride was associated with a lower risk of developing hypoglycemia and weight gain in clinical trials as well as fewer cardiovascular effects than other SUs due to minimal effects on ischemic preconditioning of cardiac myocytes. It is effective in reducing fasting plasma glucose, postprandial glucose, and glycosylated hemoglobin levels and is considered to be a useful, cost-effective treatment option for managing type 2 diabetes mellitus. Glimepiride was approved by the Food and Drug Administration (FDA) in the United States in 1995 for the treatment of T2DM. It is commonly marketed under the brand name Amaryl as oral tablets and is typically administered once daily.
Moderate
1
[ [ [ 1649, 24, 245 ] ], [ [ 1649, 24, 959 ], [ 959, 1, 245 ] ], [ [ 1649, 24, 5 ], [ 5, 63, 245 ] ], [ [ 1649, 24, 1179 ], [ 1179, 24, 245 ] ], [ [ 1649, 24, 959 ], [ 959, 40, 11426 ], [ 11426, 1, 245 ] ], [ [ 1649, 24, 1411 ], [ 1411, 1, 11426 ], [ 11426, 1, 245 ] ], [ [ 1649, 24, 5 ], [ 5, 63, 959 ], [ 959, 1, 245 ] ], [ [ 1649, 24, 1645 ], [ 1645, 24, 959 ], [ 959, 1, 245 ] ], [ [ 1649, 24, 1130 ], [ 1130, 5, 11640 ], [ 11640, 44, 245 ] ], [ [ 1649, 24, 959 ], [ 959, 1, 11499 ], [ 11499, 40, 245 ] ] ]
[ [ [ "Sermorelin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Glimepiride" ] ], [ [ "Sermorelin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Glipizide" ], [ "Glipizide", "{u} (Compound) resembles {v} (Compound)", "Glimepiride" ] ], [ [ "Sermorelin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Liraglutide" ], [ "Liraglutide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Glimepiride" ] ], [ [ "Sermorelin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Insulin lispro" ], [ "Insulin lispro", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Glimepiride" ] ], [ [ "Sermorelin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Glipizide" ], [ "Glipizide", "{u} (Compound) resembles {v} (Compound)", "Gliclazide" ], [ "Gliclazide", "{u} (Compound) resembles {v} (Compound)", "Glimepiride" ] ], [ [ "Sermorelin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tolbutamide" ], [ "Tolbutamide", "{u} (Compound) resembles {v} (Compound)", "Gliclazide" ], [ "Gliclazide", "{u} (Compound) resembles {v} (Compound)", "Glimepiride" ] ], [ [ "Sermorelin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Liraglutide" ], [ "Liraglutide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Glipizide" ], [ "Glipizide", "{u} (Compound) resembles {v} (Compound)", "Glimepiride" ] ], [ [ "Sermorelin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Metformin" ], [ "Metformin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Glipizide" ], [ "Glipizide", "{u} (Compound) resembles {v} (Compound)", "Glimepiride" ] ], [ [ "Sermorelin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pioglitazone" ], [ "Pioglitazone", "{u} (Compound) treats {v} (Disease)", "type 2 diabetes mellitus" ], [ "type 2 diabetes mellitus", "{u} (Disease) is treated by {v} (Compound)", "Glimepiride" ] ], [ [ "Sermorelin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Glipizide" ], [ "Glipizide", "{u} (Compound) resembles {v} (Compound)", "Glisoxepide" ], [ "Glisoxepide", "{u} (Compound) resembles {v} (Compound)", "Glimepiride" ] ] ]
Sermorelin may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Glimepiride (Compound) Sermorelin may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide and Liraglutide may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride Sermorelin may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro and Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride Sermorelin may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Gliclazide (Compound) and Gliclazide (Compound) resembles Glimepiride (Compound) Sermorelin may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Gliclazide (Compound) and Gliclazide (Compound) resembles Glimepiride (Compound) Sermorelin may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide and Liraglutide may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Glimepiride (Compound) Sermorelin may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Metformin may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Glimepiride (Compound) Sermorelin may cause a moderate interaction that could exacerbate diseases when taken with Pioglitazone and Pioglitazone (Compound) treats type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is treated by Glimepiride (Compound) Sermorelin may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Glisoxepide (Compound) and Glisoxepide (Compound) resembles Glimepiride (Compound)
DB00662
DB12161
717
730
[ "DDInter1873", "DDInter512" ]
Trimethobenzamide
Deutetrabenazine
Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against emesis induced by intragastric copper sulfate.
Deutetrabenazine is a novel, highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the management of chorea associated with Huntington’s disease. It is a hexahydro-dimethoxybenzoquinolizine derivative and a deuterated . The presence of deuterium in deutetrabenazine increases the half-lives of the active metabolite and prolongs their pharmacological activity by attenuating CYP2D6 metabolism of the compound . This allows less frequent dosing and a lower daily dose with improvement in tolerability . Decreased plasma fluctuations of deutetrabenazine due to attenuated metabolism may explain a lower incidence of adverse reactions associated with deutetrabenazine . Deutetrabenazine is a racemic mixture containing RR-Deutetrabenazine and SS-Deutetrabenazine [FDA Label]. Huntington's disease (HD) is a hereditary, progressive neurodegenerative disorder characterized by motor dysfunction, cognitive decline, and neuropsychiatric disturbances that interfere with daily functioning and significantly reduce the quality of life. The most prominent physical symptom of HD that may increase the risk of injury is chorea, which is an involuntary, sudden movement that can affect any muscle and flow randomly across body regions . Psychomotor symptoms of HD, such as chorea, are related to hyperactive dopaminergic neurotransmission . Deutetrabenazine depletes the levels of presynaptic dopamine by blocking VMAT2, which is responsible for the uptake of dopamine into synaptic vesicles in monoaminergic neurons and exocytotic release . As with other agents for the treatment of neurodegenerative diseases, deutetrabenazine is a drug to alleviate the motor symptoms of HD and is not proposed to halt the progression of the disease . In clinical trials of patients with HD, 12 weeks of treatment of deutetrabenazine resulted in overall improvement in mean total maximal chorea scores and motor signs than placebo . It was approved by FDA in April 2017 and is marketed under the trade name Austedo as oral tablets.
Moderate
1
[ [ [ 717, 24, 730 ] ], [ [ 717, 24, 100 ], [ 100, 24, 730 ] ], [ [ 717, 63, 13 ], [ 13, 24, 730 ] ], [ [ 717, 1, 1425 ], [ 1425, 25, 730 ] ], [ [ 717, 24, 401 ], [ 401, 25, 730 ] ], [ [ 717, 24, 100 ], [ 100, 24, 1264 ], [ 1264, 24, 730 ] ], [ [ 717, 24, 1264 ], [ 1264, 62, 112 ], [ 112, 23, 730 ] ], [ [ 717, 63, 13 ], [ 13, 24, 100 ], [ 100, 24, 730 ] ], [ [ 717, 24, 662 ], [ 662, 35, 100 ], [ 100, 24, 730 ] ], [ [ 717, 24, 272 ], [ 272, 74, 100 ], [ 100, 24, 730 ] ] ]
[ [ [ "Trimethobenzamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Deutetrabenazine" ] ], [ [ "Trimethobenzamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brompheniramine" ], [ "Brompheniramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Deutetrabenazine" ] ], [ [ "Trimethobenzamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Cyproheptadine" ], [ "Cyproheptadine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Deutetrabenazine" ] ], [ [ "Trimethobenzamide", "{u} (Compound) resembles {v} (Compound)", "Cisapride" ], [ "Cisapride", "{u} may lead to a major life threatening interaction when taken with {v}", "Deutetrabenazine" ] ], [ [ "Trimethobenzamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Promethazine" ], [ "Promethazine", "{u} may lead to a major life threatening interaction when taken with {v}", "Deutetrabenazine" ] ], [ [ "Trimethobenzamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brompheniramine" ], [ "Brompheniramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Doxepin" ], [ "Doxepin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Deutetrabenazine" ] ], [ [ "Trimethobenzamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Doxepin" ], [ "Doxepin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Metronidazole" ], [ "Metronidazole", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Deutetrabenazine" ] ], [ [ "Trimethobenzamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Cyproheptadine" ], [ "Cyproheptadine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brompheniramine" ], [ "Brompheniramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Deutetrabenazine" ] ], [ [ "Trimethobenzamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Carbinoxamine" ], [ "Carbinoxamine", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brompheniramine" ], [ "Brompheniramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Deutetrabenazine" ] ], [ [ "Trimethobenzamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Chlorpheniramine" ], [ "Chlorpheniramine", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brompheniramine" ], [ "Brompheniramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Deutetrabenazine" ] ] ]
Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine Trimethobenzamide (Compound) resembles Cisapride (Compound) and Cisapride may lead to a major life threatening interaction when taken with Deutetrabenazine Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may lead to a major life threatening interaction when taken with Deutetrabenazine Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Deutetrabenazine Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine (Compound) resembles Brompheniramine (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine (Compound) resembles Brompheniramine (Compound) and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine
DB00902
DB03128
104
140
[ "DDInter1168", "DDInter18" ]
Methdilazine
Acetylcholine
Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus.
A neurotransmitter. Acetylcholine in vertebrates is the major transmitter at neuromuscular junctions, autonomic ganglia, parasympathetic effector junctions, a subset of sympathetic effector junctions, and at many sites in the central nervous system. It is generally not used as an administered drug because it is broken down very rapidly by cholinesterases, but it is useful in some ophthalmological applications.
Moderate
1
[ [ [ 104, 24, 140 ] ], [ [ 104, 24, 1376 ], [ 1376, 24, 140 ] ], [ [ 104, 63, 85 ], [ 85, 24, 140 ] ], [ [ 104, 24, 1116 ], [ 1116, 63, 140 ] ], [ [ 104, 40, 820 ], [ 820, 24, 140 ] ], [ [ 104, 1, 830 ], [ 830, 24, 140 ] ], [ [ 104, 24, 1376 ], [ 1376, 63, 999 ], [ 999, 24, 140 ] ], [ [ 104, 63, 85 ], [ 85, 24, 1376 ], [ 1376, 24, 140 ] ], [ [ 104, 24, 1192 ], [ 1192, 24, 1376 ], [ 1376, 24, 140 ] ], [ [ 104, 24, 272 ], [ 272, 74, 1376 ], [ 1376, 24, 140 ] ] ]
[ [ [ "Methdilazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Acetylcholine" ] ], [ [ "Methdilazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Diphenhydramine" ], [ "Diphenhydramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Acetylcholine" ] ], [ [ "Methdilazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Atropine" ], [ "Atropine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Acetylcholine" ] ], [ [ "Methdilazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Umeclidinium" ], [ "Umeclidinium", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Acetylcholine" ] ], [ [ "Methdilazine", "{u} (Compound) resembles {v} (Compound)", "Alimemazine" ], [ "Alimemazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Acetylcholine" ] ], [ [ "Methdilazine", "{u} (Compound) resembles {v} (Compound)", "Phenindamine" ], [ "Phenindamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Acetylcholine" ] ], [ [ "Methdilazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Diphenhydramine" ], [ "Diphenhydramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Thiethylperazine" ], [ "Thiethylperazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Acetylcholine" ] ], [ [ "Methdilazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Atropine" ], [ "Atropine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Diphenhydramine" ], [ "Diphenhydramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Acetylcholine" ] ], [ [ "Methdilazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Glycopyrronium" ], [ "Glycopyrronium", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Diphenhydramine" ], [ "Diphenhydramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Acetylcholine" ] ], [ [ "Methdilazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Chlorpheniramine" ], [ "Chlorpheniramine", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Diphenhydramine" ], [ "Diphenhydramine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Acetylcholine" ] ] ]
Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Acetylcholine Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine may cause a moderate interaction that could exacerbate diseases when taken with Acetylcholine Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Umeclidinium and Umeclidinium may cause a moderate interaction that could exacerbate diseases when taken with Acetylcholine Methdilazine (Compound) resembles Alimemazine (Compound) and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Acetylcholine Methdilazine (Compound) resembles Phenindamine (Compound) and Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Acetylcholine Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Acetylcholine Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Acetylcholine Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium and Glycopyrronium may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Acetylcholine Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine (Compound) resembles Diphenhydramine (Compound) and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Acetylcholine
DB00572
DB00708
85
1,454
[ "DDInter136", "DDInter1718" ]
Atropine
Sufentanil
Atropine is an alkaloid originally synthesized from Atropa belladonna. It is a racemic mixture of d-and l-hyoscyamine, of which only l-hyoscyamine is pharmacologically active.[A251670,L42835] Atropine is generally available as a sulfate salt and can be administered by intravenous, subcutaneous, intramuscular, intraosseous, endotracheal and ophthalmic methods. Oral atropine is only available in combination products.[A251660,L42840] Atropine is a competitive, reversible antagonist of muscarinic receptors that blocks the effects of acetylcholine and other choline esters.[A251660,L42815,L42825,L42835] It has a variety of therapeutic applications, including pupil dilation and the treatment of anticholinergic poisoning and symptomatic bradycardia in the absence of reversible causes. Atropine is a relatively inexpensive drug and
Sufentanil is an opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent. It is administered by the intravenous, epidural and sublingual routes. Also known as _Dsuvia_, the sublingual form is used for the management of acute pain in adults that is severe to warrant the use of an opioid analgesic in certified medically supervised healthcare settings, including hospitals, surgical centers, and emergency departments . Consideration may be made in the future for the use of the sublingual form in the US military in cases where analgesia is required immediately . The sublingual form, manufactured by AcelRx Pharmaceuticals, Inc. (AcelRx), was approved on November 2, 2018 . This route of administration is intended to be a simple, effective, non-invasive analgesic option to enable healthcare professionals to rapidly manage acute pain without difficult intravenous or epidural administration , .
Moderate
1
[ [ [ 85, 24, 1454 ] ], [ [ 85, 24, 704 ], [ 704, 40, 1454 ] ], [ [ 85, 21, 28658 ], [ 28658, 60, 1454 ] ], [ [ 85, 24, 537 ], [ 537, 63, 1454 ] ], [ [ 85, 63, 13 ], [ 13, 24, 1454 ] ], [ [ 85, 35, 1442 ], [ 1442, 63, 1454 ] ], [ [ 85, 1, 1133 ], [ 1133, 64, 1454 ] ], [ [ 85, 24, 704 ], [ 704, 1, 11366 ], [ 11366, 40, 1454 ] ], [ [ 85, 24, 1322 ], [ 1322, 40, 704 ], [ 704, 40, 1454 ] ], [ [ 85, 21, 28658 ], [ 28658, 60, 704 ], [ 704, 40, 1454 ] ] ]
[ [ [ "Atropine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sufentanil" ] ], [ [ "Atropine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fentanyl" ], [ "Fentanyl", "{u} (Compound) resembles {v} (Compound)", "Sufentanil" ] ], [ [ "Atropine", "{u} (Compound) causes {v} (Side Effect)", "Vomiting" ], [ "Vomiting", "{u} (Side Effect) is caused by {v} (Compound)", "Sufentanil" ] ], [ [ "Atropine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Cyclizine" ], [ "Cyclizine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sufentanil" ] ], [ [ "Atropine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Cyproheptadine" ], [ "Cyproheptadine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sufentanil" ] ], [ [ "Atropine", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Scopolamine" ], [ "Scopolamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sufentanil" ] ], [ [ "Atropine", "{u} (Compound) resembles {v} (Compound)", "Granisetron" ], [ "Granisetron", "{u} may lead to a major life threatening interaction when taken with {v}", "Sufentanil" ] ], [ [ "Atropine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fentanyl" ], [ "Fentanyl", "{u} (Compound) resembles {v} (Compound)", "Anileridine" ], [ "Anileridine", "{u} (Compound) resembles {v} (Compound)", "Sufentanil" ] ], [ [ "Atropine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Alfentanil" ], [ "Alfentanil", "{u} (Compound) resembles {v} (Compound)", "Fentanyl" ], [ "Fentanyl", "{u} (Compound) resembles {v} (Compound)", "Sufentanil" ] ], [ [ "Atropine", "{u} (Compound) causes {v} (Side Effect)", "Vomiting" ], [ "Vomiting", "{u} (Side Effect) is caused by {v} (Compound)", "Fentanyl" ], [ "Fentanyl", "{u} (Compound) resembles {v} (Compound)", "Sufentanil" ] ] ]
Atropine may cause a moderate interaction that could exacerbate diseases when taken with Fentanyl and Fentanyl (Compound) resembles Sufentanil (Compound) Atropine (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Sufentanil (Compound) Atropine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Sufentanil Atropine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Sufentanil Atropine (Compound) resembles Scopolamine (Compound) and Atropine may cause a moderate interaction that could exacerbate diseases when taken with Scopolamine and Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Sufentanil Atropine (Compound) resembles Granisetron (Compound) and Granisetron may lead to a major life threatening interaction when taken with Sufentanil Atropine may cause a moderate interaction that could exacerbate diseases when taken with Fentanyl and Fentanyl (Compound) resembles Anileridine (Compound) and Anileridine (Compound) resembles Sufentanil (Compound) Atropine may cause a moderate interaction that could exacerbate diseases when taken with Alfentanil and Alfentanil (Compound) resembles Fentanyl (Compound) and Fentanyl (Compound) resembles Sufentanil (Compound) Atropine (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Fentanyl (Compound) and Fentanyl (Compound) resembles Sufentanil (Compound)
DB00635
DB01044
1,573
246
[ "DDInter1515", "DDInter809" ]
Prednisone
Gatifloxacin
A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955.
Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections. Gatifloxacin is available as tablets and in various aqueous solutions for intravenous therapy. It is also available as eye drops under the brand name Zymar® marketed by Allergan. The FDA withdrew its approval for the use of non-ophthalmic drug products containing gatifloxacin due to the high prevalence of gatifloxacin-associated dysglycemia adverse event reports and the high incidence of hyperglycemic and hypoglycemic episodes in patients taking gatifloxacin compared to those on macrolide antibiotics.[L43942,L44037]
Major
2
[ [ [ 1573, 25, 246 ] ], [ [ 1573, 25, 739 ], [ 739, 1, 246 ] ], [ [ 1573, 64, 1176 ], [ 1176, 1, 246 ] ], [ [ 1573, 25, 945 ], [ 945, 40, 246 ] ], [ [ 1573, 64, 1467 ], [ 1467, 40, 246 ] ], [ [ 1573, 6, 1829 ], [ 1829, 45, 246 ] ], [ [ 1573, 7, 7245 ], [ 7245, 46, 246 ] ], [ [ 1573, 21, 28741 ], [ 28741, 60, 246 ] ], [ [ 1573, 63, 589 ], [ 589, 23, 246 ] ], [ [ 1573, 24, 1479 ], [ 1479, 24, 246 ] ] ]
[ [ [ "Prednisone", "{u} may lead to a major life threatening interaction when taken with {v}", "Gatifloxacin" ] ], [ [ "Prednisone", "{u} may lead to a major life threatening interaction when taken with {v}", "Lomefloxacin" ], [ "Lomefloxacin", "{u} (Compound) resembles {v} (Compound)", "Gatifloxacin" ] ], [ [ "Prednisone", "{u} may lead to a major life threatening interaction when taken with {v}", "Moxifloxacin" ], [ "Moxifloxacin", "{u} (Compound) resembles {v} (Compound)", "Gatifloxacin" ] ], [ [ "Prednisone", "{u} may lead to a major life threatening interaction when taken with {v}", "Sparfloxacin" ], [ "Sparfloxacin", "{u} (Compound) resembles {v} (Compound)", "Gatifloxacin" ] ], [ [ "Prednisone", "{u} may lead to a major life threatening interaction when taken with {v}", "Enoxacin" ], [ "Enoxacin", "{u} (Compound) resembles {v} (Compound)", "Gatifloxacin" ] ], [ [ "Prednisone", "{u} (Compound) binds {v} (Gene)", "ALB" ], [ "ALB", "{u} (Gene) is bound by {v} (Compound)", "Gatifloxacin" ] ], [ [ "Prednisone", "{u} (Compound) upregulates {v} (Gene)", "SSBP2" ], [ "SSBP2", "{u} (Gene) is upregulated by {v} (Compound)", "Gatifloxacin" ] ], [ [ "Prednisone", "{u} (Compound) causes {v} (Side Effect)", "Agitation" ], [ "Agitation", "{u} (Side Effect) is caused by {v} (Compound)", "Gatifloxacin" ] ], [ [ "Prednisone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Cisplatin" ], [ "Cisplatin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Gatifloxacin" ] ], [ [ "Prednisone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Acetylsalicylic acid" ], [ "Acetylsalicylic acid", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Gatifloxacin" ] ] ]
Prednisone may lead to a major life threatening interaction when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Gatifloxacin (Compound) Prednisone may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Gatifloxacin (Compound) Prednisone may lead to a major life threatening interaction when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Gatifloxacin (Compound) Prednisone may lead to a major life threatening interaction when taken with Enoxacin and Enoxacin (Compound) resembles Gatifloxacin (Compound) Prednisone (Compound) binds ALB (Gene) and ALB (Gene) is bound by Gatifloxacin (Compound) Prednisone (Compound) upregulates SSBP2 (Gene) and SSBP2 (Gene) is upregulated by Gatifloxacin (Compound) Prednisone (Compound) causes Agitation (Side Effect) and Agitation (Side Effect) is caused by Gatifloxacin (Compound) Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin may cause a minor interaction that can limit clinical effects when taken with Gatifloxacin Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Gatifloxacin
DB00436
DB01101
323
60
[ "DDInter179", "DDInter285" ]
Bendroflumethiazide
Capecitabine
A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p810)
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
Moderate
1
[ [ [ 323, 24, 60 ] ], [ [ 323, 21, 29250 ], [ 29250, 60, 60 ] ], [ [ 323, 24, 286 ], [ 286, 62, 60 ] ], [ [ 323, 40, 1577 ], [ 1577, 24, 60 ] ], [ [ 323, 63, 1648 ], [ 1648, 24, 60 ] ], [ [ 323, 40, 178 ], [ 178, 63, 60 ] ], [ [ 323, 24, 970 ], [ 970, 24, 60 ] ], [ [ 323, 23, 126 ], [ 126, 25, 60 ] ], [ [ 323, 21, 29250 ], [ 29250, 60, 1176 ], [ 1176, 23, 60 ] ], [ [ 323, 21, 28921 ], [ 28921, 60, 872 ], [ 872, 62, 60 ] ] ]
[ [ [ "Bendroflumethiazide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Capecitabine" ] ], [ [ "Bendroflumethiazide", "{u} (Compound) causes {v} (Side Effect)", "Polyuria" ], [ "Polyuria", "{u} (Side Effect) is caused by {v} (Compound)", "Capecitabine" ] ], [ [ "Bendroflumethiazide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Magnesium hydroxide" ], [ "Magnesium hydroxide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Capecitabine" ] ], [ [ "Bendroflumethiazide", "{u} (Compound) resembles {v} (Compound)", "Hydroflumethiazide" ], [ "Hydroflumethiazide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Capecitabine" ] ], [ [ "Bendroflumethiazide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Aldesleukin" ], [ "Aldesleukin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Capecitabine" ] ], [ [ "Bendroflumethiazide", "{u} (Compound) resembles {v} (Compound)", "Polythiazide" ], [ "Polythiazide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Capecitabine" ] ], [ [ "Bendroflumethiazide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fluorouracil" ], [ "Fluorouracil", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Capecitabine" ] ], [ [ "Bendroflumethiazide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Warfarin" ], [ "Warfarin", "{u} may lead to a major life threatening interaction when taken with {v}", "Capecitabine" ] ], [ [ "Bendroflumethiazide", "{u} (Compound) causes {v} (Side Effect)", "Polyuria" ], [ "Polyuria", "{u} (Side Effect) is caused by {v} (Compound)", "Moxifloxacin" ], [ "Moxifloxacin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Capecitabine" ] ], [ [ "Bendroflumethiazide", "{u} (Compound) causes {v} (Side Effect)", "Dizziness" ], [ "Dizziness", "{u} (Side Effect) is caused by {v} (Compound)", "Gemifloxacin" ], [ "Gemifloxacin", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Capecitabine" ] ] ]
Bendroflumethiazide (Compound) causes Polyuria (Side Effect) and Polyuria (Side Effect) is caused by Capecitabine (Compound) Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a minor interaction that can limit clinical effects when taken with Capecitabine Bendroflumethiazide (Compound) resembles Hydroflumethiazide (Compound) and Hydroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Capecitabine Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Capecitabine Bendroflumethiazide (Compound) resembles Polythiazide (Compound) and Polythiazide may cause a moderate interaction that could exacerbate diseases when taken with Capecitabine Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Fluorouracil and Fluorouracil may cause a moderate interaction that could exacerbate diseases when taken with Capecitabine Bendroflumethiazide may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may lead to a major life threatening interaction when taken with Capecitabine Bendroflumethiazide (Compound) causes Polyuria (Side Effect) and Polyuria (Side Effect) is caused by Moxifloxacin (Compound) and Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Capecitabine Bendroflumethiazide (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Gemifloxacin (Compound) and Gemifloxacin may cause a minor interaction that can limit clinical effects when taken with Capecitabine
DB01253
DB08899
628
129
[ "DDInter664", "DDInter649" ]
Ergometrine
Enzalutamide
An ergot alkaloid with uterine and vascular smooth muscle contractile properties.
Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line treatment of prostate cancer and remission can be achieved, arising resistance is inevitable, becoming castration-resistant prostate cancer. Until recently, docetaxel is the only treatment available for metastatic CRPC; however, AR inhibitors have been developed for more targeted therapy, although first-generation AR inhibitors like bicalutamide did not substantially increase the survival rate. Second-generation such as enzalutamide is more efficacious due to a higher affinity to AR and no partial agonist activity compared to bicalutamide.[A252667,A252642] Due to a favorable pharmacological profile, a phase 1 study of enzalutamide was initiated in July 2007. Compared to the average time of 10 to 15 years for a drug to go from pre-clinical to clinical studies, enzalutamide was developed relatively rapidly.
Moderate
1
[ [ [ 628, 24, 129 ] ], [ [ 628, 63, 918 ], [ 918, 1, 129 ] ], [ [ 628, 6, 8374 ], [ 8374, 45, 129 ] ], [ [ 628, 7, 16629 ], [ 16629, 46, 129 ] ], [ [ 628, 21, 28921 ], [ 28921, 60, 129 ] ], [ [ 628, 24, 1320 ], [ 1320, 63, 129 ] ], [ [ 628, 63, 1101 ], [ 1101, 24, 129 ] ], [ [ 628, 1, 826 ], [ 826, 24, 129 ] ], [ [ 628, 24, 1250 ], [ 1250, 24, 129 ] ], [ [ 628, 64, 609 ], [ 609, 24, 129 ] ] ]
[ [ [ "Ergometrine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Enzalutamide" ] ], [ [ "Ergometrine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bicalutamide" ], [ "Bicalutamide", "{u} (Compound) resembles {v} (Compound)", "Enzalutamide" ] ], [ [ "Ergometrine", "{u} (Compound) binds {v} (Gene)", "CYP3A4" ], [ "CYP3A4", "{u} (Gene) is bound by {v} (Compound)", "Enzalutamide" ] ], [ [ "Ergometrine", "{u} (Compound) upregulates {v} (Gene)", "RPL39L" ], [ "RPL39L", "{u} (Gene) is upregulated by {v} (Compound)", "Enzalutamide" ] ], [ [ "Ergometrine", "{u} (Compound) causes {v} (Side Effect)", "Dizziness" ], [ "Dizziness", "{u} (Side Effect) is caused by {v} (Compound)", "Enzalutamide" ] ], [ [ "Ergometrine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Elagolix" ], [ "Elagolix", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Enzalutamide" ] ], [ [ "Ergometrine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bexarotene" ], [ "Bexarotene", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Enzalutamide" ] ], [ [ "Ergometrine", "{u} (Compound) resembles {v} (Compound)", "Ergotamine" ], [ "Ergotamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Enzalutamide" ] ], [ [ "Ergometrine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pazopanib" ], [ "Pazopanib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Enzalutamide" ] ], [ [ "Ergometrine", "{u} may lead to a major life threatening interaction when taken with {v}", "Clarithromycin" ], [ "Clarithromycin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Enzalutamide" ] ] ]
Ergometrine may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide (Compound) resembles Enzalutamide (Compound) Ergometrine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound) Ergometrine (Compound) upregulates RPL39L (Gene) and RPL39L (Gene) is upregulated by Enzalutamide (Compound) Ergometrine (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Enzalutamide (Compound) Ergometrine may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide Ergometrine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide Ergometrine (Compound) resembles Ergotamine (Compound) and Ergotamine may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide Ergometrine may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide Ergometrine may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
DB00283
DB00363
701
695
[ "DDInter395", "DDInter419" ]
Clemastine
Clozapine
An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness.
Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine receptors results in fewer extrapyramidal side effects, especially tardive dyskinesia. However, its promiscuity toward the muscarinic and adrenergic receptors can result in other side effects, notably gastrointestinal hypomotility and orthostatic hypotension. [L905,A215552]. Despite its effectiveness in treating both positive and negative symptoms of schizophrenia, clozapine was briefly removed from the market in various jurisdictions in 1970 due to severe agranulocytosis.[A256713,A256718] However, continued evidence of its effectiveness led to clozapine's eventual reintroduction, although with a reluctance to prescribe it. Clozapine was approved by the FDA in 1989 for treatment-resistant schizophrenia under the brand CLOZARIL. Due to its severe adverse effects profile, clozapine is only available through a restricted program under a Risk Evaluation Mitigation Strategy (REMS) called the Clozapine REMS Program.
Moderate
1
[ [ [ 701, 24, 695 ] ], [ [ 701, 24, 1178 ], [ 1178, 1, 695 ] ], [ [ 701, 24, 902 ], [ 902, 40, 695 ] ], [ [ 701, 40, 1003 ], [ 1003, 1, 695 ] ], [ [ 701, 24, 1219 ], [ 1219, 63, 695 ] ], [ [ 701, 63, 905 ], [ 905, 40, 695 ] ], [ [ 701, 63, 1174 ], [ 1174, 1, 695 ] ], [ [ 701, 6, 12523 ], [ 12523, 45, 695 ] ], [ [ 701, 63, 352 ], [ 352, 24, 695 ] ], [ [ 701, 35, 1594 ], [ 1594, 63, 695 ] ] ]
[ [ [ "Clemastine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clozapine" ] ], [ [ "Clemastine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Trifluoperazine" ], [ "Trifluoperazine", "{u} (Compound) resembles {v} (Compound)", "Clozapine" ] ], [ [ "Clemastine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clobazam" ], [ "Clobazam", "{u} (Compound) resembles {v} (Compound)", "Clozapine" ] ], [ [ "Clemastine", "{u} (Compound) resembles {v} (Compound)", "Azelastine" ], [ "Azelastine", "{u} (Compound) resembles {v} (Compound)", "Clozapine" ] ], [ [ "Clemastine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Azatadine" ], [ "Azatadine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clozapine" ] ], [ [ "Clemastine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lorazepam" ], [ "Lorazepam", "{u} (Compound) resembles {v} (Compound)", "Clozapine" ] ], [ [ "Clemastine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Temazepam" ], [ "Temazepam", "{u} (Compound) resembles {v} (Compound)", "Clozapine" ] ], [ [ "Clemastine", "{u} (Compound) binds {v} (Gene)", "CYP2D6" ], [ "CYP2D6", "{u} (Gene) is bound by {v} (Compound)", "Clozapine" ] ], [ [ "Clemastine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Trospium" ], [ "Trospium", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clozapine" ] ], [ [ "Clemastine", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Doxylamine" ], [ "Doxylamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clozapine" ] ] ]
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Clozapine (Compound) Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Clobazam and Clobazam (Compound) resembles Clozapine (Compound) Clemastine (Compound) resembles Azelastine (Compound) and Azelastine (Compound) resembles Clozapine (Compound) Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Azatadine and Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Clozapine Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Lorazepam and Lorazepam (Compound) resembles Clozapine (Compound) Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Temazepam and Temazepam (Compound) resembles Clozapine (Compound) Clemastine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Clozapine (Compound) Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Clozapine Clemastine (Compound) resembles Doxylamine (Compound) and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Clozapine
DB01284
DB15091
1,042
676
[ "DDInter1782", "DDInter1901" ]
Tetracosactide
Upadacitinib
Tetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticosteroids in the adrenal cortex. Tetracosactide exhibits the same activity as natural ACTH with regard to all its biological activities. The complex results in a product whose absorption in man is effected over a longer period of time as compared to corticotropin. Therefore, therapy may be maintained with less frequent administration.
Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by synovial inflammation and hyperplasia, autoantibody production, cartilage damage and bone destruction, leading to co-morbidities. Despite a variety of therapeutic agents available for treatment, up to 40% of the patients do not respond to current therapies, including biological therapies. The etiology of the disease is mostly unknown; however, the role of JAK as a driver of immune-mediated conditions was discovered, leading to the use of JAK as therapeutic targets for rheumatoid arthritis. To reduce dose-related toxicity (as seen with some pan-JAK inhibitors) without significantly affecting efficacy, more selective JAK1 inhibitors, upadacitinib and [filgotinib], were developed. The FDA approved upadacitinib in August 2019 and it is used for the treatment of active rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, and ankylosing spondylitis. In December 2019, it was additionally approved by the European Commission and Health Canada.[L10899,L42540] Upadacitinib is marketed under the brand name RINVOQ for oral administration.
Major
2
[ [ [ 1042, 25, 676 ] ], [ [ 1042, 24, 1430 ], [ 1430, 24, 676 ] ], [ [ 1042, 63, 122 ], [ 122, 24, 676 ] ], [ [ 1042, 64, 932 ], [ 932, 24, 676 ] ], [ [ 1042, 63, 1184 ], [ 1184, 25, 676 ] ], [ [ 1042, 24, 270 ], [ 270, 25, 676 ] ], [ [ 1042, 64, 1064 ], [ 1064, 25, 676 ] ], [ [ 1042, 25, 779 ], [ 779, 25, 676 ] ], [ [ 1042, 24, 1430 ], [ 1430, 63, 1184 ], [ 1184, 25, 676 ] ], [ [ 1042, 63, 122 ], [ 122, 23, 283 ], [ 283, 24, 676 ] ] ]
[ [ [ "Tetracosactide", "{u} may lead to a major life threatening interaction when taken with {v}", "Upadacitinib" ] ], [ [ "Tetracosactide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sipuleucel-T" ], [ "Sipuleucel-T", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Upadacitinib" ] ], [ [ "Tetracosactide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Verapamil" ], [ "Verapamil", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Upadacitinib" ] ], [ [ "Tetracosactide", "{u} may lead to a major life threatening interaction when taken with {v}", "Mifepristone" ], [ "Mifepristone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Upadacitinib" ] ], [ [ "Tetracosactide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Anakinra" ], [ "Anakinra", "{u} may lead to a major life threatening interaction when taken with {v}", "Upadacitinib" ] ], [ [ "Tetracosactide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ocrelizumab" ], [ "Ocrelizumab", "{u} may lead to a major life threatening interaction when taken with {v}", "Upadacitinib" ] ], [ [ "Tetracosactide", "{u} may lead to a major life threatening interaction when taken with {v}", "Cladribine" ], [ "Cladribine", "{u} may lead to a major life threatening interaction when taken with {v}", "Upadacitinib" ] ], [ [ "Tetracosactide", "{u} may lead to a major life threatening interaction when taken with {v}", "Smallpox (Vaccinia) Vaccine, Live" ], [ "Smallpox (Vaccinia) Vaccine, Live", "{u} may lead to a major life threatening interaction when taken with {v}", "Upadacitinib" ] ], [ [ "Tetracosactide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sipuleucel-T" ], [ "Sipuleucel-T", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Anakinra" ], [ "Anakinra", "{u} may lead to a major life threatening interaction when taken with {v}", "Upadacitinib" ] ], [ [ "Tetracosactide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Verapamil" ], [ "Verapamil", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Fedratinib" ], [ "Fedratinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Upadacitinib" ] ] ]
Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Verapamil and Verapamil may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib Tetracosactide may lead to a major life threatening interaction when taken with Mifepristone and Mifepristone may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may lead to a major life threatening interaction when taken with Upadacitinib Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may lead to a major life threatening interaction when taken with Upadacitinib Tetracosactide may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Upadacitinib Tetracosactide may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live and Smallpox (Vaccinia) Vaccine, Live may lead to a major life threatening interaction when taken with Upadacitinib Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may lead to a major life threatening interaction when taken with Upadacitinib Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Verapamil and Verapamil may cause a minor interaction that can limit clinical effects when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
DB00281
DB01136
608
772
[ "DDInter1066", "DDInter305" ]
Lidocaine
Carvedilol
Ever since its discovery and availability for sale and use in the late 1940s, lidocaine has become an exceptionally commonly used medication. In particular, lidocaine's principal mode of action in acting as a local anesthetic that numbs the sensations of tissues means the agent is indicated for facilitating local anesthesia for a large variety of surgical procedures [F4349, L5930, L5948]. It ultimately elicits its numbing activity by blocking sodium channels so that the neurons of local tissues that have the medication applied on are transiently incapable of signaling the brain regarding sensations [F4349, L5930, L5948]. In doing so, however, it can block or decrease muscle contractile, resulting in effects like vasodilation, hypotension, and irregular heart rate, among others [F4349, L5930, L5948]. As a result, lidocaine is also considered a class Ib anti-arrhythmic agent [L
Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker.[L7889,L7892] It is currently used to treat heart failure, left ventricular dysfunction, and hypertension.[L7889,L7892] The dual action of carvedilol is advantageous in combination therapies as moderate doses of 2 drugs have a decreased incidence of adverse effects compared to high dose monotherapy in the treatment of moderate hypertension. Carvedilol was granted FDA approval on 14 September 1995.
Moderate
1
[ [ [ 608, 24, 772 ] ], [ [ 608, 23, 371 ], [ 371, 1, 772 ] ], [ [ 608, 6, 12523 ], [ 12523, 45, 772 ] ], [ [ 608, 18, 5901 ], [ 5901, 45, 772 ] ], [ [ 608, 21, 28734 ], [ 28734, 60, 772 ] ], [ [ 608, 63, 702 ], [ 702, 24, 772 ] ], [ [ 608, 25, 1455 ], [ 1455, 63, 772 ] ], [ [ 608, 24, 1010 ], [ 1010, 24, 772 ] ], [ [ 608, 24, 1154 ], [ 1154, 63, 772 ] ], [ [ 608, 23, 868 ], [ 868, 63, 772 ] ] ]
[ [ [ "Lidocaine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Carvedilol" ] ], [ [ "Lidocaine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Propafenone" ], [ "Propafenone", "{u} (Compound) resembles {v} (Compound)", "Carvedilol" ] ], [ [ "Lidocaine", "{u} (Compound) binds {v} (Gene)", "CYP2D6" ], [ "CYP2D6", "{u} (Gene) is bound by {v} (Compound)", "Carvedilol" ] ], [ [ "Lidocaine", "{u} (Compound) downregulates {v} (Gene)", "GJA1" ], [ "GJA1", "{u} (Gene) is bound by {v} (Compound)", "Carvedilol" ] ], [ [ "Lidocaine", "{u} (Compound) causes {v} (Side Effect)", "Immune system disorder" ], [ "Immune system disorder", "{u} (Side Effect) is caused by {v} (Compound)", "Carvedilol" ] ], [ [ "Lidocaine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Anagrelide" ], [ "Anagrelide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Carvedilol" ] ], [ [ "Lidocaine", "{u} may lead to a major life threatening interaction when taken with {v}", "Nitrous acid" ], [ "Nitrous acid", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Carvedilol" ] ], [ [ "Lidocaine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Mefloquine" ], [ "Mefloquine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Carvedilol" ] ], [ [ "Lidocaine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pasireotide" ], [ "Pasireotide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Carvedilol" ] ], [ [ "Lidocaine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Vemurafenib" ], [ "Vemurafenib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Carvedilol" ] ] ]
Lidocaine may cause a minor interaction that can limit clinical effects when taken with Propafenone and Propafenone (Compound) resembles Carvedilol (Compound) Lidocaine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Carvedilol (Compound) Lidocaine (Compound) downregulates GJA1 (Gene) and GJA1 (Gene) is bound by Carvedilol (Compound) Lidocaine (Compound) causes Immune system disorder (Side Effect) and Immune system disorder (Side Effect) is caused by Carvedilol (Compound) Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Anagrelide and Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Carvedilol Lidocaine may lead to a major life threatening interaction when taken with Nitrous acid and Nitrous acid may cause a moderate interaction that could exacerbate diseases when taken with Carvedilol Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Carvedilol Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide and Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Carvedilol Lidocaine may cause a minor interaction that can limit clinical effects when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Carvedilol
DB01206
DB11817
37
1,259
[ "DDInter1086", "DDInter165" ]
Lomustine
Baricitinib
An alkylating agent of value against both hematologic malignancies and solid tumors.
Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune responses. Baricitinib was first approved by the European Commission (EC) in February 2017 for the treatment of rheumatoid arthritis in adults and was later approved by the FDA in 2018. The EC later approved baricitinib for the treatment of atopic dermatitis, making it the first JAK inhibitor used for this indication in Europe. While baricitinib was granted emergency use as a treatment for COVID-19 in combination with [remdesivir] under the Emergency Use Authorization (EUA) in November 2020, the FDA fully approved the use of baricitinib for the treatment of COVID-19 in May 2022.
Major
2
[ [ [ 37, 25, 1259 ] ], [ [ 37, 63, 1461 ], [ 1461, 23, 1259 ] ], [ [ 37, 24, 949 ], [ 949, 24, 1259 ] ], [ [ 37, 63, 563 ], [ 563, 24, 1259 ] ], [ [ 37, 24, 1129 ], [ 1129, 63, 1259 ] ], [ [ 37, 24, 384 ], [ 384, 25, 1259 ] ], [ [ 37, 24, 975 ], [ 975, 64, 1259 ] ], [ [ 37, 63, 60 ], [ 60, 25, 1259 ] ], [ [ 37, 25, 1011 ], [ 1011, 25, 1259 ] ], [ [ 37, 64, 1064 ], [ 1064, 25, 1259 ] ] ]
[ [ [ "Lomustine", "{u} may lead to a major life threatening interaction when taken with {v}", "Baricitinib" ] ], [ [ "Lomustine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Vitamin E" ], [ "Vitamin E", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Baricitinib" ] ], [ [ "Lomustine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clostridium tetani toxoid antigen (formaldehyde inactivated)" ], [ "Clostridium tetani toxoid antigen (formaldehyde inactivated)", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Baricitinib" ] ], [ [ "Lomustine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ganciclovir" ], [ "Ganciclovir", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Baricitinib" ] ], [ [ "Lomustine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Human adenovirus e serotype 4 strain cl-68578 antigen" ], [ "Human adenovirus e serotype 4 strain cl-68578 antigen", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Baricitinib" ] ], [ [ "Lomustine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Idelalisib" ], [ "Idelalisib", "{u} may lead to a major life threatening interaction when taken with {v}", "Baricitinib" ] ], [ [ "Lomustine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lurbinectedin" ], [ "Lurbinectedin", "{u} may lead to a major life threatening interaction when taken with {v}", "Baricitinib" ] ], [ [ "Lomustine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Capecitabine" ], [ "Capecitabine", "{u} may lead to a major life threatening interaction when taken with {v}", "Baricitinib" ] ], [ [ "Lomustine", "{u} may lead to a major life threatening interaction when taken with {v}", "Fingolimod" ], [ "Fingolimod", "{u} may lead to a major life threatening interaction when taken with {v}", "Baricitinib" ] ], [ [ "Lomustine", "{u} may lead to a major life threatening interaction when taken with {v}", "Cladribine" ], [ "Cladribine", "{u} may lead to a major life threatening interaction when taken with {v}", "Baricitinib" ] ] ]
Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Baricitinib Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir and Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen and Human adenovirus e serotype 4 strain cl-68578 antigen may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Baricitinib Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin and Lurbinectedin may lead to a major life threatening interaction when taken with Baricitinib Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Capecitabine and Capecitabine may lead to a major life threatening interaction when taken with Baricitinib Lomustine may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Baricitinib Lomustine may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Baricitinib
DB00688
DB01129
955
379
[ "DDInter1251", "DDInter1559" ]
Mycophenolate mofetil
Rabeprazole
Mycophenolate mofetil, also known as MMF or CellCept, is a prodrug of mycophenolic acid, and classified as a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). This drug is an immunosuppressant combined with drugs such as [Cyclosporine] and corticosteroids to prevent organ rejection after hepatic, renal, and cardiac transplants. It is marketed by Roche Pharmaceuticals and was granted FDA approval for the prophylaxis of transplant rejection in 1995. In addition to the above uses, mycophenolate mofetil has also been studied for the treatment of nephritis and other complications of autoimmune diseases. Unlike another immunosuppressant class, the calcineurin inhibitors, MMF generally does not cause nephrotoxicity or fibrosis.[A180799,A180805] Previously, mycophenolic acid
Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion.
Moderate
1
[ [ [ 955, 24, 379 ] ], [ [ 955, 63, 1215 ], [ 1215, 40, 379 ] ], [ [ 955, 24, 660 ], [ 660, 1, 379 ] ], [ [ 955, 63, 837 ], [ 837, 1, 379 ] ], [ [ 955, 6, 8374 ], [ 8374, 45, 379 ] ], [ [ 955, 21, 29687 ], [ 29687, 60, 379 ] ], [ [ 955, 23, 428 ], [ 428, 63, 379 ] ], [ [ 955, 24, 1132 ], [ 1132, 24, 379 ] ], [ [ 955, 62, 1031 ], [ 1031, 24, 379 ] ], [ [ 955, 24, 416 ], [ 416, 63, 379 ] ] ]
[ [ [ "Mycophenolate mofetil", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Rabeprazole" ] ], [ [ "Mycophenolate mofetil", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lansoprazole" ], [ "Lansoprazole", "{u} (Compound) resembles {v} (Compound)", "Rabeprazole" ] ], [ [ "Mycophenolate mofetil", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Esomeprazole" ], [ "Esomeprazole", "{u} (Compound) resembles {v} (Compound)", "Rabeprazole" ] ], [ [ "Mycophenolate mofetil", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pantoprazole" ], [ "Pantoprazole", "{u} (Compound) resembles {v} (Compound)", "Rabeprazole" ] ], [ [ "Mycophenolate mofetil", "{u} (Compound) binds {v} (Gene)", "CYP3A4" ], [ "CYP3A4", "{u} (Gene) is bound by {v} (Compound)", "Rabeprazole" ] ], [ [ "Mycophenolate mofetil", "{u} (Compound) causes {v} (Side Effect)", "Fungal skin infection" ], [ "Fungal skin infection", "{u} (Side Effect) is caused by {v} (Compound)", "Rabeprazole" ] ], [ [ "Mycophenolate mofetil", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Ferrous fumarate" ], [ "Ferrous fumarate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Rabeprazole" ] ], [ [ "Mycophenolate mofetil", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Gentamicin" ], [ "Gentamicin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Rabeprazole" ] ], [ [ "Mycophenolate mofetil", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Theophylline" ], [ "Theophylline", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Rabeprazole" ] ], [ [ "Mycophenolate mofetil", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Kanamycin" ], [ "Kanamycin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Rabeprazole" ] ] ]
Mycophenolate mofetil may cause a moderate interaction that could exacerbate diseases when taken with Lansoprazole and Lansoprazole (Compound) resembles Rabeprazole (Compound) Mycophenolate mofetil may cause a moderate interaction that could exacerbate diseases when taken with Esomeprazole and Esomeprazole (Compound) resembles Rabeprazole (Compound) Mycophenolate mofetil may cause a moderate interaction that could exacerbate diseases when taken with Pantoprazole and Pantoprazole (Compound) resembles Rabeprazole (Compound) Mycophenolate mofetil (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rabeprazole (Compound) Mycophenolate mofetil (Compound) causes Fungal skin infection (Side Effect) and Fungal skin infection (Side Effect) is caused by Rabeprazole (Compound) Mycophenolate mofetil may cause a minor interaction that can limit clinical effects when taken with Ferrous fumarate and Ferrous fumarate may cause a moderate interaction that could exacerbate diseases when taken with Rabeprazole Mycophenolate mofetil may cause a moderate interaction that could exacerbate diseases when taken with Gentamicin and Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Rabeprazole Mycophenolate mofetil may cause a minor interaction that can limit clinical effects when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Rabeprazole Mycophenolate mofetil may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin and Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Rabeprazole
DB00382
DB06663
62
1,154
[ "DDInter1734", "DDInter1398" ]
Tacrine
Pasireotide
A centerally active cholinesterase inhibitor that has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders. Tacrine has been discontinued for the United States market.
Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease.
Moderate
1
[ [ [ 62, 24, 1154 ] ], [ [ 62, 24, 112 ], [ 112, 23, 1154 ] ], [ [ 62, 24, 663 ], [ 663, 24, 1154 ] ], [ [ 62, 63, 912 ], [ 912, 24, 1154 ] ], [ [ 62, 24, 1662 ], [ 1662, 63, 1154 ] ], [ [ 62, 63, 702 ], [ 702, 25, 1154 ] ], [ [ 62, 24, 1011 ], [ 1011, 64, 1154 ] ], [ [ 62, 24, 322 ], [ 322, 25, 1154 ] ], [ [ 62, 25, 1510 ], [ 1510, 64, 1154 ] ], [ [ 62, 25, 1377 ], [ 1377, 25, 1154 ] ] ]
[ [ [ "Tacrine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pasireotide" ] ], [ [ "Tacrine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Metronidazole" ], [ "Metronidazole", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Pasireotide" ] ], [ [ "Tacrine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Methotrexate" ], [ "Methotrexate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pasireotide" ] ], [ [ "Tacrine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Interferon beta-1a" ], [ "Interferon beta-1a", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pasireotide" ] ], [ [ "Tacrine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Picosulfuric acid" ], [ "Picosulfuric acid", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pasireotide" ] ], [ [ "Tacrine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Anagrelide" ], [ "Anagrelide", "{u} may lead to a major life threatening interaction when taken with {v}", "Pasireotide" ] ], [ [ "Tacrine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fingolimod" ], [ "Fingolimod", "{u} may lead to a major life threatening interaction when taken with {v}", "Pasireotide" ] ], [ [ "Tacrine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Epirubicin" ], [ "Epirubicin", "{u} may lead to a major life threatening interaction when taken with {v}", "Pasireotide" ] ], [ [ "Tacrine", "{u} may lead to a major life threatening interaction when taken with {v}", "Teriflunomide" ], [ "Teriflunomide", "{u} may lead to a major life threatening interaction when taken with {v}", "Pasireotide" ] ], [ [ "Tacrine", "{u} may lead to a major life threatening interaction when taken with {v}", "Leflunomide" ], [ "Leflunomide", "{u} may lead to a major life threatening interaction when taken with {v}", "Pasireotide" ] ] ]
Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Pasireotide Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Anagrelide and Anagrelide may lead to a major life threatening interaction when taken with Pasireotide Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Pasireotide Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may lead to a major life threatening interaction when taken with Pasireotide Tacrine may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Pasireotide Tacrine may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Pasireotide
DB00486
DB00899
1,614
411
[ "DDInter1253", "DDInter1579" ]
Nabilone
Remifentanil
Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, however it is considered to be twice as active as Δ⁹-THC. Nabilone is approved by the FDA for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments [FDA Label]. Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the two most abundant cannabinoids found naturally in the resin of the marijuana plant, both of which are pharmacologically active due to their interaction with cannabinoid receptors that are
Remifentanil (marketed by Abbott as Ultiva) is a potent ultra short-acting synthetic opioid given to patients during surgery for pain relief and adjunctive to an anaesthetic. Remifentanil is a specific mu-type-opioid receptor agonist which means it reduces sympathetic nervous system tone, and causes respiratory depression and analgesia.
Moderate
1
[ [ [ 1614, 24, 411 ] ], [ [ 1614, 24, 1322 ], [ 1322, 40, 411 ] ], [ [ 1614, 24, 704 ], [ 704, 1, 411 ] ], [ [ 1614, 63, 1349 ], [ 1349, 40, 411 ] ], [ [ 1614, 21, 29212 ], [ 29212, 60, 411 ] ], [ [ 1614, 24, 662 ], [ 662, 24, 411 ] ], [ [ 1614, 24, 537 ], [ 537, 63, 411 ] ], [ [ 1614, 63, 475 ], [ 475, 24, 411 ] ], [ [ 1614, 40, 530 ], [ 530, 24, 411 ] ], [ [ 1614, 24, 222 ], [ 222, 64, 411 ] ] ]
[ [ [ "Nabilone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Remifentanil" ] ], [ [ "Nabilone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Alfentanil" ], [ "Alfentanil", "{u} (Compound) resembles {v} (Compound)", "Remifentanil" ] ], [ [ "Nabilone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fentanyl" ], [ "Fentanyl", "{u} (Compound) resembles {v} (Compound)", "Remifentanil" ] ], [ [ "Nabilone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Meperidine" ], [ "Meperidine", "{u} (Compound) resembles {v} (Compound)", "Remifentanil" ] ], [ [ "Nabilone", "{u} (Compound) causes {v} (Side Effect)", "Pulmonary function test decreased" ], [ "Pulmonary function test decreased", "{u} (Side Effect) is caused by {v} (Compound)", "Remifentanil" ] ], [ [ "Nabilone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Carbinoxamine" ], [ "Carbinoxamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Remifentanil" ] ], [ [ "Nabilone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Cyclizine" ], [ "Cyclizine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Remifentanil" ] ], [ [ "Nabilone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Morphine" ], [ "Morphine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Remifentanil" ] ], [ [ "Nabilone", "{u} (Compound) resembles {v} (Compound)", "Dronabinol" ], [ "Dronabinol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Remifentanil" ] ], [ [ "Nabilone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sibutramine" ], [ "Sibutramine", "{u} may lead to a major life threatening interaction when taken with {v}", "Remifentanil" ] ] ]
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Alfentanil and Alfentanil (Compound) resembles Remifentanil (Compound) Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Fentanyl and Fentanyl (Compound) resembles Remifentanil (Compound) Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Meperidine and Meperidine (Compound) resembles Remifentanil (Compound) Nabilone (Compound) causes Pulmonary function test decreased (Side Effect) and Pulmonary function test decreased (Side Effect) is caused by Remifentanil (Compound) Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Remifentanil Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Remifentanil Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Remifentanil Nabilone (Compound) resembles Dronabinol (Compound) and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Remifentanil Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may lead to a major life threatening interaction when taken with Remifentanil
DB00201
DB09074
1,684
1,362
[ "DDInter263", "DDInter1327" ]
Caffeine
Olaparib
Caffeine is a drug of the methylxanthine class used for a variety of purposes, including certain respiratory conditions of the premature newborn, pain relief, and to combat drowsiness. Caffeine is similar in chemical structure to [Theophylline] and [Theobromine].[A187691,L9851] It can be sourced from coffee beans, but also occurs naturally in various teas and cacao beans, which are different than coffee beans. Caffeine is also used in a variety of cosmetic products and can be administered topically, orally, by inhalation, or by injection. The caffeine citrate injection, used for apnea of the premature newborn, was initially approved by the FDA in 1999. According to an article from 2017, more than 15 million babies are born prematurely worldwide. This correlates to about 1 in 10 births. Premature birth can lead to apnea and bronchopulmonary dysplasia, a
Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Olaparib is used to treat a number of BRCA-associated tumours, including ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer.[L41100, L40908, L43792] It was first approved by the FDA and EU in December 2014, and by Health Canada in April 2016.
Moderate
1
[ [ [ 1684, 24, 1362 ] ], [ [ 1684, 24, 2 ], [ 2, 24, 1362 ] ], [ [ 1684, 24, 1619 ], [ 1619, 63, 1362 ] ], [ [ 1684, 23, 752 ], [ 752, 24, 1362 ] ], [ [ 1684, 25, 876 ], [ 876, 24, 1362 ] ], [ [ 1684, 63, 529 ], [ 529, 24, 1362 ] ], [ [ 1684, 24, 1510 ], [ 1510, 25, 1362 ] ], [ [ 1684, 24, 1580 ], [ 1580, 64, 1362 ] ], [ [ 1684, 23, 695 ], [ 695, 25, 1362 ] ], [ [ 1684, 24, 2 ], [ 2, 24, 1619 ], [ 1619, 63, 1362 ] ] ]
[ [ [ "Caffeine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Olaparib" ] ], [ [ "Caffeine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Alosetron" ], [ "Alosetron", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Olaparib" ] ], [ [ "Caffeine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Rucaparib" ], [ "Rucaparib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Olaparib" ] ], [ [ "Caffeine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Cimetidine" ], [ "Cimetidine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Olaparib" ] ], [ [ "Caffeine", "{u} may lead to a major life threatening interaction when taken with {v}", "Tizanidine" ], [ "Tizanidine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Olaparib" ] ], [ [ "Caffeine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fluvoxamine" ], [ "Fluvoxamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Olaparib" ] ], [ [ "Caffeine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Teriflunomide" ], [ "Teriflunomide", "{u} may lead to a major life threatening interaction when taken with {v}", "Olaparib" ] ], [ [ "Caffeine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Stiripentol" ], [ "Stiripentol", "{u} may lead to a major life threatening interaction when taken with {v}", "Olaparib" ] ], [ [ "Caffeine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Clozapine" ], [ "Clozapine", "{u} may lead to a major life threatening interaction when taken with {v}", "Olaparib" ] ], [ [ "Caffeine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Alosetron" ], [ "Alosetron", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Rucaparib" ], [ "Rucaparib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Olaparib" ] ] ]
Caffeine may cause a moderate interaction that could exacerbate diseases when taken with Alosetron and Alosetron may cause a moderate interaction that could exacerbate diseases when taken with Olaparib Caffeine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Olaparib Caffeine may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Olaparib Caffeine may lead to a major life threatening interaction when taken with Tizanidine and Tizanidine may cause a moderate interaction that could exacerbate diseases when taken with Olaparib Caffeine may cause a moderate interaction that could exacerbate diseases when taken with Fluvoxamine and Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Olaparib Caffeine may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Olaparib Caffeine may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol and Stiripentol may lead to a major life threatening interaction when taken with Olaparib Caffeine may cause a minor interaction that can limit clinical effects when taken with Clozapine and Clozapine may lead to a major life threatening interaction when taken with Olaparib Caffeine may cause a moderate interaction that could exacerbate diseases when taken with Alosetron and Alosetron may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
DB01100
DB06788
1,568
1,616
[ "DDInter1470", "DDInter864" ]
Pimozide
Histrelin
A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug Evaluations Annual, 1994, p403)
Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-controlled, hydrogel polymer reservoirs containing histrelin acetate that need to be replaced every 52 weeks.[L41700,L41715,L41755] Initially, histrelin implants were developed to reduce testosterone to castration levels in patients with advanced prostate cancer. The Vantas product was approved by the FDA in October 2004 for the palliative treatment of this condition. Vantas was later discontinued by Endo Pharmaceuticals Inc. on September 21, 2021. GnRH agonists are the first line of treatment for children with central precocious puberty (CPP) due to their capacity to reduce LH levels and the concentration of sex steroids. As the product Supprelin LA, histrelin is indicated for the treatment of CPP in children (approved by the FDA in May 2007).
Major
2
[ [ [ 1568, 25, 1616 ] ], [ [ 1568, 62, 112 ], [ 112, 23, 1616 ] ], [ [ 1568, 25, 1342 ], [ 1342, 24, 1616 ] ], [ [ 1568, 24, 603 ], [ 603, 63, 1616 ] ], [ [ 1568, 63, 1324 ], [ 1324, 24, 1616 ] ], [ [ 1568, 25, 927 ], [ 927, 63, 1616 ] ], [ [ 1568, 64, 600 ], [ 600, 24, 1616 ] ], [ [ 1568, 25, 57 ], [ 57, 25, 1616 ] ], [ [ 1568, 25, 868 ], [ 868, 64, 1616 ] ], [ [ 1568, 64, 1166 ], [ 1166, 25, 1616 ] ] ]
[ [ [ "Pimozide", "{u} may lead to a major life threatening interaction when taken with {v}", "Histrelin" ] ], [ [ "Pimozide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Metronidazole" ], [ "Metronidazole", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Histrelin" ] ], [ [ "Pimozide", "{u} may lead to a major life threatening interaction when taken with {v}", "Romidepsin" ], [ "Romidepsin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Histrelin" ] ], [ [ "Pimozide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Magnesium citrate" ], [ "Magnesium citrate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Histrelin" ] ], [ [ "Pimozide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Troglitazone" ], [ "Troglitazone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Histrelin" ] ], [ [ "Pimozide", "{u} may lead to a major life threatening interaction when taken with {v}", "Encorafenib" ], [ "Encorafenib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Histrelin" ] ], [ [ "Pimozide", "{u} may lead to a major life threatening interaction when taken with {v}", "Fluconazole" ], [ "Fluconazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Histrelin" ] ], [ [ "Pimozide", "{u} may lead to a major life threatening interaction when taken with {v}", "Arsenic trioxide" ], [ "Arsenic trioxide", "{u} may lead to a major life threatening interaction when taken with {v}", "Histrelin" ] ], [ [ "Pimozide", "{u} may lead to a major life threatening interaction when taken with {v}", "Vemurafenib" ], [ "Vemurafenib", "{u} may lead to a major life threatening interaction when taken with {v}", "Histrelin" ] ], [ [ "Pimozide", "{u} may lead to a major life threatening interaction when taken with {v}", "Dolasetron" ], [ "Dolasetron", "{u} may lead to a major life threatening interaction when taken with {v}", "Histrelin" ] ] ]
Pimozide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Histrelin Pimozide may lead to a major life threatening interaction when taken with Romidepsin and Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Histrelin Pimozide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate and Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with Histrelin Pimozide may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Histrelin Pimozide may lead to a major life threatening interaction when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Histrelin Pimozide may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Histrelin Pimozide may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may lead to a major life threatening interaction when taken with Histrelin Pimozide may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may lead to a major life threatening interaction when taken with Histrelin Pimozide may lead to a major life threatening interaction when taken with Dolasetron and Dolasetron may lead to a major life threatening interaction when taken with Histrelin
DB00227
DB06168
1,463
1,531
[ "DDInter1098", "DDInter281" ]
Lovastatin
Canakinumab
Lovastatin, also known as the brand name product Mevacor, is a lipid-lowering drug and fungal metabolite derived synthetically from a fermentation product of _Aspergillus terreus_. Originally named Mevinolin, lovastatin belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase, which catalyzes the conversion of HMG-CoA to mevalonic acid and is the third step in a sequence of metabolic reactions involved in the production of several compounds involved in lipid metabolism and transport including cholesterol, low-density lipoprotein (LDL) (sometimes referred to as "bad cholesterol"), and very low-density lipoprotein (VLDL). Prescribing of statin medications is considered
Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. Both heavy chains of canakinumab contain oligosaccharide chains linked to the protein backbone at asparagine 298 (Asn 298). Canakinumab binds to human IL-1β and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1alpha or IL-1 receptor antagonist (IL-1ra). Canakinumab is marketed under the brand name Ilaris and indicated for patients 4 years of age and older to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are both part of the Cryopyrin-Associated Periodic Syndromes (CAPS) as well as for patients 2 years of age and older to treat systemic juvenile idiopathic arthritis (SJIA). Clinical trials have established the administration of canakinumab every 2 weeks to be safe and effective, offering a considerable advantage over the existing treatment with the human IL-1 receptor antagonist, anakinra, which must be injected daily and which is often poorly tolerated by patients.
Moderate
1
[ [ [ 1463, 24, 1531 ] ], [ [ 1463, 24, 1362 ], [ 1362, 63, 1531 ] ], [ [ 1463, 24, 1213 ], [ 1213, 24, 1531 ] ], [ [ 1463, 63, 168 ], [ 168, 24, 1531 ] ], [ [ 1463, 35, 467 ], [ 467, 24, 1531 ] ], [ [ 1463, 25, 1668 ], [ 1668, 24, 1531 ] ], [ [ 1463, 25, 384 ], [ 384, 63, 1531 ] ], [ [ 1463, 63, 581 ], [ 581, 25, 1531 ] ], [ [ 1463, 24, 980 ], [ 980, 64, 1531 ] ], [ [ 1463, 25, 1510 ], [ 1510, 64, 1531 ] ] ]
[ [ [ "Lovastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Canakinumab" ] ], [ [ "Lovastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Olaparib" ], [ "Olaparib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Canakinumab" ] ], [ [ "Lovastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dasatinib" ], [ "Dasatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Canakinumab" ] ], [ [ "Lovastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bortezomib" ], [ "Bortezomib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Canakinumab" ] ], [ [ "Lovastatin", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Simvastatin" ], [ "Simvastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Canakinumab" ] ], [ [ "Lovastatin", "{u} may lead to a major life threatening interaction when taken with {v}", "Lenalidomide" ], [ "Lenalidomide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Canakinumab" ] ], [ [ "Lovastatin", "{u} may lead to a major life threatening interaction when taken with {v}", "Idelalisib" ], [ "Idelalisib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Canakinumab" ] ], [ [ "Lovastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Infliximab" ], [ "Infliximab", "{u} may lead to a major life threatening interaction when taken with {v}", "Canakinumab" ] ], [ [ "Lovastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tocilizumab" ], [ "Tocilizumab", "{u} may lead to a major life threatening interaction when taken with {v}", "Canakinumab" ] ], [ [ "Lovastatin", "{u} may lead to a major life threatening interaction when taken with {v}", "Teriflunomide" ], [ "Teriflunomide", "{u} may lead to a major life threatening interaction when taken with {v}", "Canakinumab" ] ] ]
Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab Lovastatin (Compound) resembles Simvastatin (Compound) and Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab Lovastatin may lead to a major life threatening interaction when taken with Lenalidomide and Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab Lovastatin may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Canakinumab Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab and Tocilizumab may lead to a major life threatening interaction when taken with Canakinumab Lovastatin may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Canakinumab
DB08912
DB09330
1,040
985
[ "DDInter462", "DDInter1352" ]
Dabrafenib
Osimertinib
Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib), in combination with Mekinist (), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene.
Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing and which has progressed following therapy with a first-generation EGFR tyrosine kinase inhibitor. Approximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs due to the presence of specific activating EGFR mutations within the tumour cells. More specifically, deletions around the LREA motif in exon 19 and exon 21 L858R point mutations are correlated with response to therapy. Development of third-generation EGFR-TKIs, such as osimertinib, has been in response to altered tumour resistance patterns following treatment and toxic side effects that impact patient quality of life. Treatment with first-generation EGFR-TKIs (gefitinib and erlotinib) has been associated with the development of resistance through activating mutations in the EGFR gene. Second-generation EGFR-TKIs (afatinib and dacomitinib) were then developed to be more potent inhibitors, although their use is associated with increased toxicity through nonspecific targeting of wild-type EGFR. In contrast, third-generation inhibitors are specific for the gate-keeper T790M mutations which increases ATP binding activity to EGFR and result in poor prognosis for late-stage disease. Furthermore, osimertinib has been shown to spare wild-type EGFR during therapy, thereby reducing non-specific binding and limiting toxicity.[A7926,A7927,A7931]
Moderate
1
[ [ [ 1040, 24, 985 ] ], [ [ 1040, 62, 168 ], [ 168, 23, 985 ] ], [ [ 1040, 63, 1247 ], [ 1247, 23, 985 ] ], [ [ 1040, 63, 1478 ], [ 1478, 24, 985 ] ], [ [ 1040, 25, 1598 ], [ 1598, 63, 985 ] ], [ [ 1040, 24, 69 ], [ 69, 63, 985 ] ], [ [ 1040, 64, 704 ], [ 704, 24, 985 ] ], [ [ 1040, 24, 1362 ], [ 1362, 24, 985 ] ], [ [ 1040, 62, 1101 ], [ 1101, 24, 985 ] ], [ [ 1040, 63, 11 ], [ 11, 25, 985 ] ] ]
[ [ [ "Dabrafenib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Osimertinib" ] ], [ [ "Dabrafenib", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Bortezomib" ], [ "Bortezomib", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Osimertinib" ] ], [ [ "Dabrafenib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sulfamethoxazole" ], [ "Sulfamethoxazole", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Osimertinib" ] ], [ [ "Dabrafenib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ivacaftor" ], [ "Ivacaftor", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Osimertinib" ] ], [ [ "Dabrafenib", "{u} may lead to a major life threatening interaction when taken with {v}", "Tazemetostat" ], [ "Tazemetostat", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Osimertinib" ] ], [ [ "Dabrafenib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pralsetinib" ], [ "Pralsetinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Osimertinib" ] ], [ [ "Dabrafenib", "{u} may lead to a major life threatening interaction when taken with {v}", "Fentanyl" ], [ "Fentanyl", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Osimertinib" ] ], [ [ "Dabrafenib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Olaparib" ], [ "Olaparib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Osimertinib" ] ], [ [ "Dabrafenib", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Bexarotene" ], [ "Bexarotene", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Osimertinib" ] ], [ [ "Dabrafenib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Toremifene" ], [ "Toremifene", "{u} may lead to a major life threatening interaction when taken with {v}", "Osimertinib" ] ] ]
Dabrafenib may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Osimertinib Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Osimertinib Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib Dabrafenib may lead to a major life threatening interaction when taken with Tazemetostat and Tazemetostat may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Pralsetinib and Pralsetinib may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib Dabrafenib may lead to a major life threatening interaction when taken with Fentanyl and Fentanyl may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib Dabrafenib may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Toremifene and Toremifene may lead to a major life threatening interaction when taken with Osimertinib
DB00705
DB01211
441
609
[ "DDInter496", "DDInter393" ]
Delavirdine
Clarithromycin
A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.
Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration.
Moderate
1
[ [ [ 441, 24, 609 ] ], [ [ 441, 6, 7524 ], [ 7524, 45, 609 ] ], [ [ 441, 21, 28879 ], [ 28879, 60, 609 ] ], [ [ 441, 63, 600 ], [ 600, 23, 609 ] ], [ [ 441, 23, 222 ], [ 222, 23, 609 ] ], [ [ 441, 24, 660 ], [ 660, 23, 609 ] ], [ [ 441, 24, 568 ], [ 568, 24, 609 ] ], [ [ 441, 25, 913 ], [ 913, 63, 609 ] ], [ [ 441, 24, 98 ], [ 98, 63, 609 ] ], [ [ 441, 63, 883 ], [ 883, 24, 609 ] ] ]
[ [ [ "Delavirdine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clarithromycin" ] ], [ [ "Delavirdine", "{u} (Compound) binds {v} (Gene)", "CYP3A5" ], [ "CYP3A5", "{u} (Gene) is bound by {v} (Compound)", "Clarithromycin" ] ], [ [ "Delavirdine", "{u} (Compound) causes {v} (Side Effect)", "Gingival bleeding" ], [ "Gingival bleeding", "{u} (Side Effect) is caused by {v} (Compound)", "Clarithromycin" ] ], [ [ "Delavirdine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fluconazole" ], [ "Fluconazole", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Clarithromycin" ] ], [ [ "Delavirdine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Sibutramine" ], [ "Sibutramine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Clarithromycin" ] ], [ [ "Delavirdine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Esomeprazole" ], [ "Esomeprazole", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Clarithromycin" ] ], [ [ "Delavirdine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clindamycin" ], [ "Clindamycin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clarithromycin" ] ], [ [ "Delavirdine", "{u} may lead to a major life threatening interaction when taken with {v}", "Apalutamide" ], [ "Apalutamide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clarithromycin" ] ], [ [ "Delavirdine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Somatrem" ], [ "Somatrem", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clarithromycin" ] ], [ [ "Delavirdine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Gefitinib" ], [ "Gefitinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clarithromycin" ] ] ]
Delavirdine (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Clarithromycin (Compound) Delavirdine (Compound) causes Gingival bleeding (Side Effect) and Gingival bleeding (Side Effect) is caused by Clarithromycin (Compound) Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a minor interaction that can limit clinical effects when taken with Clarithromycin Delavirdine may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Clarithromycin Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Esomeprazole and Esomeprazole may cause a minor interaction that can limit clinical effects when taken with Clarithromycin Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Clindamycin and Clindamycin may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin Delavirdine may lead to a major life threatening interaction when taken with Apalutamide and Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin
DB06792
DB12455
1,606
933
[ "DDInter1023", "DDInter1336" ]
Lanthanum carbonate
Omadacycline
Lanthanum carbonate is a phosphate binder commonly used in clinical practice. It is marketed under the trade name _Fosrenol_ by Shire Pharmaceuticals. It is the largest of all pills filled in community pharmacies. Sometimes patients forget that Fosrenol is not swallowed whole, but instead should be chewed. This has led to severe choking. It is prescribed for treating high phosphate levels, mainly found in patients with chronic kidney disease. Lanthanum should be taken with meals and binds to phosphate in the diet, preventing phosphate absorption in the intestine.
Omadacycline has been used in trials studying the treatment of Bacterial Pneumonia, Bacterial Infections, Community-Acquired Infections, and Skin Structures and Soft Tissue Infections. Omadacycline represents a significant advance over the well-known tetracycline family, and has been shown to be highly effective in animal models at treating increasingly problematic, clinically prevalent infections caused by gram-positive bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA), and by gram-negative, atypical and anaerobic bacteria, including those resistant to currently available classes of antibiotics and known to cause diseases such as pneumonias, urinary tract infections, skin diseases and blood-borne infections in both the hospital and community settings.
Moderate
1
[ [ [ 1606, 24, 933 ] ], [ [ 1606, 24, 428 ], [ 428, 63, 933 ] ], [ [ 1606, 63, 1596 ], [ 1596, 24, 933 ] ], [ [ 1606, 24, 428 ], [ 428, 63, 1384 ], [ 1384, 24, 933 ] ], [ [ 1606, 63, 1596 ], [ 1596, 24, 1384 ], [ 1384, 24, 933 ] ], [ [ 1606, 63, 126 ], [ 126, 63, 417 ], [ 417, 24, 933 ] ], [ [ 1606, 24, 428 ], [ 428, 62, 1114 ], [ 1114, 24, 933 ] ], [ [ 1606, 63, 1596 ], [ 1596, 23, 1114 ], [ 1114, 24, 933 ] ], [ [ 1606, 63, 126 ], [ 126, 24, 1517 ], [ 1517, 25, 933 ] ], [ [ 1606, 24, 943 ], [ 943, 24, 1473 ], [ 1473, 63, 933 ] ] ]
[ [ [ "Lanthanum carbonate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Omadacycline" ] ], [ [ "Lanthanum carbonate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ferrous fumarate" ], [ "Ferrous fumarate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Omadacycline" ] ], [ [ "Lanthanum carbonate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iron" ], [ "Iron", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Omadacycline" ] ], [ [ "Lanthanum carbonate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ferrous fumarate" ], [ "Ferrous fumarate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Magaldrate" ], [ "Magaldrate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Omadacycline" ] ], [ [ "Lanthanum carbonate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iron" ], [ "Iron", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Magaldrate" ], [ "Magaldrate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Omadacycline" ] ], [ [ "Lanthanum carbonate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Warfarin" ], [ "Warfarin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sucralfate" ], [ "Sucralfate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Omadacycline" ] ], [ [ "Lanthanum carbonate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ferrous fumarate" ], [ "Ferrous fumarate", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Zinc sulfate" ], [ "Zinc sulfate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Omadacycline" ] ], [ [ "Lanthanum carbonate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iron" ], [ "Iron", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Zinc sulfate" ], [ "Zinc sulfate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Omadacycline" ] ], [ [ "Lanthanum carbonate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Warfarin" ], [ "Warfarin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Isotretinoin" ], [ "Isotretinoin", "{u} may lead to a major life threatening interaction when taken with {v}", "Omadacycline" ] ], [ [ "Lanthanum carbonate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sarecycline" ], [ "Sarecycline", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Magnesium gluconate" ], [ "Magnesium gluconate", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Omadacycline" ] ] ]
Lanthanum carbonate may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumarate and Ferrous fumarate may cause a moderate interaction that could exacerbate diseases when taken with Omadacycline Lanthanum carbonate may cause a moderate interaction that could exacerbate diseases when taken with Iron and Iron may cause a moderate interaction that could exacerbate diseases when taken with Omadacycline Lanthanum carbonate may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumarate and Ferrous fumarate may cause a moderate interaction that could exacerbate diseases when taken with Magaldrate and Magaldrate may cause a moderate interaction that could exacerbate diseases when taken with Omadacycline Lanthanum carbonate may cause a moderate interaction that could exacerbate diseases when taken with Iron and Iron may cause a moderate interaction that could exacerbate diseases when taken with Magaldrate and Magaldrate may cause a moderate interaction that could exacerbate diseases when taken with Omadacycline Lanthanum carbonate may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Sucralfate and Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Omadacycline Lanthanum carbonate may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumarate and Ferrous fumarate may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfate may cause a moderate interaction that could exacerbate diseases when taken with Omadacycline Lanthanum carbonate may cause a moderate interaction that could exacerbate diseases when taken with Iron and Iron may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfate may cause a moderate interaction that could exacerbate diseases when taken with Omadacycline Lanthanum carbonate may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Isotretinoin and Isotretinoin may lead to a major life threatening interaction when taken with Omadacycline Lanthanum carbonate may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline and Sarecycline may cause a moderate interaction that could exacerbate diseases when taken with Magnesium gluconate and Magnesium gluconate may cause a moderate interaction that could exacerbate diseases when taken with Omadacycline
DB01097
DB09312
1,377
967
[ "DDInter1033", "DDInter103" ]
Leflunomide
Antilymphocyte immunoglobulin (horse)
Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999.
Equine anti-thymocyte globulin is composed of purified gamma globulin containing primarily IgG against human thymus lymphocytes. It is formed by inoculating a horse with an antigen (human thymoyctes) which then induces the horse immune system's B-lymphocytes to produce IgG immunoglobulins specific for that antigen. The result is polyclonal IgG that is then purified from the horse's serum to produce a usable drug product that can be used for immunosuppression. Although the exact mechanism of action is unknown, equine anti-thymocyte globulin targets a variety of immune system proteins including lymphocyte surface proteins, granulocytes, platelets, bone marrow cells, and other cell types. Equine ATG is currently indicated for the suppression of the immune system to prevent renal transplant rejection and in the treatment of aplastic anemia. Induction of T cell apoptosis and resulting T-cell lymphopenia found in vivo is credited for its therapeutic effect in these conditions. There are currently various ATG products available, which differ in the source of inoculated animal (rabbit, horse, or pig) and in the type of antigen product used to produce immunoglobulin (thymocytes, peripheral T cells, etc.).
Major
2
[ [ [ 1377, 25, 967 ] ], [ [ 1377, 23, 1193 ], [ 1193, 62, 967 ] ], [ [ 1377, 62, 1461 ], [ 1461, 62, 967 ] ], [ [ 1377, 25, 1683 ], [ 1683, 24, 967 ] ], [ [ 1377, 25, 1531 ], [ 1531, 63, 967 ] ], [ [ 1377, 64, 66 ], [ 66, 24, 967 ] ], [ [ 1377, 24, 1430 ], [ 1430, 63, 967 ] ], [ [ 1377, 25, 1137 ], [ 1137, 64, 967 ] ], [ [ 1377, 64, 1064 ], [ 1064, 25, 967 ] ], [ [ 1377, 25, 1292 ], [ 1292, 25, 967 ] ] ]
[ [ [ "Leflunomide", "{u} may lead to a major life threatening interaction when taken with {v}", "Antilymphocyte immunoglobulin (horse)" ] ], [ [ "Leflunomide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Zinc gluconate" ], [ "Zinc gluconate", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Antilymphocyte immunoglobulin (horse)" ] ], [ [ "Leflunomide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Vitamin E" ], [ "Vitamin E", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Antilymphocyte immunoglobulin (horse)" ] ], [ [ "Leflunomide", "{u} may lead to a major life threatening interaction when taken with {v}", "Ustekinumab" ], [ "Ustekinumab", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Antilymphocyte immunoglobulin (horse)" ] ], [ [ "Leflunomide", "{u} may lead to a major life threatening interaction when taken with {v}", "Canakinumab" ], [ "Canakinumab", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Antilymphocyte immunoglobulin (horse)" ] ], [ [ "Leflunomide", "{u} may lead to a major life threatening interaction when taken with {v}", "Efalizumab" ], [ "Efalizumab", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Antilymphocyte immunoglobulin (horse)" ] ], [ [ "Leflunomide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Sipuleucel-T" ], [ "Sipuleucel-T", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Antilymphocyte immunoglobulin (horse)" ] ], [ [ "Leflunomide", "{u} may lead to a major life threatening interaction when taken with {v}", "Measles virus vaccine live attenuated" ], [ "Measles virus vaccine live attenuated", "{u} may lead to a major life threatening interaction when taken with {v}", "Antilymphocyte immunoglobulin (horse)" ] ], [ [ "Leflunomide", "{u} may lead to a major life threatening interaction when taken with {v}", "Cladribine" ], [ "Cladribine", "{u} may lead to a major life threatening interaction when taken with {v}", "Antilymphocyte immunoglobulin (horse)" ] ], [ [ "Leflunomide", "{u} may lead to a major life threatening interaction when taken with {v}", "Deferiprone" ], [ "Deferiprone", "{u} may lead to a major life threatening interaction when taken with {v}", "Antilymphocyte immunoglobulin (horse)" ] ] ]
Leflunomide may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Antilymphocyte immunoglobulin (horse) Leflunomide may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Antilymphocyte immunoglobulin (horse) Leflunomide may lead to a major life threatening interaction when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Antilymphocyte immunoglobulin (horse) Leflunomide may lead to a major life threatening interaction when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Antilymphocyte immunoglobulin (horse) Leflunomide may lead to a major life threatening interaction when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Antilymphocyte immunoglobulin (horse) Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Antilymphocyte immunoglobulin (horse) Leflunomide may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated and Measles virus vaccine live attenuated may lead to a major life threatening interaction when taken with Antilymphocyte immunoglobulin (horse) Leflunomide may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Antilymphocyte immunoglobulin (horse) Leflunomide may lead to a major life threatening interaction when taken with Deferiprone and Deferiprone may lead to a major life threatening interaction when taken with Antilymphocyte immunoglobulin (horse)
DB00514
DB01403
506
9
[ "DDInter527", "DDInter1175" ]
Dextromethorphan
Methotrimeprazine
Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors. Dextromethorphan was granted FDA approval before 3 December 1957.[A215412,L14997]
A phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604)
Major
2
[ [ [ 506, 25, 9 ] ], [ [ 506, 24, 1178 ], [ 1178, 40, 9 ] ], [ [ 506, 24, 401 ], [ 401, 24, 9 ] ], [ [ 506, 24, 1630 ], [ 1630, 1, 9 ] ], [ [ 506, 63, 508 ], [ 508, 40, 9 ] ], [ [ 506, 6, 12523 ], [ 12523, 45, 9 ] ], [ [ 506, 7, 8386 ], [ 8386, 57, 9 ] ], [ [ 506, 21, 28705 ], [ 28705, 60, 9 ] ], [ [ 506, 25, 1053 ], [ 1053, 24, 9 ] ], [ [ 506, 24, 1374 ], [ 1374, 63, 9 ] ] ]
[ [ [ "Dextromethorphan", "{u} may lead to a major life threatening interaction when taken with {v}", "Methotrimeprazine" ] ], [ [ "Dextromethorphan", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Trifluoperazine" ], [ "Trifluoperazine", "{u} (Compound) resembles {v} (Compound)", "Methotrimeprazine" ] ], [ [ "Dextromethorphan", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Promethazine" ], [ "Promethazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Methotrimeprazine" ] ], [ [ "Dextromethorphan", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Perphenazine" ], [ "Perphenazine", "{u} (Compound) resembles {v} (Compound)", "Methotrimeprazine" ] ], [ [ "Dextromethorphan", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Promazine" ], [ "Promazine", "{u} (Compound) resembles {v} (Compound)", "Methotrimeprazine" ] ], [ [ "Dextromethorphan", "{u} (Compound) binds {v} (Gene)", "CYP2D6" ], [ "CYP2D6", "{u} (Gene) is bound by {v} (Compound)", "Methotrimeprazine" ] ], [ [ "Dextromethorphan", "{u} (Compound) upregulates {v} (Gene)", "MTHFD2" ], [ "MTHFD2", "{u} (Gene) is downregulated by {v} (Compound)", "Methotrimeprazine" ] ], [ [ "Dextromethorphan", "{u} (Compound) causes {v} (Side Effect)", "Drowsiness" ], [ "Drowsiness", "{u} (Side Effect) is caused by {v} (Compound)", "Methotrimeprazine" ] ], [ [ "Dextromethorphan", "{u} may lead to a major life threatening interaction when taken with {v}", "Procarbazine" ], [ "Procarbazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Methotrimeprazine" ] ], [ [ "Dextromethorphan", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Abiraterone" ], [ "Abiraterone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Methotrimeprazine" ] ] ]
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Methotrimeprazine (Compound) Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Methotrimeprazine Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Perphenazine and Perphenazine (Compound) resembles Methotrimeprazine (Compound) Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine (Compound) resembles Methotrimeprazine (Compound) Dextromethorphan (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Methotrimeprazine (Compound) Dextromethorphan (Compound) upregulates MTHFD2 (Gene) and MTHFD2 (Gene) is downregulated by Methotrimeprazine (Compound) Dextromethorphan (Compound) causes Drowsiness (Side Effect) and Drowsiness (Side Effect) is caused by Methotrimeprazine (Compound) Dextromethorphan may lead to a major life threatening interaction when taken with Procarbazine and Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Methotrimeprazine Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Methotrimeprazine
DB00747
DB00844
1,442
314
[ "DDInter1647", "DDInter1257" ]
Scopolamine
Nalbuphine
Scopolamine is a tropane alkaloid isolated from members of the _Solanaceae_ family of plants, similar to [atropine] and [hyoscyamine], all of which structurally mimic the natural neurotransmitter [acetylcholine].[A228423, A228763] Scopolamine was first synthesized in 1959, but to date, synthesis remains less efficient than extracting scopolamine from plants. As an acetylcholine analogue, scopolamine can antagonize muscarinic acetylcholine receptors (mAChRs) in the central nervous system and throughout the body, inducing several therapeutic and adverse effects related to alteration of parasympathetic nervous system and cholinergic signalling.[A228758, L31578] Due to its dose-dependent adverse effects, scopolamine was the first drug to be offered commercially as a transdermal delivery system, Scopoderm TTS®, in 1981.[A228423,
A narcotic used as a pain medication. It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors. Nalbuphine is the only opioid analgesic that is not a controlled substance in the United States.
Moderate
1
[ [ [ 1442, 24, 314 ] ], [ [ 1442, 63, 828 ], [ 828, 40, 314 ] ], [ [ 1442, 63, 421 ], [ 421, 1, 314 ] ], [ [ 1442, 63, 475 ], [ 475, 25, 314 ] ], [ [ 1442, 24, 560 ], [ 560, 40, 314 ] ], [ [ 1442, 21, 28714 ], [ 28714, 60, 314 ] ], [ [ 1442, 63, 1219 ], [ 1219, 24, 314 ] ], [ [ 1442, 24, 262 ], [ 262, 24, 314 ] ], [ [ 1442, 24, 1264 ], [ 1264, 63, 314 ] ], [ [ 1442, 74, 85 ], [ 85, 24, 314 ] ] ]
[ [ [ "Scopolamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nalbuphine" ] ], [ [ "Scopolamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Oxycodone" ], [ "Oxycodone", "{u} (Compound) resembles {v} (Compound)", "Nalbuphine" ] ], [ [ "Scopolamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Hydromorphone" ], [ "Hydromorphone", "{u} (Compound) resembles {v} (Compound)", "Nalbuphine" ] ], [ [ "Scopolamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Morphine" ], [ "Morphine", "{u} may lead to a major life threatening interaction when taken with {v}", "Nalbuphine" ] ], [ [ "Scopolamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Oxymorphone" ], [ "Oxymorphone", "{u} (Compound) resembles {v} (Compound)", "Nalbuphine" ] ], [ [ "Scopolamine", "{u} (Compound) causes {v} (Side Effect)", "Asthenia" ], [ "Asthenia", "{u} (Side Effect) is caused by {v} (Compound)", "Nalbuphine" ] ], [ [ "Scopolamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Azatadine" ], [ "Azatadine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nalbuphine" ] ], [ [ "Scopolamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clidinium" ], [ "Clidinium", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nalbuphine" ] ], [ [ "Scopolamine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Doxepin" ], [ "Doxepin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nalbuphine" ] ], [ [ "Scopolamine", "{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Atropine" ], [ "Atropine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nalbuphine" ] ] ]
Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Oxycodone and Oxycodone (Compound) resembles Nalbuphine (Compound) Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Hydromorphone and Hydromorphone (Compound) resembles Nalbuphine (Compound) Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threatening interaction when taken with Nalbuphine Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Oxymorphone and Oxymorphone (Compound) resembles Nalbuphine (Compound) Scopolamine (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Nalbuphine (Compound) Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Azatadine and Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Nalbuphine Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Clidinium and Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Nalbuphine Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Nalbuphine Scopolamine (Compound) resembles Atropine (Compound) and Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine may cause a moderate interaction that could exacerbate diseases when taken with Nalbuphine
DB00468
DB01238
1,424
673
[ "DDInter1557", "DDInter118" ]
Quinine
Aripiprazole
An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It was used commonly and as a bitter and flavoring agent, and is still useful for the treatment of babesiosis. Quinine is also useful in some muscular disorders, especially nocturnal leg cramps and myotonia congenita, because of its direct effects on muscle membrane and sodium channels. The mechanisms of its antimalarial effects are not well understood.
Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects through agonism of dopaminergic and 5-HT1A receptors and antagonism of alpha-adrenergic and 5-HT2A receptors.[L45859,A4393] Aripiprazole was given FDA approval on November 15, 2002.
Moderate
1
[ [ [ 1424, 24, 673 ] ], [ [ 1424, 24, 851 ], [ 851, 1, 673 ] ], [ [ 1424, 24, 827 ], [ 827, 40, 673 ] ], [ [ 1424, 6, 3958 ], [ 3958, 45, 673 ] ], [ [ 1424, 21, 28827 ], [ 28827, 60, 673 ] ], [ [ 1424, 23, 112 ], [ 112, 23, 673 ] ], [ [ 1424, 63, 618 ], [ 618, 24, 673 ] ], [ [ 1424, 24, 823 ], [ 823, 63, 673 ] ], [ [ 1424, 25, 1011 ], [ 1011, 63, 673 ] ], [ [ 1424, 24, 888 ], [ 888, 24, 673 ] ] ]
[ [ [ "Quinine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Aripiprazole" ] ], [ [ "Quinine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Nefazodone" ], [ "Nefazodone", "{u} (Compound) resembles {v} (Compound)", "Aripiprazole" ] ], [ [ "Quinine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Trazodone" ], [ "Trazodone", "{u} (Compound) resembles {v} (Compound)", "Aripiprazole" ] ], [ [ "Quinine", "{u} (Compound) binds {v} (Gene)", "KCNH2" ], [ "KCNH2", "{u} (Gene) is bound by {v} (Compound)", "Aripiprazole" ] ], [ [ "Quinine", "{u} (Compound) causes {v} (Side Effect)", "Orthostatic hypotension" ], [ "Orthostatic hypotension", "{u} (Side Effect) is caused by {v} (Compound)", "Aripiprazole" ] ], [ [ "Quinine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Metronidazole" ], [ "Metronidazole", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Aripiprazole" ] ], [ [ "Quinine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Abarelix" ], [ "Abarelix", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Aripiprazole" ] ], [ [ "Quinine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Triclabendazole" ], [ "Triclabendazole", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Aripiprazole" ] ], [ [ "Quinine", "{u} may lead to a major life threatening interaction when taken with {v}", "Fingolimod" ], [ "Fingolimod", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Aripiprazole" ] ], [ [ "Quinine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tamoxifen" ], [ "Tamoxifen", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Aripiprazole" ] ] ]
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Nefazodone and Nefazodone (Compound) resembles Aripiprazole (Compound) Quinine may cause a moderate interaction that could exacerbate diseases when taken with Trazodone and Trazodone (Compound) resembles Aripiprazole (Compound) Quinine (Compound) binds KCNH2 (Gene) and KCNH2 (Gene) is bound by Aripiprazole (Compound) Quinine (Compound) causes Orthostatic hypotension (Side Effect) and Orthostatic hypotension (Side Effect) is caused by Aripiprazole (Compound) Quinine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Aripiprazole Quinine may cause a moderate interaction that could exacerbate diseases when taken with Abarelix and Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Aripiprazole Quinine may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole and Triclabendazole may cause a moderate interaction that could exacerbate diseases when taken with Aripiprazole Quinine may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Aripiprazole Quinine may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Aripiprazole
DB00843
DB01362
479
497
[ "DDInter583", "DDInter960" ]
Donepezil
Iohexol
In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and in some cases, is used to manage other types of dementia. Donepezil was first approved by the FDA in 1996, and its extended-release form was approved in combination with [Memantine] in 2014 to manage moderate and severe forms of Alzheimer's dementia.[L7916,L7937] A donepezil transdermal delivery system, Adlarity, was approved by the FDA in March 2022 for the treatment of Alzheimer's dementia. Though it does not alter the progression of Alzheimer's disease, donepezil is effective in managing the symptoms of its associated dementia.
Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality.
Major
2
[ [ [ 479, 25, 497 ] ], [ [ 479, 21, 28681 ], [ 28681, 60, 497 ] ], [ [ 479, 63, 999 ], [ 999, 25, 497 ] ], [ [ 479, 24, 1264 ], [ 1264, 25, 497 ] ], [ [ 479, 24, 129 ], [ 129, 64, 497 ] ], [ [ 479, 62, 1274 ], [ 1274, 25, 497 ] ], [ [ 479, 23, 678 ], [ 678, 25, 497 ] ], [ [ 479, 25, 593 ], [ 593, 25, 497 ] ], [ [ 479, 21, 28681 ], [ 28681, 60, 1523 ], [ 1523, 24, 497 ] ], [ [ 479, 21, 28787 ], [ 28787, 60, 258 ], [ 258, 40, 497 ] ] ]
[ [ [ "Donepezil", "{u} may lead to a major life threatening interaction when taken with {v}", "Iohexol" ] ], [ [ "Donepezil", "{u} (Compound) causes {v} (Side Effect)", "Hypersensitivity" ], [ "Hypersensitivity", "{u} (Side Effect) is caused by {v} (Compound)", "Iohexol" ] ], [ [ "Donepezil", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Thiethylperazine" ], [ "Thiethylperazine", "{u} may lead to a major life threatening interaction when taken with {v}", "Iohexol" ] ], [ [ "Donepezil", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Doxepin" ], [ "Doxepin", "{u} may lead to a major life threatening interaction when taken with {v}", "Iohexol" ] ], [ [ "Donepezil", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Enzalutamide" ], [ "Enzalutamide", "{u} may lead to a major life threatening interaction when taken with {v}", "Iohexol" ] ], [ [ "Donepezil", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Flurbiprofen" ], [ "Flurbiprofen", "{u} may lead to a major life threatening interaction when taken with {v}", "Iohexol" ] ], [ [ "Donepezil", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Oxamniquine" ], [ "Oxamniquine", "{u} may lead to a major life threatening interaction when taken with {v}", "Iohexol" ] ], [ [ "Donepezil", "{u} may lead to a major life threatening interaction when taken with {v}", "Bupropion" ], [ "Bupropion", "{u} may lead to a major life threatening interaction when taken with {v}", "Iohexol" ] ], [ [ "Donepezil", "{u} (Compound) causes {v} (Side Effect)", "Hypersensitivity" ], [ "Hypersensitivity", "{u} (Side Effect) is caused by {v} (Compound)", "Labetalol" ], [ "Labetalol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Iohexol" ] ], [ [ "Donepezil", "{u} (Compound) causes {v} (Side Effect)", "Dermatitis" ], [ "Dermatitis", "{u} (Side Effect) is caused by {v} (Compound)", "Iodixanol" ], [ "Iodixanol", "{u} (Compound) resembles {v} (Compound)", "Iohexol" ] ] ]
Donepezil (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Iohexol (Compound) Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may lead to a major life threatening interaction when taken with Iohexol Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may lead to a major life threatening interaction when taken with Iohexol Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Iohexol Donepezil may cause a minor interaction that can limit clinical effects when taken with Flurbiprofen and Flurbiprofen may lead to a major life threatening interaction when taken with Iohexol Donepezil may cause a minor interaction that can limit clinical effects when taken with Oxamniquine and Oxamniquine may lead to a major life threatening interaction when taken with Iohexol Donepezil may lead to a major life threatening interaction when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Iohexol Donepezil (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Labetalol (Compound) and Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Iohexol Donepezil (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Iodixanol (Compound) and Iodixanol (Compound) resembles Iohexol (Compound)
DB00470
DB01200
530
469
[ "DDInter601", "DDInter243" ]
Dronabinol
Bromocriptine
Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effects of smoking cannabis such as increased appetite, reduced pain, and changes in emotional and cognitive processes. Due to its evidence as an appetite stimulant and an anti-nauseant, Dronabinol is approved for use in anorexia associated with weight loss in patients with AIDS and for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments [FDA Label]. Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the two most abundant cannabinoids found naturally in
Bromocriptine mesylate is a semisynthetic ergot alkaloid derivative with potent dopaminergic activity. It inhibits prolactin secretion and may be used to treat dysfunctions associated with hyperprolactinemia. Bromocriptine is also indicated for the management of signs and symptoms of Parkinsonian Syndrome, as well as the treatment of acromegaly. Bromocriptine has been associated with pulmonary fibrosis, and can also cause sustained suppression of somatotropin (growth hormone) secretion in some patients with acromegaly. In 1995, the FDA withdrew the approval of bromocriptine mesylate for the prevention of physiological lactation after finding that bromocriptine was not shown to be safe for use.[L43942,L43947] It continues to be used for the indications mentioned above.
Moderate
1
[ [ [ 530, 24, 469 ] ], [ [ 530, 6, 8374 ], [ 8374, 45, 469 ] ], [ [ 530, 21, 28787 ], [ 28787, 60, 469 ] ], [ [ 530, 24, 401 ], [ 401, 24, 469 ] ], [ [ 530, 63, 701 ], [ 701, 24, 469 ] ], [ [ 530, 24, 407 ], [ 407, 63, 469 ] ], [ [ 530, 1, 1614 ], [ 1614, 24, 469 ] ], [ [ 530, 6, 8374 ], [ 8374, 45, 344 ], [ 344, 1, 469 ] ], [ [ 530, 21, 28787 ], [ 28787, 60, 1131 ], [ 1131, 1, 469 ] ], [ [ 530, 21, 28952 ], [ 28952, 60, 401 ], [ 401, 24, 469 ] ] ]
[ [ [ "Dronabinol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bromocriptine" ] ], [ [ "Dronabinol", "{u} (Compound) binds {v} (Gene)", "CYP3A4" ], [ "CYP3A4", "{u} (Gene) is bound by {v} (Compound)", "Bromocriptine" ] ], [ [ "Dronabinol", "{u} (Compound) causes {v} (Side Effect)", "Dermatitis" ], [ "Dermatitis", "{u} (Side Effect) is caused by {v} (Compound)", "Bromocriptine" ] ], [ [ "Dronabinol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Promethazine" ], [ "Promethazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bromocriptine" ] ], [ [ "Dronabinol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Clemastine" ], [ "Clemastine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bromocriptine" ] ], [ [ "Dronabinol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Opium" ], [ "Opium", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bromocriptine" ] ], [ [ "Dronabinol", "{u} (Compound) resembles {v} (Compound)", "Nabilone" ], [ "Nabilone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bromocriptine" ] ], [ [ "Dronabinol", "{u} (Compound) binds {v} (Gene)", "CYP3A4" ], [ "CYP3A4", "{u} (Gene) is bound by {v} (Compound)", "Ergoloid mesylate" ], [ "Ergoloid mesylate", "{u} (Compound) resembles {v} (Compound)", "Bromocriptine" ] ], [ [ "Dronabinol", "{u} (Compound) causes {v} (Side Effect)", "Dermatitis" ], [ "Dermatitis", "{u} (Side Effect) is caused by {v} (Compound)", "Methysergide" ], [ "Methysergide", "{u} (Compound) resembles {v} (Compound)", "Bromocriptine" ] ], [ [ "Dronabinol", "{u} (Compound) causes {v} (Side Effect)", "Nightmare" ], [ "Nightmare", "{u} (Side Effect) is caused by {v} (Compound)", "Promethazine" ], [ "Promethazine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bromocriptine" ] ] ]
Dronabinol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bromocriptine (Compound) Dronabinol (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Bromocriptine (Compound) Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Bromocriptine Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Bromocriptine Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Bromocriptine Dronabinol (Compound) resembles Nabilone (Compound) and Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Bromocriptine Dronabinol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ergoloid mesylate (Compound) and Ergoloid mesylate (Compound) resembles Bromocriptine (Compound) Dronabinol (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Methysergide (Compound) and Methysergide (Compound) resembles Bromocriptine (Compound) Dronabinol (Compound) causes Nightmare (Side Effect) and Nightmare (Side Effect) is caused by Promethazine (Compound) and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Bromocriptine
DB00281
DB01339
608
728
[ "DDInter1066", "DDInter1922" ]
Lidocaine
Vecuronium
Ever since its discovery and availability for sale and use in the late 1940s, lidocaine has become an exceptionally commonly used medication. In particular, lidocaine's principal mode of action in acting as a local anesthetic that numbs the sensations of tissues means the agent is indicated for facilitating local anesthesia for a large variety of surgical procedures [F4349, L5930, L5948]. It ultimately elicits its numbing activity by blocking sodium channels so that the neurons of local tissues that have the medication applied on are transiently incapable of signaling the brain regarding sensations [F4349, L5930, L5948]. In doing so, however, it can block or decrease muscle contractile, resulting in effects like vasodilation, hypotension, and irregular heart rate, among others [F4349, L5930, L5948]. As a result, lidocaine is also considered a class Ib anti-arrhythmic agent [L
Monoquaternary homolog of pancuronium. A non-depolarizing neuromuscular blocking agent with shorter duration of action than pancuronium. Its lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination as well as its short duration of action and easy reversibility provide advantages over, or alternatives to, other established neuromuscular blocking agents.
Moderate
1
[ [ [ 608, 24, 728 ] ], [ [ 608, 24, 1610 ], [ 1610, 1, 728 ] ], [ [ 608, 24, 1579 ], [ 1579, 40, 728 ] ], [ [ 608, 6, 4973 ], [ 4973, 45, 728 ] ], [ [ 608, 21, 28642 ], [ 28642, 60, 728 ] ], [ [ 608, 23, 1220 ], [ 1220, 24, 728 ] ], [ [ 608, 23, 416 ], [ 416, 25, 728 ] ], [ [ 608, 24, 1610 ], [ 1610, 1, 1665 ], [ 1665, 1, 728 ] ], [ [ 608, 24, 1579 ], [ 1579, 40, 1610 ], [ 1610, 1, 728 ] ], [ [ 608, 6, 4973 ], [ 4973, 45, 613 ], [ 613, 23, 728 ] ] ]
[ [ [ "Lidocaine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Vecuronium" ] ], [ [ "Lidocaine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Rocuronium" ], [ "Rocuronium", "{u} (Compound) resembles {v} (Compound)", "Vecuronium" ] ], [ [ "Lidocaine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pancuronium" ], [ "Pancuronium", "{u} (Compound) resembles {v} (Compound)", "Vecuronium" ] ], [ [ "Lidocaine", "{u} (Compound) binds {v} (Gene)", "ABCB1" ], [ "ABCB1", "{u} (Gene) is bound by {v} (Compound)", "Vecuronium" ] ], [ [ "Lidocaine", "{u} (Compound) causes {v} (Side Effect)", "Shock" ], [ "Shock", "{u} (Side Effect) is caused by {v} (Compound)", "Vecuronium" ] ], [ [ "Lidocaine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Dexamethasone" ], [ "Dexamethasone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Vecuronium" ] ], [ [ "Lidocaine", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Kanamycin" ], [ "Kanamycin", "{u} may lead to a major life threatening interaction when taken with {v}", "Vecuronium" ] ], [ [ "Lidocaine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Rocuronium" ], [ "Rocuronium", "{u} (Compound) resembles {v} (Compound)", "Pipecuronium" ], [ "Pipecuronium", "{u} (Compound) resembles {v} (Compound)", "Vecuronium" ] ], [ [ "Lidocaine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Pancuronium" ], [ "Pancuronium", "{u} (Compound) resembles {v} (Compound)", "Rocuronium" ], [ "Rocuronium", "{u} (Compound) resembles {v} (Compound)", "Vecuronium" ] ], [ [ "Lidocaine", "{u} (Compound) binds {v} (Gene)", "ABCB1" ], [ "ABCB1", "{u} (Gene) is bound by {v} (Compound)", "Irinotecan" ], [ "Irinotecan", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Vecuronium" ] ] ]
Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Rocuronium and Rocuronium (Compound) resembles Vecuronium (Compound) Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Pancuronium and Pancuronium (Compound) resembles Vecuronium (Compound) Lidocaine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Vecuronium (Compound) Lidocaine (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Vecuronium (Compound) Lidocaine may cause a minor interaction that can limit clinical effects when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Vecuronium Lidocaine may cause a minor interaction that can limit clinical effects when taken with Kanamycin and Kanamycin may lead to a major life threatening interaction when taken with Vecuronium Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Rocuronium and Rocuronium (Compound) resembles Pipecuronium (Compound) and Pipecuronium (Compound) resembles Vecuronium (Compound) Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Pancuronium and Pancuronium (Compound) resembles Rocuronium (Compound) and Rocuronium (Compound) resembles Vecuronium (Compound) Lidocaine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Irinotecan (Compound) and Irinotecan may cause a minor interaction that can limit clinical effects when taken with Vecuronium
DB01030
DB06650
869
1,500
[ "DDInter1835", "DDInter1324" ]
Topotecan
Ofatumumab
An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.
Ofatumumab is a novel anti-CD20 monoclonal antibody that targets B-cells. It is an IgG1κ human monoclonal antibody produced from a recombinant murine cell line (NS0) via transgenic mouse and hybridoma technology. Ofatumumab works by recognizing antigens that are expressed on the tumour cells in certain cancers; however, the antigen is not tumour-specific and can also be found in normal B-cells. Ofatumumab was first approved by the FDA in 2009. It is used in the treatment of recurrent, progressive, or recurrent chronic lymphocytic leukemia (CLL) or CLL in treatment-naive patients in whom fludarabine-based therapy is considered inappropriate. Ofatumumab is used as monotherapy or in combination with other medications, depending on the patient profile and previous treatment history. Although it has a similar molecular mechanism of action as [rituximab], another CD-20 monoclonal antibody used in the treatment of rheumatoid arthritis and B-cell non-Hodgkin's lymphoma, ofatumumab has a higher affinity towards CD20. Ofatumumab is available for intravenous administration and is marketed as Arzerra. In Phase III clinical trials consisting of subjects with relapsing forms of multiple sclerosis (RMS), subcutaneous administration of ofatumumab reduced the number of relapses and delayed disease progression. In February 2020, FDA and EMA approved Supplemental Biologics License Application (sBLA) and Marketing Authorization Application (MAA), respectively, for ofatumumab for the treatment of RMS in adults. The FDA subsequently approved ofatumumab for the treatment of RMS on August 20, 2020. The potential therapeutic use of ofatumumab in various lymphomas and rheumatoid arthritis has also been investigated.
Moderate
1
[ [ [ 869, 24, 1500 ] ], [ [ 869, 24, 270 ], [ 270, 63, 1500 ] ], [ [ 869, 24, 259 ], [ 259, 24, 1500 ] ], [ [ 869, 63, 66 ], [ 66, 24, 1500 ] ], [ [ 869, 25, 1510 ], [ 1510, 64, 1500 ] ], [ [ 869, 64, 1057 ], [ 1057, 25, 1500 ] ], [ [ 869, 63, 1064 ], [ 1064, 25, 1500 ] ], [ [ 869, 25, 1377 ], [ 1377, 25, 1500 ] ], [ [ 869, 24, 270 ], [ 270, 24, 1129 ], [ 1129, 63, 1500 ] ], [ [ 869, 24, 1129 ], [ 1129, 63, 270 ], [ 270, 63, 1500 ] ] ]
[ [ [ "Topotecan", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ofatumumab" ] ], [ [ "Topotecan", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ocrelizumab" ], [ "Ocrelizumab", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ofatumumab" ] ], [ [ "Topotecan", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Rilonacept" ], [ "Rilonacept", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ofatumumab" ] ], [ [ "Topotecan", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Efalizumab" ], [ "Efalizumab", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ofatumumab" ] ], [ [ "Topotecan", "{u} may lead to a major life threatening interaction when taken with {v}", "Teriflunomide" ], [ "Teriflunomide", "{u} may lead to a major life threatening interaction when taken with {v}", "Ofatumumab" ] ], [ [ "Topotecan", "{u} may lead to a major life threatening interaction when taken with {v}", "Etanercept" ], [ "Etanercept", "{u} may lead to a major life threatening interaction when taken with {v}", "Ofatumumab" ] ], [ [ "Topotecan", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Cladribine" ], [ "Cladribine", "{u} may lead to a major life threatening interaction when taken with {v}", "Ofatumumab" ] ], [ [ "Topotecan", "{u} may lead to a major life threatening interaction when taken with {v}", "Leflunomide" ], [ "Leflunomide", "{u} may lead to a major life threatening interaction when taken with {v}", "Ofatumumab" ] ], [ [ "Topotecan", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ocrelizumab" ], [ "Ocrelizumab", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Human adenovirus e serotype 4 strain cl-68578 antigen" ], [ "Human adenovirus e serotype 4 strain cl-68578 antigen", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ofatumumab" ] ], [ [ "Topotecan", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Human adenovirus e serotype 4 strain cl-68578 antigen" ], [ "Human adenovirus e serotype 4 strain cl-68578 antigen", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ocrelizumab" ], [ "Ocrelizumab", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ofatumumab" ] ] ]
Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Ofatumumab Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Ofatumumab Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Ofatumumab Topotecan may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Ofatumumab Topotecan may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Ofatumumab Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Ofatumumab Topotecan may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Ofatumumab Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen and Human adenovirus e serotype 4 strain cl-68578 antigen may cause a moderate interaction that could exacerbate diseases when taken with Ofatumumab Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen and Human adenovirus e serotype 4 strain cl-68578 antigen may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Ofatumumab
DB00460
DB01067
612
959
[ "DDInter1929", "DDInter826" ]
Verteporfin
Glipizide
Verteporfin, marketed as Visudyne, is a benzoporphyrin derivative. It is used as a photosensitizer in photodynamic therapy to eliminate abnormal blood vessels in wet form macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 nm in the presence of oxygen, produces highly reactive short-lived singlet oxygen and other reactive oxygen radicals, resulting in local damage to the endothelium and blockage of the vessels.
Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guidelines by Diabetes Canada, sulfonylurea drugs are considered a second-line glucose-lowering therapy following metformin. Because sulfonylureas require functional pancreatic beta cells for their therapeutic effectiveness, sulfonylureas are more commonly used for early-stage type 2 diabetes when there is no progressed pancreatic failure. Compared to the first-generation sulfonylureas, such as [tolbutamide] and [chlorpropamide], second-generation sulfonylureas contain a more non-polar side chain in their chemical structure, which enhances their hypoglycemic potency. Compared to other members of the sulfonylurea drug group, glipizide displays rapid absorption and onset of action with the shortest half-life and duration of action, reducing the risk for long-lasting hypoglycemia that is often observed with blood glucose-lowering agents. Glipizide was first approved by the FDA in 1994 and is available in extended-release tablets under the brand name Glucotrol®, as well as in combination with metformin under the brand name Metaglip®.
Moderate
1
[ [ [ 612, 24, 959 ] ], [ [ 612, 63, 245 ], [ 245, 40, 959 ] ], [ [ 612, 24, 1411 ], [ 1411, 1, 959 ] ], [ [ 612, 21, 30573 ], [ 30573, 60, 959 ] ], [ [ 612, 24, 1479 ], [ 1479, 24, 959 ] ], [ [ 612, 63, 1101 ], [ 1101, 24, 959 ] ], [ [ 612, 24, 1040 ], [ 1040, 63, 959 ] ], [ [ 612, 25, 213 ], [ 213, 25, 959 ] ], [ [ 612, 63, 245 ], [ 245, 1, 370 ], [ 370, 40, 959 ] ], [ [ 612, 24, 1411 ], [ 1411, 1, 1036 ], [ 1036, 1, 959 ] ] ]
[ [ [ "Verteporfin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Glipizide" ] ], [ [ "Verteporfin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Glimepiride" ], [ "Glimepiride", "{u} (Compound) resembles {v} (Compound)", "Glipizide" ] ], [ [ "Verteporfin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tolbutamide" ], [ "Tolbutamide", "{u} (Compound) resembles {v} (Compound)", "Glipizide" ] ], [ [ "Verteporfin", "{u} (Compound) causes {v} (Side Effect)", "Retinal haemorrhage" ], [ "Retinal haemorrhage", "{u} (Side Effect) is caused by {v} (Compound)", "Glipizide" ] ], [ [ "Verteporfin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Acetylsalicylic acid" ], [ "Acetylsalicylic acid", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Glipizide" ] ], [ [ "Verteporfin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bexarotene" ], [ "Bexarotene", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Glipizide" ] ], [ [ "Verteporfin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dabrafenib" ], [ "Dabrafenib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Glipizide" ] ], [ [ "Verteporfin", "{u} may lead to a major life threatening interaction when taken with {v}", "Aminolevulinic acid" ], [ "Aminolevulinic acid", "{u} may lead to a major life threatening interaction when taken with {v}", "Glipizide" ] ], [ [ "Verteporfin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Glimepiride" ], [ "Glimepiride", "{u} (Compound) resembles {v} (Compound)", "Glyburide" ], [ "Glyburide", "{u} (Compound) resembles {v} (Compound)", "Glipizide" ] ], [ [ "Verteporfin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tolbutamide" ], [ "Tolbutamide", "{u} (Compound) resembles {v} (Compound)", "Chlorpropamide" ], [ "Chlorpropamide", "{u} (Compound) resembles {v} (Compound)", "Glipizide" ] ] ]
Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound) Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Glipizide (Compound) Verteporfin (Compound) causes Retinal haemorrhage (Side Effect) and Retinal haemorrhage (Side Effect) is caused by Glipizide (Compound) Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Glipizide Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Glipizide Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Glipizide Verteporfin may lead to a major life threatening interaction when taken with Aminolevulinic acid and Aminolevulinic acid may lead to a major life threatening interaction when taken with Glipizide Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glyburide (Compound) and Glyburide (Compound) resembles Glipizide (Compound) Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Chlorpropamide (Compound) and Chlorpropamide (Compound) resembles Glipizide (Compound)
DB00601
DB06317
453
1,626
[ "DDInter1073", "DDInter630" ]
Linezolid
Elotuzumab
Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci. Linezolid exerts its antibacterial activity by inhibiting the initiation of bacterial protein synthesis - more specifically, it binds to the 23S ribosomal RNA of the 50S subunit[A11227,A199050] and, in doing so, prevents the formation of the 70S initiation complex which is essential for bacterial reproduction. Linezolid was initially approved in 2000 and was the first member of the oxazolidinone antibiotic class. A second member of this class, [tedizolid], was approved by the FDA in 2014 and is considered generally more effective and tolerable than its predecessor.
Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family member 7, a cell surface glycoprotein. Elotuzumab consists of the complementary determining regions (CDR) of the mouse antibody, MuLuc63, grafted onto human IgG1 heavy and kappa light chain frameworks. Elotuzumab is produced in NS0 cells by recombinant DNA technology. Elotuzumab has a theoretical mass of 148.1 kDa for the intact antibody. Elotuzumab was approved on November 30, 2015 by the U.S. Food and Drug Administration. Elotuzumab is marketed under the brand Empliciti™ by Bristol-Myers Squibb.
Moderate
1
[ [ [ 453, 24, 1626 ] ], [ [ 453, 24, 973 ], [ 973, 24, 1626 ] ], [ [ 453, 63, 597 ], [ 597, 24, 1626 ] ], [ [ 453, 24, 310 ], [ 310, 63, 1626 ] ], [ [ 453, 25, 1011 ], [ 1011, 64, 1626 ] ], [ [ 453, 64, 1057 ], [ 1057, 25, 1626 ] ], [ [ 453, 25, 1377 ], [ 1377, 25, 1626 ] ], [ [ 453, 24, 973 ], [ 973, 63, 1463 ], [ 1463, 24, 1626 ] ], [ [ 453, 63, 597 ], [ 597, 24, 973 ], [ 973, 24, 1626 ] ], [ [ 453, 24, 1488 ], [ 1488, 24, 973 ], [ 973, 24, 1626 ] ] ]
[ [ [ "Linezolid", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Elotuzumab" ] ], [ [ "Linezolid", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Paclitaxel" ], [ "Paclitaxel", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Elotuzumab" ] ], [ [ "Linezolid", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Chloramphenicol" ], [ "Chloramphenicol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Elotuzumab" ] ], [ [ "Linezolid", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Cabazitaxel" ], [ "Cabazitaxel", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Elotuzumab" ] ], [ [ "Linezolid", "{u} may lead to a major life threatening interaction when taken with {v}", "Fingolimod" ], [ "Fingolimod", "{u} may lead to a major life threatening interaction when taken with {v}", "Elotuzumab" ] ], [ [ "Linezolid", "{u} may lead to a major life threatening interaction when taken with {v}", "Etanercept" ], [ "Etanercept", "{u} may lead to a major life threatening interaction when taken with {v}", "Elotuzumab" ] ], [ [ "Linezolid", "{u} may lead to a major life threatening interaction when taken with {v}", "Leflunomide" ], [ "Leflunomide", "{u} may lead to a major life threatening interaction when taken with {v}", "Elotuzumab" ] ], [ [ "Linezolid", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Paclitaxel" ], [ "Paclitaxel", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lovastatin" ], [ "Lovastatin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Elotuzumab" ] ], [ [ "Linezolid", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Chloramphenicol" ], [ "Chloramphenicol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Paclitaxel" ], [ "Paclitaxel", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Elotuzumab" ] ], [ [ "Linezolid", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fludarabine" ], [ "Fludarabine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Paclitaxel" ], [ "Paclitaxel", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Elotuzumab" ] ] ]
Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab Linezolid may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Elotuzumab Linezolid may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Elotuzumab Linezolid may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Elotuzumab Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Lovastatin and Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine and Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab
DB01320
DB06595
651
1,491
[ "DDInter783", "DDInter1214" ]
Fosphenytoin
Midostaurin
Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repetitive firing of action potentials.
Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hematopoietic tumors . It was approved on April 28, 2017 and has shown to increase the overall survival rate in patients with AML as an adjunct therapy along with chemotherapeutic agents.
Major
2
[ [ [ 651, 25, 1491 ] ], [ [ 651, 25, 1135 ], [ 1135, 62, 1491 ] ], [ [ 651, 63, 112 ], [ 112, 23, 1491 ] ], [ [ 651, 24, 761 ], [ 761, 24, 1491 ] ], [ [ 651, 63, 888 ], [ 888, 24, 1491 ] ], [ [ 651, 25, 1017 ], [ 1017, 63, 1491 ] ], [ [ 651, 64, 613 ], [ 613, 24, 1491 ] ], [ [ 651, 24, 5 ], [ 5, 63, 1491 ] ], [ [ 651, 25, 866 ], [ 866, 24, 1491 ] ], [ [ 651, 40, 998 ], [ 998, 24, 1491 ] ] ]
[ [ [ "Fosphenytoin", "{u} may lead to a major life threatening interaction when taken with {v}", "Midostaurin" ] ], [ [ "Fosphenytoin", "{u} may lead to a major life threatening interaction when taken with {v}", "Naloxegol" ], [ "Naloxegol", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Midostaurin" ] ], [ [ "Fosphenytoin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Metronidazole" ], [ "Metronidazole", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Midostaurin" ] ], [ [ "Fosphenytoin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Saxagliptin" ], [ "Saxagliptin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Midostaurin" ] ], [ [ "Fosphenytoin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Tamoxifen" ], [ "Tamoxifen", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Midostaurin" ] ], [ [ "Fosphenytoin", "{u} may lead to a major life threatening interaction when taken with {v}", "Lorlatinib" ], [ "Lorlatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Midostaurin" ] ], [ [ "Fosphenytoin", "{u} may lead to a major life threatening interaction when taken with {v}", "Irinotecan" ], [ "Irinotecan", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Midostaurin" ] ], [ [ "Fosphenytoin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Liraglutide" ], [ "Liraglutide", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Midostaurin" ] ], [ [ "Fosphenytoin", "{u} may lead to a major life threatening interaction when taken with {v}", "Cobimetinib" ], [ "Cobimetinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Midostaurin" ] ], [ [ "Fosphenytoin", "{u} (Compound) resembles {v} (Compound)", "Phenylbutazone" ], [ "Phenylbutazone", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Midostaurin" ] ] ]
Fosphenytoin may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Midostaurin Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Midostaurin Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin Fosphenytoin may lead to a major life threatening interaction when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin Fosphenytoin may lead to a major life threatening interaction when taken with Irinotecan and Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide and Liraglutide may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin Fosphenytoin may lead to a major life threatening interaction when taken with Cobimetinib and Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin Fosphenytoin (Compound) resembles Phenylbutazone (Compound) and Phenylbutazone may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
DB05239
DB12095
866
179
[ "DDInter425", "DDInter1760" ]
Cobimetinib
Telotristat ethyl
Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or metastatic BRAF V600 mutation-positive melanoma.
Telotristat ethyl is a prodrug of telotristat that was approved by the FDA in March 2017 as Xermelo. It was previously referred to as telotristat etiprate, the hippurate salt form; however, the FDA recommends the use of the name of the neutral form rather than that of the salt.[A252937, A252942] Currently, telotristat ethyl is used to treat carcinoid syndrome diarrhea from neuroendocrine tumors that are inadequately controlled by short-acting somatostatin analog (SSA) treatment. Neuroendocrine cells are cells that secrete regulatory peptides and biogenic amines in response to chemical, neural, or other types of stimuli. Neuroendocrine tumors (NET) arising from these cells can therefore secrete chemical mediators into the bloodstream to cause side effects in distant sites, a phenomenon called carcinoid syndrome. The most common peptides and amines secreted by NET are histamines, tachykinins, kallikrein, and serotonin. Overexposure to serotonin can cause severe diarrhea, one of the main clinical symptoms of carcinoid syndrome. Serotonin is metabolized in the urinary metabolite 5-hydroxy indole acetic acid (u5-HIAA), and high levels of u5-HIAA is associated with poor survival outcome in patients with NET. The first line treatment of carcinoid syndrome diarrhea is SSA, but symptoms still reoccur over the course of the disease.
Major
2
[ [ [ 866, 25, 179 ] ], [ [ 866, 24, 214 ], [ 214, 24, 179 ] ], [ [ 866, 63, 1213 ], [ 1213, 24, 179 ] ], [ [ 866, 25, 1593 ], [ 1593, 24, 179 ] ], [ [ 866, 25, 283 ], [ 283, 63, 179 ] ], [ [ 866, 64, 1419 ], [ 1419, 24, 179 ] ], [ [ 866, 24, 971 ], [ 971, 63, 179 ] ], [ [ 866, 24, 1476 ], [ 1476, 64, 179 ] ], [ [ 866, 24, 124 ], [ 124, 25, 179 ] ], [ [ 866, 25, 1017 ], [ 1017, 64, 179 ] ] ]
[ [ [ "Cobimetinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Telotristat ethyl" ] ], [ [ "Cobimetinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Fostamatinib" ], [ "Fostamatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Telotristat ethyl" ] ], [ [ "Cobimetinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Dasatinib" ], [ "Dasatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Telotristat ethyl" ] ], [ [ "Cobimetinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Crizotinib" ], [ "Crizotinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Telotristat ethyl" ] ], [ [ "Cobimetinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Fedratinib" ], [ "Fedratinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Telotristat ethyl" ] ], [ [ "Cobimetinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Imatinib" ], [ "Imatinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Telotristat ethyl" ] ], [ [ "Cobimetinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Gilteritinib" ], [ "Gilteritinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Telotristat ethyl" ] ], [ [ "Cobimetinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Brigatinib" ], [ "Brigatinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Telotristat ethyl" ] ], [ [ "Cobimetinib", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Glasdegib" ], [ "Glasdegib", "{u} may lead to a major life threatening interaction when taken with {v}", "Telotristat ethyl" ] ], [ [ "Cobimetinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Lorlatinib" ], [ "Lorlatinib", "{u} may lead to a major life threatening interaction when taken with {v}", "Telotristat ethyl" ] ] ]
Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl Cobimetinib may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl Cobimetinib may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl Cobimetinib may lead to a major life threatening interaction when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may lead to a major life threatening interaction when taken with Telotristat ethyl Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib and Glasdegib may lead to a major life threatening interaction when taken with Telotristat ethyl Cobimetinib may lead to a major life threatening interaction when taken with Lorlatinib and Lorlatinib may lead to a major life threatening interaction when taken with Telotristat ethyl
DB00030
DB06655
1,685
5
[ "DDInter934", "DDInter1077" ]
Insulin human
Liraglutide
Human Insulin, also known as Regular Insulin, is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin. Typically prescribed for the management of diabetes mellitus, insulin is a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle. Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis among many other functions. Insulin is an important treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys
Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmitic acid) with a glutamic acid spacer on the remaining lysine residue at position 26 of the peptide precursor. Liraglutide was granted FDA approval on January 25, 2010.
Moderate
1
[ [ [ 1685, 24, 5 ] ], [ [ 1685, 23, 1103 ], [ 1103, 23, 5 ] ], [ [ 1685, 24, 743 ], [ 743, 23, 5 ] ], [ [ 1685, 24, 1142 ], [ 1142, 24, 5 ] ], [ [ 1685, 24, 192 ], [ 192, 63, 5 ] ], [ [ 1685, 25, 1299 ], [ 1299, 24, 5 ] ], [ [ 1685, 25, 255 ], [ 255, 63, 5 ] ], [ [ 1685, 63, 521 ], [ 521, 24, 5 ] ], [ [ 1685, 24, 1101 ], [ 1101, 25, 5 ] ], [ [ 1685, 25, 246 ], [ 246, 25, 5 ] ] ]
[ [ [ "Insulin human", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Liraglutide" ] ], [ [ "Insulin human", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Amcinonide" ], [ "Amcinonide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Liraglutide" ] ], [ [ "Insulin human", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Lisinopril" ], [ "Lisinopril", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Liraglutide" ] ], [ [ "Insulin human", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Orlistat" ], [ "Orlistat", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Liraglutide" ] ], [ [ "Insulin human", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Esterified estrogens" ], [ "Esterified estrogens", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Liraglutide" ] ], [ [ "Insulin human", "{u} may lead to a major life threatening interaction when taken with {v}", "Trovafloxacin" ], [ "Trovafloxacin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Liraglutide" ] ], [ [ "Insulin human", "{u} may lead to a major life threatening interaction when taken with {v}", "Delafloxacin" ], [ "Delafloxacin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Liraglutide" ] ], [ [ "Insulin human", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Goserelin" ], [ "Goserelin", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Liraglutide" ] ], [ [ "Insulin human", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Bexarotene" ], [ "Bexarotene", "{u} may lead to a major life threatening interaction when taken with {v}", "Liraglutide" ] ], [ [ "Insulin human", "{u} may lead to a major life threatening interaction when taken with {v}", "Gatifloxacin" ], [ "Gatifloxacin", "{u} may lead to a major life threatening interaction when taken with {v}", "Liraglutide" ] ] ]
Insulin human may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Liraglutide Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Lisinopril and Lisinopril may cause a minor interaction that can limit clinical effects when taken with Liraglutide Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Orlistat and Orlistat may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Esterified estrogens and Esterified estrogens may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide Insulin human may lead to a major life threatening interaction when taken with Trovafloxacin and Trovafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide Insulin human may lead to a major life threatening interaction when taken with Delafloxacin and Delafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Liraglutide Insulin human may lead to a major life threatening interaction when taken with Gatifloxacin and Gatifloxacin may lead to a major life threatening interaction when taken with Liraglutide
DB01001
DB11124
688
209
[ "DDInter1632", "DDInter1560" ]
Salbutamol
Racepinephrine
Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formulated as a racemic mixture of the R- and S-isomers. The R-isomer has 150 times greater affinity for the beta2-receptor than the S-isomer and the S-isomer has been associated with toxicity. This lead to the development of levalbuterol, the single R-isomer of salbutamol. However, the high cost of levalbuterol compared to salbutamol has deterred wide-spread use of this enantiomerically pure version of the drug. Salbutamol is generally used for acute episodes of bronchospasm caused by bronchial asthma,
Racepinephrine is a racemic mixture consisting of d- and l- enantiomers. Epinephrine is a non-selective α- and β-adrenergic receptor agonist. It is a bronchodilator used in the temporary relief of mild symptoms of intermittent asthma including wheezing, tightness of chest and shortness of breath. It is an active ingredient in oral inhalation over-the-counter products as racepinephrine hydrochloride.
Moderate
1
[ [ [ 688, 24, 209 ] ], [ [ 688, 23, 1042 ], [ 1042, 23, 209 ] ], [ [ 688, 62, 1573 ], [ 1573, 23, 209 ] ], [ [ 688, 63, 1674 ], [ 1674, 24, 209 ] ], [ [ 688, 24, 22 ], [ 22, 24, 209 ] ], [ [ 688, 64, 290 ], [ 290, 25, 209 ] ], [ [ 688, 23, 1042 ], [ 1042, 62, 1674 ], [ 1674, 24, 209 ] ], [ [ 688, 62, 1573 ], [ 1573, 40, 870 ], [ 870, 23, 209 ] ], [ [ 688, 62, 218 ], [ 218, 1, 423 ], [ 423, 23, 209 ] ], [ [ 688, 23, 423 ], [ 423, 40, 1573 ], [ 1573, 23, 209 ] ] ]
[ [ [ "Salbutamol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Racepinephrine" ] ], [ [ "Salbutamol", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Tetracosactide" ], [ "Tetracosactide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Racepinephrine" ] ], [ [ "Salbutamol", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Prednisone" ], [ "Prednisone", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Racepinephrine" ] ], [ [ "Salbutamol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Orciprenaline" ], [ "Orciprenaline", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Racepinephrine" ] ], [ [ "Salbutamol", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Ephedrine" ], [ "Ephedrine", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Racepinephrine" ] ], [ [ "Salbutamol", "{u} may lead to a major life threatening interaction when taken with {v}", "Cocaine" ], [ "Cocaine", "{u} may lead to a major life threatening interaction when taken with {v}", "Racepinephrine" ] ], [ [ "Salbutamol", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Tetracosactide" ], [ "Tetracosactide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Orciprenaline" ], [ "Orciprenaline", "{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}", "Racepinephrine" ] ], [ [ "Salbutamol", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Prednisone" ], [ "Prednisone", "{u} (Compound) resembles {v} (Compound)", "Fludrocortisone" ], [ "Fludrocortisone", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Racepinephrine" ] ], [ [ "Salbutamol", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Beclomethasone dipropionate" ], [ "Beclomethasone dipropionate", "{u} (Compound) resembles {v} (Compound)", "Ciclesonide" ], [ "Ciclesonide", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Racepinephrine" ] ], [ [ "Salbutamol", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Ciclesonide" ], [ "Ciclesonide", "{u} (Compound) resembles {v} (Compound)", "Prednisone" ], [ "Prednisone", "{u} may cause a minor interaction that can limit clinical effects when taken with {v}", "Racepinephrine" ] ] ]
Salbutamol may cause a minor interaction that can limit clinical effects when taken with Tetracosactide and Tetracosactide may cause a minor interaction that can limit clinical effects when taken with Racepinephrine Salbutamol may cause a minor interaction that can limit clinical effects when taken with Prednisone and Prednisone may cause a minor interaction that can limit clinical effects when taken with Racepinephrine Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline and Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Racepinephrine Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine and Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with Racepinephrine Salbutamol may lead to a major life threatening interaction when taken with Cocaine and Cocaine may lead to a major life threatening interaction when taken with Racepinephrine Salbutamol may cause a minor interaction that can limit clinical effects when taken with Tetracosactide and Tetracosactide may cause a minor interaction that can limit clinical effects when taken with Orciprenaline and Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Racepinephrine Salbutamol may cause a minor interaction that can limit clinical effects when taken with Prednisone and Prednisone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may cause a minor interaction that can limit clinical effects when taken with Racepinephrine Salbutamol may cause a minor interaction that can limit clinical effects when taken with Beclomethasone dipropionate and Beclomethasone dipropionate (Compound) resembles Ciclesonide (Compound) and Ciclesonide may cause a minor interaction that can limit clinical effects when taken with Racepinephrine Salbutamol may cause a minor interaction that can limit clinical effects when taken with Ciclesonide and Ciclesonide (Compound) resembles Prednisone (Compound) and Prednisone may cause a minor interaction that can limit clinical effects when taken with Racepinephrine